







de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden, 
volgens besluit van het College voor Promoties







Promotor:   Prof. Dr. Ir. LM Havekes
Copromotores:   Dr. Ir. K Willems van Dijk
   Dr. PCN Rensen
Overige leden:  Prof. Dr. BK Groen (UMCG, Groningen)
   Prof. Dr. RR Frants
   Prof. Dr. JA Romijn
   Dr. HMG Princen (TNO, Leiden)
   
The research described in this thesis was financially supported by the Netherlands 
Organization for Health Care Research Medical Sciences (ZON-MW project nr. 
948 000 04) and by grants from the Nutrigenomics Consortium/Top Institute Food 
and Nutrition (NGC/TIFN) and the Center of Medical Systems Biology (CMSB) 
established by The Netherlands Genomics Initiative/Netherlands Organization 
for Scientific Research (NGI/NWO).
Studies presented in this thesis were performed at the department of Human 
Genetics and the department of Endocrinology, Leiden University Medical Center, 
Leiden, the Netherlands and at the Gaubius Laboratory, TNO Quality of Life, 
Leiden, The Netherlands.
Financial support by the Netherlands Heart Foundation for the publication of this 
thesis is gratefully acknowledged.

Colophon
© S. Bijland, 2010. All rights reserved. No part of this publication may be reproduced 
or transmitted in any form or by any means, without prior permission in writing 
from the author.
ISBN: 978949109801 7
Cover design and Illustrations © S. Bijland
Print by F&N Boekservices Eigenbeheer
Financial support for the publication of this thesis was kindly provided by 
J.E. Juriaanse Stichting 
Novo Nordisk 
Servier Nederland Farma B.V.
Table of contents
Chapter 1        
General Introduction       9 
Chapter 2 
CETP does not affect triglyceride production or clearance in   25
ApoE*3-Leiden mice 
Journal of Lipid Research 2010; 51: 97-102
Chapter 3 
Fenofibrate increases VLDL-triglyceride production despite   39
reducing plasma triglyceride levels in ApoE*3-Leiden.CETP mice
The Journal of Biological Chemistry 2010;285(33):25168-75
Chapter 4 
Rifampicin decreases plasma HDL and VLDL mainly by impairing  63
particle production in ApoE*3-Leiden.CETP mice
Manuscript in preparation
Chapter 5 
Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic  81
steatosis and hypolipidemia mainly by impairing lipoprotein 
production in ApoE*3-Leiden.CETP mice
Submitted
Chapter 6 
Gene expression profiles distinguish fasting and  high-fat diet   109
induced steatosis
Chapter 7 
General discussion       127 
Chapter 8
References        140
Summary        162 
Nederlandse samenvatting voor niet-ingewijden    166  
List of publications       170  






Lipids are essential for life and fulfil multiple functions in energy homeostasis and cellular biology. Two of these lipids are cholesterol, the structural component of cell membranes and steroid hormones, and 
triglycerides (TG), the main source of energy for both exercise and storage. Excess 
intake of energy increases the storage of TG and results in overweight and obesity. 
Since obesity is becoming ever more prevalent in our society due to a sedentary 
lifestyle combined with a calorie-rich Western diet, it is important to understand 
pathways involved in the uptake, distribution, oxidation and storage of TG. 
 In fact, obesity is a global epidemic as stated by the World Health Organization1 
and a major public health concern since excessive overweight is associated with 
various diseases such as diabetes mellitus type 2 (DM2) and cardiovascular 
disease (CVD)2. The link between TG metabolism, obesity and the development 
of pathology is subject to intense investigation. TG are composed of a glycerol 
backbone and three fatty acids (FA). Prior to transmembrane transport, TG are 
hydrolyzed to FA and after they have been taken up, these FA are re-esterified 
to TG for storage. Since free FA (FFA) are cytotoxic3, it is thought that the 
(mis)handling and distribution of TG derived FA plays a central role in the 
pathogenesis of overweight related diseases such as DM2 and CVD4, 5.
Lipoprotein Metabolism
The most common lipids in our diet are cholesterol and TG. Since lipids are 
hydrophobic, they are transported in the circulation in water-soluble spherical 
particles called lipoproteins. These lipoproteins carry TG and esterified cholesterol 
(cholesteryl esters, CE) in their core, surrounded by a shell of phospholipids, 
free cholesterol and proteins termed apolipoproteins (apo’s). Based on their 
composition and origin, lipoproteins can be divided into five major classes 
e.g. chylomicrons, very low density lipoprotein (VLDL), intermediate density 
lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein 
(HDL)6. Lipid metabolism can roughly be divided in three major pathways: the 
exogenous pathway important for transport of dietary lipids, the endogenous 
pathway important for the transport of lipids during fasting and the reverse 






In the intestine, dietary lipid is emulsified by the action of bile and TG are 
hydrolyzed in glycerol and FA by pancreatic lipase7. Cholesterol, glycerol and 
FA are absorbed by the intestinal cells where FA are re-esterified to TG. The TG 
and cholesterol are packaged in chylomicrons and secreted in the lymph from 
which they are transported to the blood circulation8, 9. Nascent chylomicrons 
are rich in TG but also contain phospholipids, CE and apolipoproteins apoAI, 
apoAIV, apoB48 and apoCs10. Upon entering the circulation, chylomicrons are 
processed by lipoprotein lipase (LPL)8. LPL hydrolyzes TG, thereby delivering 
FA to peripheral tissues were it can be used as energy source (heart and skeletal 
muscle) or can be stored in adipose tissue. The resulting TG depleted remnant 
chylomicrons are taken up by the liver, mainly via apoE specific recognition 


































Figure 1. Schematic overview of lipoprotein metabolism.
See text for explanation. CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FC, 
free cholesterol; FFA, free fatty acids; LCAT, lecithin:cholesterol acyltransferase; LDLr, 
LDL receptor; LPL, lipoprotein lipase; LRP, LDLr related protein; PL, phospholipid; SR-BI, 
scavenger receptor BI; TG, triglycerides.
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Endogenous pathway
Especially in the postprandial state, the liver is the main site of secretion of 
cholesterol and TG, packaged in VLDL for transport to peripheral tissues. The 
intracellular formation of VLDL in hepatocytes will be discussed in detail later. 
After VLDL enters the circulation, the particle is further enriched with apoE 
and apoCs10. Similar to chylomicrons, the TG content of VLDL can be lipolyzed 
into FA by LPL and used as energy source. VLDL-TG thus predominantly 
functions as a source of FA under fasting conditions. The processing of VLDL 
by LPL results in the formation of IDL (or VLDL-remnant) which can be 
further processed to become cholesterol-rich LDL10. The LDLr can bind and 
internalize both apoE and apoB containing particles10. VLDL remnants are 
predominantly cleared by the liver LDLr via apoE, whereas LDL is depleted 
from most apolipoproteins except for apoB and is cleared by the liver and 
peripheral LDLr10. High levels of apoB containing lipoproteins (chylomicrons, 
VLDL, IDL, and LDL) can lead to accumulation of lipids in the vascular wall 
and the development of atherosclerosis13, 14.
Reverse cholesterol transport
HDL is responsible for the removal of excess cholesterol from peripheral tissues. 
In the liver and intestine, nascent HDL is formed from apoAI and phospholipids. 
The biosynthesis of HDL is dependent on the hepatic or intestinal ATP-binding 
cassette transporter A1 (ABCA1)15. In the circulation, HDL is enriched with 
phospholipids from chylomicrons and VLDL via phospholipid transfer protein 
(PLTP)16, and cholesterol from the periphery via ABCA1, ABCGI and probably 
also scavenger receptor BI (SR-BI)15, 17. Cholesterol is subsequently esterified 
by lecithin:cholesterol acyltransferase (LCAT) into CE that are stored in the 
core of HDL17. The HDL particle expands due to cholesterol accumulation 
and matures into spherical HDL, which can acquire apolipoproteins including 
apoAII, apoAIV, apoAV, apoCI, apoCII, apoCIII and apoE10, 18. HDL-derived 
cholesterol can be taken up by the liver via SR-BI19, 20, 21. In the liver excess of 
cholesterol is secreted in the bile thereby maintaining cholesterol homeostasis22. 
 The lipids in HDL can be exchanged with other lipoproteins through 
the interaction with PLTP to exchange phospholipids16 and cholesteryl ester 




by liver, spleen, macrophages and adipose tissue24. CETP is predominantly 
associated with HDL in the circulation and mediates the exchange of CE 
and TG between apoB containing lipoproteins and HDL17. This results in a 
net flux of TG from (V)LDL to HDL in exchange for CE. The majority of CE 
from HDL is transferred to apoB containing lipoproteins thereby creating a 
more atherogenic profile with low levels of HDL-C and high levels of LDL-C. 
Furthermore, cholesterol transported to LDL by CETP can be taken up by the 
liver via the LDLr pathway thereby facilitating an alternative route for reverse 
cholesterol transport mediated by SR-BI.
VLDL triglyceride and fatty acid metabolism
VLDL assembly
In the liver, TG is secreted in VLDL particles. The assembly of these particles 
starts in the endoplasmatic reticulum (ER) where newly synthesized apoB is 
cotranslationally lipidated by microsomal triglyceride transfer protein (MTP)25, 26. 
Each VLDL particle contains one apoB molecule. Since the transcription 
of apoB is relatively constant, regulation occurs at the posttranscriptional 
level. Whether apoB is targeted for degradation or lipidated is dependent 
on the availability of phospholipid and free cholesterol to form the surface 
monolayer, the availability of neutral lipids (TG and CE) to form the core 
and the presence of MTP which is necessary for the translocation, folding 
and lipidation of apoB27. When apoB is lipidated and targeted away from 
proteosomal degradation, a pre-VLDL particle is formed and released in 
the lumen of the ER where it can either be retained and degraded or further 
lipidated to form VLDL. This VLDL particle contains only a small amount of 
TG and is transported to the Golgi complex for secretion. In the Golgi, the VLDL 
particle can undergo a second step of lipidation in which the particle is loaded 
with bulk TG after which the mature TG-rich VLDL particle is secreted25, 27. 
 The assembly of VLDL is highly dependent on the presence of TG in the 
hepatocyte. The origin of the FA of these TG is represented in figure 2. Most 
of the FA used for VLDL-TG secretion originates from the plasma. These FFA 
are released from the adipose tissue or are spill over from peripheral lipolysis 
of chylomicron-TG and VLDL-TG and taken up by the liver28, 29. Other sources 
of TG include previously accumulated cytosolic TG stores in the liver, receptor 
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mediated uptake of TG-rich lipoproteins (TLR), and TG esterification from de 
novo synthesized FA. De novo lipogenesis (DNL) in the liver is stimulated in the 
fed state28. FA are depleted from the liver by oxidation of FA (b-oxidation), which 
lowers the FA available for TG synthesis. A different source for the formation of 
TG is the phospholipid phosphatidylcholine (PC). Although phospholipids are 
mainly involved in structuring the VLDL particles, evidence accumulates that 
phospholipids themselves can also contribute to TG synthesis30, 31, 32. However 
the precise metabolic pathways involved in the conversion of phospholipids 
to TG are unknown. 
Lipoprotein lipase
Enzymes responsible for the hydrolysis of TG to FA and glycerol are collectively 
named lipases33, 34. Lipases hydrolyse the ester bonds of mono-, di-, and 
triglycerides, CE and phospholipids. This family of lipases consists of pancreatic 
lipase, present in the gut and necessary for the absorption of lipid by the 
intestine7, adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), 
endothelial lipase (EL), hepatic lipase (HL) and LPL. LPL is expressed in most 
tissues, yet most abundantly in tissues that utilize FA for energy or storage (e.g. 
heart, skeletal muscle and adipose tissue)33. To become active, LPL  is translocated 
to the luminal surface of endothelial cells lining the secreting tissues providing 









Figure 2. Schematic overview of sources of fatty acids and TG for VLDL synthesis. 
See text for explanation. DNL, de novo lipogenesis; (F)FA, (free) fatty acids; LPL, lipoprotein 




of heparin sulfate proteoglycans (HSPGs)12 and glycosylphosphatidylinositol-
anchored high density lipoprotein binding protein 1 (GPIHBP1)35. Once TG-
rich lipoproteins dock at the platform, LPL mediates the hydrolysis of TG 
and the released FA are for a large part taken up in the underlying tissue. 
 The regulation of LPL is tissue-specific and dependent on nutritional status. 
In the postprandial state, FA are primarily used for storage and therefore LPL 
activity is high in adipose tissue36, 37. During fasting, FA are primarily used 
as energy substrate and LPL activity is high in muscle36, 37.  Several factors 
influence the activity of LPL, some of which are transported by the TG-rich 
lipoproteins themselves. ApoCII is an essential co-factor for LPL activity38 and 
apoAV is a stimulator of LPL mediated lipolysis by guiding the lipoproteins 
to the lipolysis platform39, 40. However, apolipoproteins are also able to 
inhibit LPL. ApoCIII is a strong LPL inhibitor by affecting both the docking 
of TG-rich lipoproteins to the lipolytic site as well as directly inhibiting LPL 
itself41. ApoCI is also able to interact with LPL thereby inhibiting its activity42. 
Another group of inhibitors of LPL are the angiopoietin-like protein (Angptl) 
3, that suppresses LPL activity and Angptl 4 that inhibits LPL by promoting 
the conversion of active LPL dimers into inactive LPL monomers43. These 
monomers can be released in the circulation thereby enhancing the binding 
and/or internalization of lipoproteins44. FA derived after lipolysis can be used 
for b-oxidation or stored in the form of TG by esterification. 
Hormone sensitive lipase
In the fed state, adipose tissue is the major site of TG storage. There is a 
continuous cycle of lipolysis and (re-) esterification in the adipose tissue which 
is mediated by HSL and AGTL, which is termed the futile FA cycle45, 46. During 
intracellular lipolysis, generated glycerol diffuses to the circulation and FA can 
be released in the circulation or re-esterified to form TG again. The balance 
between lipolysis and re-esterification therefore determines the plasma levels 
of FA. During the fed state, the rate of lipolysis by HSL is inhibited by insulin47 
resulting in a net uptake of FA and accumulation of TG in the adipocytes. 
During fasting, HSL is stimulated by hormones such as glucagon47 resulting in 
the release of FA into the circulation. These FA can be oxidized by other tissues, 
can be taken up by the liver for b-oxidation or can be metabolized into ketone 
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bodies that can serve as energy source for other tissues. FA from the circulation 
can also be re-esterified into TG and used as source for VLDL-TG production. 
This futile cycling of FA between liver and adipose tissue enables the body to 
adapt rapidly to changes in energy requirement.
Intracellular FA handling
FA are an important metabolic substrate but are extremely cytotoxic3. Therefore 
the uptake, transport and storage of FA is intensively regulated and plasma 
FA levels show relative little variation. After lipolysis, FA are taken up by 
the underlying tissue by passive diffusion across cell membrane or active 
transport which is facilitated by FA transporters such as FA translocase CD3648 
and plasma-membrane-associated FA-binding protein (FABPpm)49. In the cell, 
cytosolic FA binding protein (FABPc) and FA transport proteins (FATPs) target 
the FA to intracellular sites for conversion such as mitochondria for b-oxidation50. 
Diacylglycerol acyltransferases (DGATs) mediate the re-esterification of 
surplus FA so they can be stored as TG in intracellular lipid droplets. FA also 
act as important signalling molecules and modulate transcription factors 
to regulate the expression of genes involved in nutrient sensing and lipid 
metabolism. This is mediated by G-protein coupled receptors whereby GPR40 
and GPR120 are activated by medium and long chain fatty acids51, and GPR41 
and GPR43 are activated by short chain fatty acids52. Activation of these FA 
receptors promotes the secretion of hormones involved in metabolism, such as 
insulin (GPR4053, GPR12054), leptin (GPR4155) and GLP-1 (GPR12056), but can 
also influence our immune response (GPR4357, 58, GPR12054).
Transcriptional regulation of TG and FA metabolism
Changes in the expression of genes involved in lipid metabolism are mediated by 
members of the nuclear receptor superfamily of ligand-dependent transcription 
factors. These nuclear receptors bind to target genes as heterodimers with 
retinoid X receptors (RXRs). In the presence of a ligand, these nuclear receptors 
recruit co-activator complexes resulting in the activation of transcription of 
the target gene59. In the absence of ligand, a co-repressor complex is recruited 
thereby preventing transcription. Binding of the ligand to the nuclear receptor 




switching from repression to gene activation59. A third mechanism through 
which nuclear receptors act is by transrepression, involving the indirect 
binding of ligand-bound nuclear receptors to proteins instead of the target 
gene59, 60 thereby enabling to control complex gene expression programs. There 
are several mechanisms through which transrepression can occur including 
competition and cross-coupling61. With competition the activated nuclear 
receptor competes for the binding of the co-activator complex in situations 
in which specific co-activators are limited. As a result, less co-activators are 
available for other transcription factors thereby inhibiting their gene activation. 
Cross-coupling on the other hand, involves the formation of a complex of the 
activated nuclear receptor with other activated transcription factors resulting 
in direct inhibition of each others transcriptional activity. 
PPARs
Peroxisome proliferators activated receptors (PPARs) play a major role in 
lipid metabolism. This group of transcription factors consists of three different 
members that are activated by FA and eicosanoids. PPARa is highly expressed 
in metabolic active tissue such as liver, heart and muscle62. PPARa activation 
upregulates the expression of genes involved in TG hydrolysis (e.g. apoCIII63 
and LPL64) and in FA uptake (e.g. CD36)65, 66 thereby lowering plasma TG 
levels. In the liver, PPARa also increases the expression of genes involved 
in FA import into mitochondria (e.g. CPT1)67 and b-oxidation (e.g. acyl-CoA 
synthetase)62, thereby reducing the intracellular FA concentrations. PPARg 
expression is highest in adipose tissue where it affects the expression of genes 
involved in adipocyte differentiation68, 69. Furthermore, PPARg has a major 
role in postprandial lipid metabolism. During the postprandial phase, PPARg 
expression is highest70 and upregulates the expression of genes involved in FA 
uptake and trapping64, 66, resulting in the storage of lipids in adipocytes71. PPARd 
is ubiquitously expressed72 and enhances FA transport and oxidation. This 
results in depletion of triglyceride stores in tissues such as fat and muscle73, 74. 
Overall, PPARs act as lipid sensors and are able to regulate lipid homeostasis 
in multiple organs dependent on nutritional and/or energy status.
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SREBP
Sterol regulatory element binding proteins (SREBPs) are also major regulators 
of lipid metabolism and are activated when cells become depleted of 
cholesterol75. There are three isoforms, SREBP1a and SREBP1c that share 
the same gene and SREBP2. SREBP1c is an important downstream target for 
both the liver X receptor (LXR)76 and farnesoid X receptor (FXR)77 and is the 
major regulator of hepatic FA and TG metabolism78. When carbohydrates and 
saturated FA are abundant, SREBP1c expression is activated and TG storage 
is increased78. While during fasting, SREBP1c is inhibited and FA oxidation is 
increased78.
Xenobiotic receptors
Activation of the xenobiotic receptors by environmental chemicals and drugs 
induces the expression of proteins important for the metabolism, deactivation 
and transport of these chemicals. However, pathways used for xenobiotic 
metabolism overlap with pathways involved in lipid metabolism. Constitutive 
androstane receptor (CAR) and pregnane X receptor (PXR) both belong to 
the nuclear receptor family and decrease the expression of genes involved in 
b-oxidation79, 80, 81. Furthermore, PXR increases the uptake of FA in the liver of 
mice by increasing the expression of CD36 and increases the hepatic expression 
of lipogenic genes82. Overall activation of xenobiotic receptors can lead to 
changes in hepatic and plasma lipid profiles83, 84, 85 and PXR or CAR activating 
drugs can even lead to lipid accumulation in the liver of patients86, 87.
PGC-1
One of the co-regulators of nuclear receptors involved in the control of energy 
metabolism is the PPARg coactivator-1 (PGC-1) family. Several targets of PGC-1 
are PPARs73, 88, PXR89, CAR90 and also non-nuclear receptors such as SREBP-191 
and forkhead box O1 (FOXO1)92. In the liver, PGC-1 signalling is increased 
during fasting and activates gene expression involved in FA oxidation by co-
activating PPARa92, 93. This increase in FA oxidation is required to produce 
substrates necessary for the production of glucose and is mediated through 
PGC-1a and PGC-1b91, 92, 93. PGC-1b also activates the expression of genes 




The association between lipid and glucose metabolism
In addition to lipids, carbohydrates are an important source of energy in our 
diet. Complex carbohydrates such as starch are digested into glucose prior to 
absorption in the gut. After a meal, blood glucose levels rise, which results in the 
release of insulin into the circulation by the pancreas. Insulin is a central anabolic 
hormone that regulates both glucose and lipid metabolism94. The main action of 
insulin is to decrease excessive glucose by stimulating metabolism and storage. 
The liver is a central player in glucose homeostasis, since it can store glucose in 
the form of glycogen for later use95. However, due to limited glycogen storage 
insulin promotes de novo lipogenesis from excessive glucose to produce FA. 
 Under fasting conditions, blood glucose levels drop and since the brain is 
highly dependent on glucose, glucose levels need to be maintained. In response 
to glucose lowering, insulin is no longer produced by the pancreas to prevent 
further storage of glucose. In addition, glucose oxidation is lowered and FA 
oxidation increased in tissue, thereby preventing further usage of glucose. The 
drop in glucose levels stimulates the production of glucagon by the pancreas. 
Under the influence of glucagon, glucose can rapidly be mobilized from hepatic 
glycogen stores (glycogenolysis) and released into the circulation to provide 
tissues with glucose that can not function without it, such as the brain. When 
these glycogen stores become depleted, the liver starts producing glucose from 
substrates such as amino acids and glycerol (gluconeogenesis) to maintain 
blood glucose levels96. During prolonged fasting, glucose is no longer readily 
available and ketone bodies are used as energy source instead. Ketone bodies 
are produced in the liver from fatty acids, a process known as ketogenesis, and 
provide an alternative energy source for tissues, such as the brain, to maintain 
its function.
Pathology of lipid and glucose metabolism in the metabolic syndrome
Since lipid and glucose metabolism are tightly linked, disturbances in 
one metabolic pathway in general also involves the other. Excessive 
calorie intake and a diet rich in saturated fat predisposes to obesity and 
concomitantly dyslipidemia, which is characterized by high levels of TG 
(hypertriglyceridemia), high levels of small, dense LDL-C and low levels of 
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HDL-C. This is also known as the metabolic syndrome, which refers to a cluster 
of correlated disorders including obesity, dyslipidemia, insulin resistance and 
hypertension97. The metabolic syndrome but also all the various components 
themselves are associated with an increased risk to develop DM2 and CVD98, 99, 100. 
The metabolic syndrome comprises storage of excess TG in non-adipose, 
resulting in unresponsiveness of this tissue to insulin, also known as insulin 
resistance101, 102, 103. Insulin resistance of the liver results in impaired repression 
of glucose production in response to insulin, resulting in high blood glucose. To 
compensate for insulin resistance, the pancreas starts to produce more insulin 
to maintain normal glucose levels. When the demand on the pancreas to 
produce insulin exceeds its capacity, the pancreas is damaged, leading to DM2. 
 A combination of increased storage of TG in the liver and insulin 
resistance is associated with increased secretion of VLDL-TG104, 105. In 
addition, insulin resistance is also associated with increased lipolysis of TG 
in adipose tissue by HSL resulting in more FA flux from adipose tissue to 
the liver, thereby increasing the liver TG stores. The increased production of 
VLDL-TG by the liver can result in hypertriglyceridemia, thereby providing 
more apoB lipoprotein acceptors for the transfer of cholesterol by CETP. As 
a result HDL becomes depleted of cholesterol and LDL-C levels increase106. 
 A high level of LDL-C is the major cause of atherosclerosis. Cholesterol 
rich LDL particles can invade the arterial wall where they are oxidized and 
cause local damage13, 14. Monocytes are attracted to the site of damage and 
differentiate into macrophages that can incorporate the LDL particles thereby 
becoming cholesterol rich foam cells13, 14. The accumulation of these cholesterol 
rich foam cells results in the formation of plaques. Rupture of these plaques 
can lead to an infarct, damaging surrounding tissue13, 14. 
Models to study lipoprotein metabolism
Dyslipidemia in humans is a multifactorial disease with both genetic and 
environmental origins. Due to the complexity of many dyslipidemias, 
animal models have been developed to investigate specific components of 
dyslipidemia to gain more insight in the mechanisms involved. Mice are a 
commonly used model since they are easy to breed, genetically homogeneous 




genetically manipulated by both changing the expression of endogenous 
genes and by introducing novel genes. Unfortunately, lipid metabolism in 
mice is somewhat different compared to humans. Mice are very efficient in 
clearing apoE-containing lipoproteins from circulation, which results in low 
levels of apoB containing lipoproteins such as VLDL and LDL. In addition, 
mice lack the enzyme CETP and have high levels of HDL compared to humans. 
 Several mouse models have been developed which are more similar to 
human lipoprotein metabolism such as the LDL receptor-deficient (LDLr-/-) 
and apolipoprotein E-deficient (ApoE-/-) (reviewed in107). The mouse model 
used in this thesis to study TG and FA metabolism is the transgenic ApoE*3-
Leiden (E3L) mouse. E3L mice carry the human apoCI gene and a variant 
of the human ApoE*3 gene which causes a genetic form of hyperlipidemia 
in humans108, 109. Expression of these transgenes in E3L mice is associated 
with decreased LPL activity, a disturbed interaction of lipoproteins with 
the LDLr and LRP and impaired hepatic clearance of apoE containing 
lipoproteins. Together this is associated with a more human-like lipoprotein 
metabolism that is characterized by elevated levels of VLDL and LDL. 
 On a standard chow diet, E3L mice have moderately increased levels of 
plasma TG and cholesterol. However, E3L mice are highly responsive to diets 
rich in fat and cholesterol, resulting in strong increases in plasma TG and 
cholesterol levels110. The E3L mice have been used to study (V)LDL metabolism 
in response to various hypolipidemic drugs. In contrast to the often used 
LDLr-/- and ApoE-/- hyperlipidemic mouse models, E3L mice have been shown 
to respond in a human-like manner to a large number of drugs that modify 
LDL-C. These drugs include statins111, 112, 113, fibrates114, 115 and cholesterol uptake 
inhibitors115. However, mice naturally lack CETP, important for both (V)LDL and 
HDL cholesterol metabolism. Therefore E3L mice have recently been crossed 
with mice expressing human CETP under control of its own promoter. The 
resulting E3L.CETP transgenic mice resemble human lipoprotein metabolism 
even more closely compared to E3L mice by the redistribution of cholesterol 
from HDL to (V)LDL116. As a result, these E3L.CETP mice respond to both LDL 
and HDL modifiers85, 114, 117, 118, 119 and are a valuable model to study the effects of 
pharmaceuticals on lipoprotein metabolism.
22
Outline
The research in this thesis focuses on the regulation of TG and FA 
metabolism to get a better understanding of TG and FA metabolism in 
health and disease. The effect of CETP on TG metabolism is studied by 
using the E3L mouse model in Chapter 2. Previous studies have shown that 
expression of CETP in E3L mice results in a shift of cholesterol from HDL 
to apoB containing lipoproteins. Since CETP simultaneously exchanges 
CE with TG, we set out to evaluate whether the impact of CETP on TG 
metabolism is similar to the impact of CETP on cholesterol metabolism. 
 The mechanisms underlying the TG-lowering effect of the PPARa 
agonist fenofibrate are studied using E3L.CETP mice in Chapter 3. This 
TG-lowering effect of fenofibrate has been attributed to both increased TG 
clearance and decreased VLDL-TG production. However, since data on the 
effect of fenofibrate on VLDL production are controversial, we aimed to 
investigate the mechanism underlying the TG-lowering effect of fenofibrate. 
 The effects of the antibiotic rifampicine on TG metabolism 
are discussed in Chapter 4. This drug is a potent PXR activator 
that induces hepatic steatosis in both humans and rodents. 
 Chapter 5 describes the effect of perfluoroakyl sulfonates (PFAS) on 
lipid metabolism. PFAS are very useful for water and oil repellence, but 
are therefore also extremely resistant to degradation. As a consequence 
PFAS accumulate in the environment and can be found in the blood of 
both wildlife as well as humans. PFAS are considered to act as PPARa 
agonist thereby affecting lipid metabolism. Our aim was to investigate the 
effects of PFAS on both TG and cholesterol metabolism in E3L.CETP mice. 
 Hepatic steatosis affects both lipid and glucose metabolism and is 
associated with insulin resistance. In mice, both prolonged fasting and feeding 
a high fat diet induces hepatic steatosis, however only after a high fat diet, 
hepatic steatosis is associated with insulin resistance. Chapter 6 describes the 
differences in the hepatic gene expression profile of mice fasted for 16 hours 
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The cholesteryl ester transfer protein (CETP) facilitates the bidirectional transfer of cholesteryl esters and triglycerides (TG) between HDL and (V)LDL. By shifting cholesterol in plasma from HDL to (V)LDL in 
exchange for VLDL-TG, CETP aggravates atherosclerosis in hyperlipidemic 
ApoE*3-Leiden (E3L) mice. The aim of this study was to investigate the 
role of CETP in TG metabolism and high fat diet-induced obesity by using 
E3L mice with and without the expression of human CETP gene. On chow, 
plasma lipid levels were comparable between both male and female E3L and 
E3L.CETP mice. Further mechanistic studies were performed using male mice. 
CETP expression increased the level of TG in HDL. CETP did not affect the 
postprandial plasma TG response, nor the hepatic VLDL-TG and VLDL-apoB 
production rate. Moreover, CETP did not affect the plasma TG clearance rate 
or organ-specific TG uptake after infusion of VLDL-like emulsion particles. In 
line with the absence of an effect of CETP on tissue-specific TG uptake, CETP 
also did not affect weight gain in response to a high fat diet. In conclusion, the 
CETP-induced increase of TG in the HDL fraction of E3L mice is not associated 
with changes in the production of TG or with tissue-specific clearance of TG 
from the plasma.




Cardiovascular disease (CVD) is one of the major causes of mortality 
in the Western world, and dyslipidemia is an important risk factor 
in the development of CVD. Low levels of HDL-cholesterol (C), high 
levels of VLDL- and LDL-C and high levels of triglycerides (TG) are 
independent risk factors for CVD120, 121. The ratio of (V)LDL-C to HDL-C is 
to a great extent affected by the cholesteryl ester transfer protein (CETP). 
 CETP mediates the bidirectional exchange of cholesteryl esters and TG 
between HDL and (V)LDL. CETP shifts cholesterol in plasma from HDL to 
(V)LDL and thereby aggravates atherosclerosis in the E3L mouse model 
which has a human-like lipoprotein metabolism116. The HDL-C-lowering 
effect of CETP has prompted the development of pharmacological CETP 
inhibitors, such as torcetrapib, as adjuvant therapy to the widely prescribed 
LDL-lowering statins. Although the first CETP inhibitor torcetrapib, 
recently failed116, 122, at least two novel CETP inhibitors (i.e. JTT-705 
and anacetrapib) are currently in different phases of clinical trials123, 124. 
 Despite the well described effects of CETP on plasma cholesterol metabolism, 
the role of CETP in TG metabolism has been studied less well. The torcetrapib 
and JTT-705 trials showed that inhibition of CETP in humans affects both the 
cholesterol and TG distribution over lipoproteins125, 126. It was also reported 
that JTT-705 reduces plasma TG in patients with combined hyperlipidemia127, 
which may reveal a beneficial effect of CETP inhibition on plasma TG levels. 
Furthermore, in rabbits, enrichment of HDL with TG by CETP increases the 
catabolism of HDL by hepatic lipase (HL)128. Thus, CETP has the potential to 
affect TG metabolism, which may have effects on tissue-specific lipid 
accumulation.
 VLDL-derived TG are lipolyzed in peripheral tissues by the enzyme 
lipoprotein lipase (LPL), whereas HDL-derived TG are presumably lipolyzed 
by HL and thus shunted to the liver. Therefore, we hypothesized that the CETP 
mediated net transfer of TG from (V)LDL to HDL modulates the tissue-specific 





Human CETP transgenic mice which express CETP under control of its natural 
flanking regions (strain 5203)129 were obtained from Jackson Laboratories (Bar 
Harbor, MC) and crossbred with E3L mice108 in our local animal facility to 
obtain heterozygous E3L.CETP mice116. Mice (12-16 weeks old) were housed in 
a temperature and humidity-controlled environment and were fed a standard 
chow diet with free access to water. Mice of 12 weeks of age were fed a high 
fat diet (60 energy% derived from bovine fat; D 12492, Research Diet Services, 
Wijk bij Duurstede, The Netherlands) for 12 weeks to induce obesity. Body 
weight was measured during the intervention and the delta was calculated. 
All animal experiments were approved by the Animal Ethics Committee from 
the Leiden University Medical Center and The Netherlands Organization for 
Applied Scientific Research (TNO), Leiden, The Netherlands. 
Plasma parameters
Plasma was obtained after overnight fasting (unless indicated otherwise) via 
tail vein bleeding in chilled paraoxon-coated capillary tubes to prevent ex vivo 
lipolysis, and assayed for TG and total cholesterol using commercially available 
kits 1488872 and 236691 from Roche Molecular Biochemicals (Indianapolis, IN, 
USA), respectively. Plasma CETP mass was analyzed using the CETP ELISA 
kit from ALPCO Diagnostics (Salem, NH, USA). FFA were measured using 
NEFA C kit from Wako Diagnostics (Instruchemie, Delfzijl, the Netherlands). 
HL activity in plasma was determined by measuring plasma triacylglycerol 
hydrolase activity as described earlier130.
Lipoprotein profiling 
To determine the lipid distribution over plasma lipoproteins, lipoproteins 
were separated using fast protein liquid chromatography (FPLC). Plasma was 
pooled per group, and 50 μL of each pool was injected onto a Superose 6 PC 
3.2/30 column (Äkta System, Amersham Pharmacia Biotech, Piscataway, NJ, 
USA) and eluted at a constant flow rate of 50 μL/min in PBS, 1 mM EDTA, 
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pH 7.4. Fractions of 50 μL were collected and assayed for cholesterol and TG 
as described above.
Postprandial response
Mice were fasted overnight with food withdrawn at 6:00 p.m. the day before the 
experiment. Mice received an intragastric olive oil load (Carbonell, Cordoba, 
Spain) of 200 μL. Prior to the bolus and 1, 2, 3, 4, 6 and 10 h after the bolus, 
blood samples (30 μL) were drawn via tail bleeding for TG determination as 
described above. The circulating levels were corrected for the levels of TG 
prior to the bolus and the area under the curve (AUC) was calculated over the 
period of 0-10 h using GraphPad software.
Hepatic VLDL-TG and VLDL-apoB production
Mice were fasted for 4 h with food withdrawn at 5:00 a.m. prior to the start 
of the experiment. During the experiment, mice were sedated with 6.25 mg/
kg acepromazine (Alfasan), 6.25 mg/kg midazolam (Roche), and 0.3125 mg/
kg fentanyl (Janssen-Cilag). At t=0 min blood was taken via tail bleeding and 
mice were i.v. injected with 100 μL PBS containing 100 μCi Trans35S label to 
measure de novo total apoB synthesis. After 30 min, the animals received 500 
mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body weight as a 
10% (w/w) solution in sterile saline, to prevent systemic lipolysis of newly 
secreted hepatic VLDL-TG131. Additional blood samples were taken at t=15, 
30, 60, and 90 min after tyloxapol injection and used for determination of 
plasma TG concentration. At 120 min, the animals were sacrificed and blood 
was collected by orbital puncture for isolation of VLDL by density gradient 
ultracentrifugation. 35S-labeled total apoB content was measured in the VLDL 
fraction after precipitation with isopropanol132, 133, 134.
In vivo clearance of VLDL-like emulsion particles
Glycerol tri[3H]oleate-labeled VLDL-like emulsion particles (80 nm) were 
prepared as described by Rensen et al.135. In short, radiolabeled emulsions were 
obtained by adding 200 μCi of glycerol tri[3H]oleate (triolein, TO) to 100 mg of 
emulsion lipids before sonication (isotope obtained from GE Healthcare, Little 
Chalfont, U.K.). Mice were fasted 4 h, sedated as described above and injected 
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with the radiolabeled emulsion particles (1.0 mg TG in 200 μL PBS) in the 
tail vein at 9:00 a.m. At indicated time points after injection, blood was taken 
from the tail vein to determine the serum decay of [3H]TO. At 15 min after 
injection, plasma was collected by orbital puncture and mice were sacrificed 
by cervical dislocation. Organs were harvested and saponified to determine 
[3H]TO uptake.
Tissue-specific FFA uptake from plasma TG
Mice were fasted for 4 h with food withdrawn at 5:00 a.m. prior to the start 
of the experiment. During the experiment, mice were sedated as described 
above. At t=0 min blood was taken via tail bleeding and mice received a 
continuous i.v. infusion of [3H]TO-labeled VLDL-like emulsion particles for 2 h 
(4.4 μCi [3H]TO and 1.2 μCi [14C]FA)136. Blood samples were taken using chilled 
paraoxon-coated capillaries by tail bleeding at 90 and 120 min of infusion to 
ensure that steady-state conditions had been reached. Subsequently, mice 
were sacrificed and organs were quickly harvested and snap-frozen in liquid 
nitrogen. Analysis and calculations were performed as described136. 
Statistical analysis
Differences between groups were determined with the unpaired T-test for 
normally distributed data (GraphPad Prism 5 software, La Jolla, CA). A 
P-value of less than 0.05 was considered statistically significant. Data are 
presented as means ± SEM.
Results
Plasma lipids, lipoprotein profiles and hepatic lipase activity
To investigate the role of CETP in TG metabolism, male and female E3L and 
E3L.CETP mice were fasted overnight and plasma lipid levels were determined 
(Table 1). Expression of CETP had no effect on total plasma lipid levels. Since 
we did not detect a difference between males and females, we decided to 
use males only for all subsequent experiments. Plasma lipoprotein profiles 
were determined on pooled plasma. Expression of CETP resulted in a shift of 
cholesterol from HDL to VLDL (Fig. 1A), as seen previously116, 119. Furthermore, 
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a small amount of TG was detected in the HDL fraction upon expression of 
CETP (insert Fig. 1B). HL activity was did not differ between E3L and E3L.
CETP mice (3.9 ± 1.5 vs 3.2 ± 1.3 μmol FFA/h/mL, respectively). This indicates 
that there is exchange of TG from the VLDL to the HDL fraction by CETP, 
which may be indicative of changes in TG metabolism. 
Table 1. Plasma parameters after an overnight fast.
 
males females
E3L E3L.CETP E3L E3L.CETP
triglycerides (mM) 2.39 ± 0.13 2.45 ± 0.26 2.59 ± 0.33 2.31 ± 0.46
total cholesterol (mM) 3.26 ± 0.11 2.91 ± 0.29 3.11 ± 0.23 3.09 ± 0.45
free fatty acids (mM) 1.09 ± 0.06 1.18 ± 0.07 1.18 ± 0.09 1.31 ± 0.10
CETP (mg/mL) n.d. 3.78 ± 0.36 n.d. 3.51 ± 0.43
Plasma was obtained from overnight fasted male and female E3L and E3L.CETP mice 
on a chow diet (n=12 per group). Plasma triglycerides, total cholesterol, free fatty acids 
and CETP levels were measured, n.d.; not detected.
Figure 1. Plasma lipoprotein profiles. 
12 h fasted mice were bled. Plasma was collected, pooled per group (n=12), and subjected 
to FPLC to separate lipoproteins Distribution of cholesterol (A) and triglycerides (B) over 
lipoproteins was determined.
32
Postprandial TG clearance 
To examine whether CETP-mediated transfer of TG from VLDL to HDL 
influences plasma TG metabolism, we determined postprandial TG response. 
After an overnight fast, mice received an intragastric gavage of olive oil. 
Plasma TG concentrations were measured over a 10 h-period and the AUC 
was calculated. Expression of CETP in E3L mice did not affect the postprandial 
TG changes in plasma (Fig. 2).
Figure 3. VLDL-TG and VLDL-apoB production. 
4 h fasted mice were consecutively injected with 
Trans35S label and tyloxapol and blood samples 
were drawn up to 90 min (n=4-6 per group). TG 
concentrations were determined in plasma and 
plotted as the increase in plasma TG (A). After 
120 min, the total VLDL fraction was isolated 
by ultracentrifugation and the rate of newly 
synthesized VLDL-apoB (B) and the ratio of TG 
over apoB (C) was calculated.
Figure 2. Postprandial plasma TG response. 
Overnight fasted mice received an 
intragastric olive oil gavage and blood 
samples were drawn up to 10 h (n=6-9 per 
group). Plasma TG concentrations were 
determined and area under the curve (AUC0-10) 
was calculated.
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VLDL-TG and VLDL-apoB production
To further examine the effect of CETP on TG metabolism we determined 
VLDL production. After 4 h of fasting, mice were injected with Trans35S and 
tyloxapol and the accumulation of endogenous VLDL-TG in plasma was 
measured over time. As is evident from Fig. 3A, the VLDL-TG production rate, 
as determined from the slope of the curve, was unchanged upon expression of 
CETP. Furthermore, the rate of VLDL-apoB production (Fig. 3B) as well as the 
ratio of TG over apoB (Fig. 3C), reflecting the amount of TG per VLDL particle, 
did not differ between E3L and E3L.CETP mice. 
VLDL-like emulsion-TG clearance
Clearance of TG from circulation is also a major determinant of TG metabolism 
and therefore we examined the effect of CETP on TG clearance from VLDL-like 
emulsions, which have previously been shown to mimic the metabolic behaviour 
of TG-rich lipoproteins135, 137. After 4 h fasting, mice were injected with a bolus of 
[3H]TO-labeled VLDL-like emulsion particles. The decay of [3H]TO in plasma 
was not affected by the expression of CETP (Fig. 4). The tissue-specific uptake 
of [3H]TO was not different between E3L and E3L.CETP mice (data not shown). 
To determine the body distribution of TG-derived FA in steady state, [3H]TO-
labeled VLDL-like emulsion particles together with albumin-bound [14C]FA 
were continuously infused for 2 h. No difference was observed in the serum 
half-life of [3H]TO between E3L and E3L.CETP mice (Fig. 5A). Also, the uptake 
of [3H]TO-derived radioactivity by liver, muscle, white adipose tissue (WAT) 
Figure 4. Plasma TG clearance. 
4 h fasted mice were injected with 1 mg TG 
as a constituent of VLDL-like [3H]TO-labeled 
emulsion particles (n=4-8 per group). Blood 
was collected at the indicated time points and 
radioactivity was measured in plasma. 
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and brown adipose tissue (BAT) was not altered due to the expression of CETP 
(Fig. 5B). The serum half-life and organ specific uptake of [14C]FA were also not 
changed upon expression of CETP (data not shown).
High fat diet-induced obesity
We and others have previously shown that modulation of tissue-specific TG-
derived FA delivery can have a major impact on the development of high fat 
diet-induced obesity (reviewed in138). To exclude the possibility that CETP 
expression results in a minor change in tissue-specific TG-derived FA uptake 
that over a prolonged period would affect the development of obesity, E3L 
and E3L.CETP mice were fed a high fat diet (60% energy% in the form of fat) 
for 12 weeks, and body weight was measured over time. The high fat diet did 
not affect plasma CETP levels in E3L.CETP mice  (3.8 ± 0.4 μg/mL on chow 
and 3.6 ± 0.3 μg/mL on high fat diet). Furthermore the high fat diet resulted 
in a similar decrease in plasma TG in both E3L and E3L.CETP mice (1.04 ± 0.11 
and 0.92 ± 0.14 mmol/L, respectively). CETP did not affect the high fat diet-
induced body weight gain at any time point during the 12 weeks (Fig. 6).
 
Figure 5. Plasma derived TG distribution over tissues.
4 h fasted mice were infused for 2 h with a trace of VLDL-like [3H]TO-labeled emulsion 
particles (n=7 per group). Blood and organs were collected. Radioactivity was measured in 
plasma lipid fractions after thin layer chromatography and the plasma half-life of [3H]TO 
was calculated (A). The specific [3H]TG activity in plasma was calculated based on the TG 
level, and the uptake of plasma TG by liver, skeletal muscle, white adipose tissue (WAT) 
and brown adipose tissue (BAT) was calculated (B). 




Novel drugs that inhibit CETP activity as therapy to increase HDL-C levels are 
in various stages of development123, 124. The rationale for development of these 
drugs is based on HDL-lowering effect of CETP due to the redistribution of 
cholesterol from HDL toward (V)LDL. Since CETP transfers both cholesterol 
and TG between lipoproteins, we here focused on the effect of CETP on TG 
metabolism. We studied the effect of CETP expression in E3L mice. The E3L 
mice display a human-like lipoprotein metabolism, and are an established 
model for hyperlipidemia and atherosclerosis (as reviewed in115). We 
recently reported the HDL-lowering and pro-atherogenic properties of CETP 
expression on the E3L background116. In this study, after 4 hour fasting, plasma 
cholesterol were somewhat higher in the E3L.CETP mice. In the current study, 
we find no changes in plasma total cholesterol and TG after overnight fasting. 
We do find a small increase in TG in the HDL fraction upon expression of 
CETP in E3L mice. Despite this relative increase in HDL-TG, CETP did not 
affect the postprandial TG response, hepatic VLDL-TG production, clearance 
of TG from VLDL-like emulsion particles and the development of high fat 
diet-induced obesity. These findings suggest that CETP-mediated transfer of 
TG from (V)LDL to HDL does not reflect a substantial effect on overall plasma 
TG metabolism in E3L mice. 
 There is some controversy on the effects of CETP on TG metabolism in 
various mouse models. Studies in mice, expressing simian CETP, show that 
on an atherogenic diet expression of CETP results in increased production 
Figure 6. High fat diet-induced obesity.
Mice were fed a high fat diet and body 
weight was measured during the dietary 
intervention and the increase in bodyweight 
was calculated (n=12 per group). 
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and clearance of TG139. Others have demonstrated that mice expressing 
human CETP when fed a regular chow diet show no alterations in VLDL-TG 
production140, 141. However, Salerno et al.140 showed that CETP-expressing mice 
have an increased postprandial TG response and decreased clearance of TG 
from the circulation. This was attributed to a decrease in LPL activity and LPL 
gene transcription. We did not find changes in the postprandial TG response or 
in the clearance of TG from the circulation in E3L.CETP mice versus E3L mice. 
We also did not find an effect of CETP in E3L mice on high fat diet-induced 
obesity. Since modification of tissue-specific FA delivery can significantly 
affect high-fat diet-induced obesity, this further confirms the absence of even a 
subtle effect of CETP on tissue-specific TG-derived FA uptake. It seems likely 
that the explanation for the discrepancy of our data with those of Salerno et 
al.140 is associated with the more human-like lipoprotein metabolism on the 
E3L background as indicated by presence of a substantial amount of apoB-
containing lipoproteins.
Enrichment of HDL with TG has a major impact on HDL metabolism. In 
humans, it has been demonstrated that cholesterol and apoAI within TG-rich 
HDL are cleared more rapidly as compared to those within TG-poor HDL142. 
Similar observations have been made in various animal models128, 143, 144. Thus, 
CETP-mediated TG enrichment of HDL has measurable effects on the kinetics 
of HDL-C and HDL-apoAI. Although these changes in HDL kinetics have the 
potential to have a substantial effect on TG metabolism, our results implicate 
that the CETP-mediated TG transfer does not alter the kinetics of TG clearance 
from the circulation.
This may be explained by the apparently small contribution of HDL-TG to 
the overall flux of TG. Especially in the postprandial state, the amount of TG 
in chylomicrons exceeds the amount of TG in HDL by far, even when CETP 
activity is high. Alternatively, HDL-TG may be readily lipolyzed by HL and 
the fate of the resulting FA may not be quantitatively different from FA derived 
from VLDL-TG. During lipolysis of VLDL-TG by LPL, a significant fraction of 
FA leaks to the circulation and is subsequently cleared by the liver136. Since it 
has been postulated that HDL-TG-derived FA are also cleared by the liver128, 
the fate of a substantial fraction of VLDL-TG derived FA and HDL-TG derived 
FA will thus be indistinguishable.
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In conclusion, we show that expression of CETP does not affect overall TG 
metabolism and high fat diet-induced obesity in E3L mice. This implicates 
that, at least under relatively normolipidemic conditions, pharmacological 
CETP inhibition is unlikely to disturb TG metabolism. 
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The PPARa activator fenofibrate efficiently decreases plasma triglycerides (TG), which is generally attributed to enhanced VLDL-TG clearance and decreased VLDL-TG production. However, since data 
on the effect of fenofibrate on VLDL production are controversial, we aimed to 
investigate in (more) detail the mechanism underlying the TG-lowering effect 
by studying VLDL-TG production and clearance using ApoE*3-Leiden.CETP 
mice, a unique mouse model for human-like lipoprotein metabolism. Male mice 
were fed a Western-type diet for 4 weeks, followed by the same diet without 
or with fenofibrate (30 mg/kg bodyweight/day) for 4 weeks. Fenofibrate 
strongly lowered plasma cholesterol (-38%; P<0.001) and TG (-60%; P<0.001) 
caused by reduction of VLDL. Fenofibrate markedly accelerated VLDL-TG 
clearance, as judged from a reduced plasma half-life of intravenously injected 
glycerol tri[3H]oleate-labeled VLDL-like emulsion particles (-68%; P<0.01). 
This was associated with an increased post-heparin LPL activity (+110%; 
P<0.0001) and an increased uptake of VLDL-derived fatty acids by skeletal 
muscle, white adipose tissue and liver. Concomitantly, fenofibrate markedly 
increased the VLDL-TG production rate (+73%; P<0.0001) but not the VLDL-
apoB production rate. Kinetic studies using [3H]palmitic acid showed that 
fenofibrate increased VLDL-TG production by equally increasing incorporation 
of re-esterified plasma FA and liver TG into VLDL, which was supported by 
hepatic gene expression profiling data. We conclude that fenofibrate decreases 
plasma TG by enhancing LPL-mediated VLDL-TG clearance, which results in 
a compensatory increase in VLDL-TG production by the liver.
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Introduction
The lipid-lowering agent fenofibrate reduces plasma triglyceride (TG) levels and 
increases HDL-cholesterol (HDL-C) levels, which generates a less atherogenic 
lipid phenotype120, 121. Fenofibrate acts through activation of peroxisome 
proliferator-activated receptor alpha (PPARa) thereby altering the expression 
of genes involved in lipid metabolism145, 146, 147. Several mechanisms of action 
have been proposed through which fenofibrate lowers TG levels, including 
increased VLDL-TG clearance and decreased hepatic TG production147.
VLDL-TG clearance is governed by lipoprotein lipase (LPL), of which the 
expression is potently induced by PPARa64. In addition, it has been shown that 
PPARa agonists down-regulate the expression of the LPL inhibitor apoCIII, 
and up-regulate the expression of the LPL activator apoAV63. Altogether this 
results in an increase in LPL-mediated lipolysis and clearance of VLDL. Indeed, 
two human studies show that fenofibrate increases the fractional catabolic rate 
(FCR) of VLDL-apoB in patients with hypertriglyceridemia without or with 
type 2 diabetes148, 149, which is associated with increased LPL activity148. 
Hepatic VLDL production is dependent on the availability of fatty acids (FA) 
which is determined by de novo FA synthesis, FA/TG uptake from the circulation 
and b-oxidation of FA in the liver. PPARa has been shown to influence VLDL 
production in mice. PPARa deficiency in mice increased hepatic VLDL-TG 
production150, 151, and the selective PPARa agonist Wy14643 lowered VLDL-
TG production, at least in severely hypertriglyceridemic Angptl4 transgenic 
mice152. Limited data exist on the specific effect of fenofibrate on hepatic 
VLDL production. Although in vitro experiments using cultured hepatocytes 
show that fenofibrate, among other fibrates, decreases the production of both 
VLDL-TG and apoB153, 154, in patients with the metabolic syndrome, fenofibrate 
treatment had no effect on the VLDL-apoB production rate149.
Our aim was to investigate in detail the mechanism underlying the 
VLDL-TG lowering effect of fenofibrate in vivo. We used ApoE*3-Leiden.
CETP (E3L.CETP) mice108, 116 that express human CETP under control of its 
natural flanking regions129. These mice have an attenuated clearance of apoB-
containing lipoproteins and, therefore, show a human-like lipoprotein profile 
on a cholesterol-rich Western-type diet114, 116. Our data show that treatment of 
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E3L.CETP mice on a Western-type diet with fenofibrate decreases plasma 
VLDL-TG as explained by increased VLDL-TG clearance resulting from 
enhanced LPL activity, but increases VLDL-TG production by increasing 
lipidation of apoB with TG that is equally derived from esterification of plasma 
FA and hepatic stores. 
Materials and Methods
Animals
Hemizygous human CETP transgenic mice, expressing a human CETP 
minigene under the control of its natural flanking regions129 were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and crossbred with hemizygous 
E3L mice108 at our Institutional Animal Facility to obtain E3L.CETP mice116. In 
this study, male E3L.CETP and wild-type mice (both C57Bl/6 background) 
were used, housed under standard conditions in conventional cages with 
free access to food and water. At the age of 12 weeks, mice were fed a semi-
synthetic cholesterol-rich diet, containing 0.25% (w/w) cholesterol, 1% (w/w) 
corn oil and 14% (w/w) bovine fat (Western-type diet) (Hope Farms, Woerden, 
The Netherlands) for four weeks. Upon randomization according to plasma 
total cholesterol (TC) and triglyceride (TG) levels, mice received Western-type 
diet without or with 30 mg/kg bodyweight/day (0.03%, w/w) fenofibrate 
(Sigma, St. Louis, MO, USA). This dose is relevant to the human situation, 
as it corresponds with 210 mg fenofibrate per day for a 70 kg-person taking 
into account a 10-fold higher (drug) metabolism in mice. Experiments were 
performed after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am. 
The institutional Ethical Committee on Animal Care and Experimentation has 
approved all experiments.
Plasma parameters
Plasma was obtained via tail vein bleeding as described130 and assayed for TC 
and TG, using the commercially available enzymatic kits 236691 and 11488872 
(Roche Molecular Biochemicals, Indianapolis, IN, USA), respectively. The 
distribution of lipids over plasma lipoproteins was determined using fast 
protein liquid chromatography (FPLC). Plasma was pooled per group, and 50 
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μL of each pool was injected onto a Superose 6 PC 3.2/30 column (Äkta System, 
Amersham Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant 
flow rate of 50 μL/min in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 μL were 
collected and assayed for TC and TG as described above. HDL was isolated 
after precipitation of apoB-containing lipoproteins from 20 μL EDTA plasma 
by adding 10 μL heparin (LEO Pharma, The Netherlands; 500 U/mL) and 10 
μL 0.2 M MnCl2. The mixtures were incubated for 20 min at room temperature 
and centrifuged for 15 min at 13,000 rpm at 4°C. HDL-C was measured in 
the supernatant using enzymatic kit 236691 (Roche Molecular Biochemicals, 
Indianapolis, IN, USA).
In vivo clearance of VLDL-like emulsion particles
Glycerol tri[3H]oleate (triolein, TO)- and [1a,2a(n)-14C]cholesteryl oleate 
(CO)-double labeled VLDL-like emulsion particles (80 nm) were prepared as 
described by Rensen et al.135. In short, radiolabeled emulsions were obtained by 
adding 100 μCi of [3H]TO and 10 μCi of [14C]CO to 100 mg of emulsion lipids 
before sonication (isotopes obtained from GE Healthcare, Little Chalfont, U.K.). 
Mice were fasted for 4 h, sedated with 6.25 mg/kg acepromazine (Alfasan), 
6.25 mg/kg midazolam (Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag) 
and injected with the radiolabeled emulsion particles (1.0 mg TG in 200 μL 
PBS) via the tail vein. At indicated time points after injection, blood was taken 
from the tail vein to determine the serum decay of [3H]TO and [14C]CO. At 30 
min after injection, plasma was collected by orbital puncture and mice were 
sacrificed by cervical dislocation. Organs were harvested and saponified to 
determine [3H]TO and [14C]CO uptake.
Hepatic lipase and lipoprotein lipase assay
To liberate LPL from endothelium, 4 h fasted mice were injected intra-
peritoneally with heparin (0.5 U/g bodyweight; Leo Pharmaceutical Products 
BV., Weesp, The Netherlands) and blood was collected after 20 min. Total hepatic 
lipase (HL) and LPL activity was analyzed as modified from Zechner155. In 
short, 10 μL of post-heparin plasma was incubated with 0.2 mL of TG substrate 
mixture containing triolein (4.6 mg/mL) and [3H]TO (2.5 μCi/mL) 130 for 30 
min at 37°C in the presence or absence of 1 M NaCl, which completely inhibits 
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LPL activity, to estimate both the HL and LPL activity. The LPL activity was 
calculated as the fraction of total triacylglycerol hydrolase activity that was 
inhibited by the presence of 1 M NaCl and is expressed as the amount of free 
FA released per hour per mL of plasma.
Hepatic VLDL-TG and VLDL-apoB production
Mice were fasted for 4 h prior to the start of the experiment. During the 
experiment, mice were sedated as described above. At t=0 min blood was 
taken via tail bleeding and mice were i.v. injected with 100 μL PBS containing 
100 μCi Trans35S label to measure de novo total apoB synthesis. After 30 min, 
the animals received 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per 
kg body weight as a 10% (w/w) solution in sterile saline, to prevent systemic 
lipolysis of newly secreted hepatic VLDL-TG131. Additional blood samples 
were taken at t=15, 30, 60, and 90 min after tyloxapol injection and used for 
determination of plasma TG concentration. At 120 min, the animals were 
sacrificed and blood was collected by orbital puncture for isolation of VLDL 
by density gradient ultracentrifugation. 35S-apoB was measured in the VLDL 
fraction after apoB-specific precipitation with isopropanol134, 133, 132.
Hepatic lipid analysis
Livers were isolated and partly homogenized (30 sec at 5,000 rpm) in saline 
(approx. 10% wet w/v) using a mini-bead beater (Biospec Products, Inc., 
Bartlesville, OK, USA). Lipids were extracted as described156 and separated 
by high performance thin layer chromatography (HPTLC). Lipid spots were 
stained with color reagent (5 g MnCl2.4H2O, 32 mL 95-97% H2SO4 added to 960 
mL of CH3OH:H2O 1:1 v/v) and quantified using TINA
® version 2.09 software 
(Raytest, Straubenhardt, Germany).
Hepatic gene expression analysis
Total RNA was extracted from individual livers using RNA-Bee (Bio-Connect, 
Huissen, The Netherlands) and glass beads according to the manufacturer’s 
instructions. The RNA was further purified using the nucleospin RNA II 
kit (Machery-Nagel, Düren, Germany) according to the manufacturer’s 
instructions. The integrity of each RNA sample obtained was examined by 
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Agilent Lab-on-a-chip technology using a RNA 6000 Nano LabChip kit and a 
Bioanalyzer 2100 (Agilent Technologies, Amstelveen, The Netherlands). The 
Affymetrix 3’ IVT-Express labeling Kit (#901229) and the protocols optimized 
by Affymetrix were used to synthesize Biotin-labeled cRNA (from 100 ng of 
total RNA) for microarray hybridization. For the hybridization 15 μg cRNA 
was used for further fragmentation and finally 10 μg for the hybridizations. The 
quality of intermediate products (that is, biotin-labeled cRNA and fragmented 
cRNA) was again checked. 
Microarray analysis was carried out using an Affymetrix technology 
platform and Affymetrix GeneChip® mouse genome 430 2.0 arrays. Briefly, 
fragmented cRNA was mixed with spiked controls and hybridized with 
murine GeneChip® 430 2.0 arrays. The hybridization, probe array washing 
and staining, and washing procedures were executed as described in the 
Affymetrix protocols, and probe arrays were scanned with a Hewlett-Packard 
Gene Array Scanner (ServiceXS, Leiden, The Netherlands). Quality control 
of microarray data was performed using BioConductor packages (including 
simpleaffy and affyplm), through the NuGO pipeline that is available as 
a Genepattern procedure on http://nbx2.nugo.org157. All samples passed 
the QC. Raw signal intensities (from CEL-files) were normalized using the 
GCRMA algorithm (gc-rma slow). For annotation of probes and summarization 
of signals from probes representing one gene the custom MNBI CDF-file 
was used (based on EntrezGene, version 11.0.2) (http://brainarray.mbni.
med.umich.edu/Brainarray/Database/CustomCDF/cdfreadme.htm). This 
resulted in expression values for 16331 genes, represented by unique Entrez 
gene identifiers. Genes were filtered for expression above 5 in 3 or more 
samples, resulting in a set of 11587 genes that was used for further analysis. 
Gene expression data were log-transformed (base 2). 
Statistical analysis on resulting data was performed using the moderated 
t-test (Limma: http://bioinf.wehi.edu.au/limma/) with correction for multiple 
testing158. Cut-off for statistically significant changes was set at corrected 
P-value (q-value) <0.05. In addition, T-profiler analysis159 was performed using 
expression values corrected for mean expression in the control group. This 
analysis resulted in scores (t-scores) and significance values for functional gene 
sets and biological processes (based on gene ontology annotation). Gene sets 
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and biological processes with significant scores (>4 or <-4) in 5 or 6 animals per 
group were selected. A hierarchical clustering of these pathways and biological 
processes and their scores in all samples was generated in GenePattern (Broad 
Institute, MIT, USA)160.
Analysis of pathways contributing to hepatic VLDL-TG secretion
Mice were fasted for 2 h with food withdrawn at 8:00 a.m. prior to the start of 
the experiment. During the experiment, mice were sedated as described above. 
At t=-2 h mice received a continuous i.v. infusion of 3H-labeled FA ([9,10(n)-3H]
palmitic acid in sterile saline with 2% BSA) at a rate of 100 μL/h (1.6 μCi/h). 
Blood samples were taken at t=-30 and 0 min, and the mice received 500 mg 
of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body weight as a 10% 
(w/w) solution in sterile saline. Additional blood samples were taken at t=15, 
30, 60, and 90 min after tyloxapol injection. All blood samples were taken using 
chilled paraoxon-coated capillaries. 
Plasma TG and FA were determined as described above. The amount of 
3H-activity in the FA and TG fraction of all plasma samples was determined 
after lipid extraction from plasma according to Bligh and Dyer156. The lipid 
fraction was dried under nitrogen, dissolved into chloroform/methanol (5:1 
[vol/vol]) and subjected to thin layer chromatography (TLC) on silica gel 
plates by using hexane/diethylether/acetic acid (83:16:1, vol/vol/vol) as 
resolving solution. Triolein and palmitic acid were used as internal standards. 
Plasma samples obtained at t=-30 and 0 min were used to ensure steady state 
was reached for the specific activity (SA) of both [3H]FA as well as [3H]TG prior 
to the tyloxapol injection. 
The production rate of [3H]TG and TG was calculated from the slope of 
the curve from t=0 to t=90 min and expressed as dpm/min and nmol/min, 
respectively. As the production rate of [3H]TG represents the rate of FA 
produced as TG, the production rate of FA within TG was calculated by 
multiplying the TG production rate by 3. This production rate represents the 
total rate of FA incorporation into VLDL-TG. The specific activity (SA) of the 
VLDL precursor pool (pTG) is given by the ratio of [3H]TG production and 
TG production (Equation 1; production rate is indicated with an accent ‘). 
The relative contribution of plasma FA to the VLDL-TG precursor pool can 
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be estimated by dividing the SA of the pTG pool by the average SA of plasma 
FFA (Equation 2; average was taken over the time interval t=-30 to +60 min). 
Equation 2 gives the ratio of the rate of incorporation of FA in VLDL-TG, that 
is directly derived from plasma (V1), and the total rate of FA incorporation into 
VLDL-TG (V1+V2; see also Fig. 6C); the contribution of liver TG to VLDL-TG 
is represented by V2. By Equation 1 and 2 and the definition (TG)’ = V1+V2, we 
obtain an expression for V1 (Equation 3). 
Equation 1: SA pTG = ([3H]TG)’ / (TG)’ [dpm/μmol TG]
Equation 2: Contribution of plasma FA to VLDL-TG production 
  = (SA pTG / SA-FAt-30–+60)*100 (%)
Equation 3: V1 = ([
3H]TG)’ / SA-FAt-30 – +60 [nmol/min] 
Statistical analysis
All data are presented as means ± SEM unless indicated otherwise. Data were 
analyzed using the unpaired Student’s t test. P-values less than 0.05 were 
considered statistically significant.
Results
Fenofibrate decreases VLDL and increases HDL in E3L.CETP mice
To confirm that fenofibrate decreases VLDL-TG in E3L.CETP mice, mice 
were fed a cholesterol-rich Western-type diet for 4 weeks (t0). Mice were 
randomized, and fed the same diet without (time-matched control group) 
or with fenofibrate (30 mg/kg bodyweight/day) for another 4 weeks (t4). At 
both t0 and t4, plasma was assayed for lipids (Fig. 1). As compared to the 
time-matched control group, fenofibrate decreased plasma cholesterol (-38%; 
5.0±0.2 versus 8.0±0.7 mmol/L; P<0.001) (Fig. 1A). Lipoprotein profiling 
showed that this was the net effect of a large reduction of VLDL-C (~85%) and 
an increase in HDL-C (~55%) (Fig. 1B). The increase in HDL-C was confirmed 
by directly measuring HDL-C in plasma after precipitation of apoB-containing 
lipoproteins (+52%; 2.1±0.1 versus 1.4±0.1 mmol/L; P<0.001) (Fig. 1C). 
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The decrease in VLDL-C was accompanied by a large reduction in plasma TG 
(-60%; 0.7±0.2 versus 1.9±0.2; P<0.001) (Fig. 1D), which was specific for VLDL 
(not shown).
Fenofibrate increases VLDL-TG clearance by enhancing VLDL-TG hydrolysis and 
hepatic uptake of VLDL remnants
Plasma VLDL-TG levels are determined by the balance between VLDL-TG 
production and VLDL-TG clearance. To evaluate whether an increased VLDL-
TG clearance may contribute to the fenofibrate-mediated reduction in VLDL-
TG levels, control and fenofibrate-treated E3L.CETP mice were injected with 
Figure 1. Fenofibrate decreases VLDL-TG and VLDL-cholesterol in E3L.CETP mice.
Mice received a Western-type diet without and with fenofibrate (0.03% w/w). At baseline 
(t0) and after 4 weeks of intervention (t4), 4 h-fasted blood was taken and plasma was 
assayed for total cholesterol (A). After 4 weeks of intervention cholesterol distribution over 
lipoproteins was determined (B). At t0 and t4, HDL-cholesterol (C) and TG (D) were also 
assayed. Data are means ± SEM (n=8). ***P<0.001.
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[3H]TO- and [14C]CO-labeled VLDL-like emulsion particles and the plasma 
clearance was determined (Fig. 2). Fenofibrate reduced the plasma half-life of 
[3H]TO as compared to time-matched control mice by -68% (t1/2 = 6.8±0.9 min 
versus 21.0±6.3 min; P<0.005) (Fig. 2A) as reflected by an increase in uptake of 
[3H]TO-derived activity by liver, skeletal muscle and white adipose tissue (Fig. 
2B). Likewise, fenofibrate reduced the plasma half-life of [14C]CO by -80% (t1/2 
= 11.0±1.7 min versus 56.6±11.7 min; P<0.005) (Fig 2C), as mainly reflected by 
an increased uptake of [14C]CO by the liver (Fig. 2D). 
Figure 2. Fenofibrate increases the clearance of VLDL-like emulsion particles in E3L.
CETP mice.
Mice received a Western-type diet without or with fenofibrate (0.03% w/w). After 4 h 
fasting, mice were injected with [3H]TO and [14C]CO-labeled VLDL-like emulsion particles 
(1 mg TG) and plasma samples were taken at indicated time points to determine the plasma 
clearance of [3H]TO (A) and [14C]CO (C). At 30 min after injection, the uptake of 3H-activity 
(B) and 14C-activity (D) was determined in liver, heart, skeletal muscle and gonadal white 
adipose tissue (gWAT). Data are means ± SEM (n=5). *P<0.05; **P<0.01; ***P<0.001.
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To determine whether the accelerated clearance of VLDL-like emulsion 
particles was due to an increase in the lipolytic activity of plasma, HL and LPL 
activity was determined in plasma after heparin injection (Fig. 3). Fenofibrate 
increased postheparin plasma HL activity by +67% (12.3±1.4 versus 7.4±0.9 
μmol FFA/h/mL; P<0.0001) as well as postheparin plasma LPL activity by 
+110% (25.1±3.1 versus 12.0±2.5 μmol FFA/h/mL; P<0.0001).
Fenofibrate increases VLDL-TG production but not VLDL-apoB production
To determine the effect of fenofibrate on VLDL-TG production by the liver, 
control and fenofibrate-treated E3L.CETP mice were injected with Trans35S 
and tyloxapol and VLDL production was determined (Fig. 4). Surprisingly, 
fenofibrate caused an increase in the accumulation of plasma TG (Fig. 4A). 
The VLDL-TG production rate, as determined from the slope of the curve, was 
increased by +73% (11.8±0.6 versus 6.8±0.5 μmol TG/h; P<0.0001) (Fig. 4B). 
The rate of VLDL-apoB production was not altered (Fig. 4C), indicating that 
fenofibrate increases the lipidation of VLDL particles in the liver rather than the 
number of VLDL particles secreted from the liver. Fenofibrate thus increased 
the amount of TG per mg of VLDL protein by +58% (48.3±4.0 versus 30.9±2.7 
μmol/mg; P<0.01) (Fig. 4D). 
To exclude the possibility that the paradoxical increase VLDL-TG 
production was specific for E3L.CETP mice, we also determined the effect of 
fenofibrate on VLDL production in wild-type mice (Fig. 5). Like in E3L.CETP 
mice, fenofibrate increased the VLDL-TG production rate (10.0±0.3 versus 
7.3±0.3 μmol TG/h; P<0.0001) (Fig. 5A, B). Furthermore, fenofibrate slightly 
Figure 3. Fenofibrate increases hepatic lipase 
and lipoprotein lipase activity in postheparin 
plasma of E3L.CETP mice.
Mice received a Western-type diet without or 
with fenofibrate (0.03% w/w). After 4 h fasting, 
heparin was injected and postheparin plasma 
was collected. Plasma was incubated with a [3H]
TO-containing substrate mixture in the absence 
or presence of 1 M NaCl, to estimate both the HL 
and LPL activity. Data are means ± SEM (n=8). 
****P<0.0001
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decreased the VLDL-apoB production rate (32.2±1.7 versus 37.3±1.6; P<0.05) 
(Fig. 5C) and increased the amount of TG per mg of VLDL protein (28.4±0.7 
versus 25.4±0.8 μmol/mg; P<0.05) (Fig. 5D).
Figure 4. Fenofibrate increases hepatic VLDL-TG production in E3L.CETP mice.
Mice received a Western-type diet without or with fenofibrate (0.03% w/w). After 4 h fasting, 
mice were consecutively injected with Trans35S label (t=-30 min) and tyloxapol (t=0 min) and 
blood samples were drawn up to 90 min after tyloxapol injection. Plasma TG concentrations 
were determined and plotted as the increase in plasma TG as compared to baseline (A). The 
rate of TG production was calculated from the slopes of the curves from the individual mice 
(B). After 120 min, the total VLDL fraction was isolated by ultracentrifugation and the rate 
of newly synthesized VLDL-35S-apoB (C) as well as the amount of triglycerides (TG), total 
cholesterol (TC) and phospholipids (PL) per mg VLDL protein (D) was measured. Data are 
means ± SEM (n=9). *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001
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Fenofibrate decreases hepatic lipid content
Since an increase in VLDL production may result from an increased hepatic 
TG content161, 27, we determined the effect of fenofibrate on hepatic lipid levels 
(Fig. 6). However, fenofibrate in fact tended to reduce the hepatic TG content 
by -20% (59.9±6.5 versus 74.5±7.2 mg/mg protein; P=0.162) (Fig. 6A). In 
addition, fenofibrate decreased the hepatic free cholesterol content by -19% 
Figure 5. Fenofibrate increases hepatic VLDL-TG production in wild-type mice.
Mice received a Western-type diet without or with fenofibrate (0.03% w/w). After 
4 h fasting, mice were consecutively injected with Trans35S label and tyloxapol 
and blood samples were drawn up to 90 min after tyloxapol injection. Plasma TG 
concentrations were determined and plotted as the increase in plasma TG (A). 
The rate of TG production was calculated from the slopes of the curves from 
the individual mice (B). After 120 min, the total VLDL fraction was isolated by 
ultracentrifugation and the rate of newly synthesized VLDL-apoB (C) as well as 
the amount of triglycerides (TG), total cholesterol (TC) and phospholipids (PL) per 
mg protein (D) was measured. Data are means ± SD (n=8-10). *P<0.05; ***P<0.001.
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(11.7±0.3 versus 14.3±0.6 mg/mg protein; P<0.01) (Fig. 6B) as well as the 
hepatic cholesteryl ester content by -51% (11.9±0.6 versus 24.6±1.4; P<0.0001) 
(Fig. 6C).
Fenofibrate increases expression of hepatic genes involved in FA uptake and transport
To further investigate the mechanism(s) by which fenofibrate affects VLDL-
TG metabolism, we determined the hepatic expression profile of 16331 well 
characterized mouse genes. As compared to the control group, fenofibrate 
resulted in 2924 differentially expressed genes. Pathway analysis, based on 
gene ontology annotation, revealed that fenofibrate up-regulated gene sets 
related to PPAR activation and lipid/energy metabolism and down-regulated 
gene sets related to inflammation (Supplemental Fig. 1).
A selection of genes involved in VLDL metabolism is depicted in Table 1. As 
expected, fenofibrate upregulated genes involved in FA oxidation including 
Cpt1a, Cpt1b, Acox1, Acaa1a, Acaa1b and Acaa2. In line with our observation 
that fenofibrate increases VLDL-TG clearance and LPL activity in postheparin 
plasma, fenofibrate largely upregulated Lpl and slightly decreased Apoc3. 
Figure 6. Fenofibrate decreases hepatic lipid 
content in E3L.CETP mice.
Mice received a Western-type diet without 
or with fenofibrate (0.03% w/w). Livers 
were collected after a 4 h fast and lipids 
were extracted. Triglycerides (TG) (A), free 
cholesterol (FC) (B) and cholesteryl esters 
(CE) (C) were quantified. Data are means ± 
SEM (n=6). **P<0.01; ***P<0.001
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Fenofibrate did not largely affect FA/TG synthesis genes, apart from increasing 
Dgat1. Rather, fenofibrate upregulated genes involved in FA uptake (Cd36, 
Ldlr), FA transport (Slc27a1, Slc27a2, Slc27a4 and Slc27a5), FA binding (Fabp1, 
Fabp2, Fabp4 and Fabp7), FA activation (Acsl1, Acsl3, Acsl4 and Acsl5) and VLDL 
assembly (Mttp). Taken together, these data suggest that fenofibrate increases 
hepatic VLDL-TG secretion through increased hepatic uptake, intracellular 
trafficking and secretion of excess FA derived from extrahepatic LPL-derived 
lipolysis, rather than by increased de novo FA synthesis.
Table 1. Effect of fenofibrate on hepatic expression of genes involved in 
VLDL metabolism
 
 Protein Gene Fold change (vs control) Corrected P-value
FA oxidation
CPT1a Cpt1a +1.28 0.010
CPT1b Cpt1b +6.08 <0.001
ACO Acox1 +1.51 <0.001
Thiolase Acaa1a +1.89 <0.001
Thiolase Acaa1b +1.29 <0.001
Thiolase Acaa2 +1.21 <0.001
Lipolysis
LPL Lpl +4.63 <0.001
ApoCI Apoc1 -1.03 0.235
ApoCII Apoc2 -1.04 0.402
ApoCIII Apoc3 -1.08 0.014
ApoAV Apoa5 -1.15 0.065
GPIHBP1 Gpihbp1 1.08 0.344
FA/TG synthesis
SREBP1a/c Srebf1 -1.11 0.350
FAS Fasn +1.90 0.068
DGAT1 Dgat1 +1.48 0.002
DGAT2 Dgat2 -1.17 0.046
SCD1 Scd1 +1.24 0.207
SCD2 Scd2 +1.09 0.247
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Protein Gene Fold change (vs control) Corrected P-value
FA uptake and transport
FATPa1 Slc27a1 +4.59 <0.001
FATPa2 Slc27a2 +1.15 0.001
FATPa4 Slc27a4 +3.30 <0.001
FATPa5 Slc27a5 -1.07 0.181
CD36 Cd36 +3.42 <0.001
LDLR Ldlr +1.52 0.016
PCSK9 Pcsk9 +1.64 0.110
FA binding and activation
FABP1 Fabp1 +1.10 0.012
FABP2 Fabp2 +1.36 0.006
FABP4 Fabp4 +2.19 <0.001
FABP6 Fabp6 +1.05 0.412
FABP7 Fabp7 -3.48 <0.001
ACSL1 Acsl1 +2.15 <0.001
ACSL3 Acsl3 +3.07 <0.001
ACSL4 Acsl4 +1.58 <0.001
ACSL5 Acsl5 +1.49 0.001
VLDL assembly
ApoB Apob -1.02 0.374
ApoBEC Apobec1 1.00 0.515
MTP Mttp +1.42 <0.001
Mice received a Western-type diet without or with fenofibrate (0.03% w/w). Livers 
were collected after a 4 h fast, total RNA was extracted, and gene expression analysis 
was performed using Affymetrix GeneChip mouse genome 430 2.0 arrays. Data are 
expressed as mean fold change as compared to the control group (n=6 per group). 
Values in bold are considered significant (corrected P-value or q-value <0.05).
Fenofibrate increases VLDL-TG production by equally increasing incorporation of re-
esterified plasma FA and liver-derived TG into VLDL
We next investigated whether the increase in VLDL-TG production is 
solely the result of an increased flux of plasma FA towards the liver, and 
subsequent incorporation into nascent VLDL after re-esterification into TG. 
Hereto, we continuously infused [3H]palmitic acid while measuring the linear 
accumulation of VLDL-derived TG and [3H]TG in plasma after injection of 
tyloxapol (Fig. 7).
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Fenofibrate not only increased the production rate of both VLDL-TG (+31%; 
P<0.05) (Fig. 7A), which is consistent with Fig 4A, but also increased the 
production rate of VLDL-[3H]TG (+63%; P<0.05) (Fig. 7B). Fig. 7C schematically 
represents the model used to determine the contribution of plasma FA (V1) 
as compared to contribution of liver TG (V2) to the VLDL-TG production 
(V1 + V2). Calculating the ratio of V1 over V1+V2 shows that the estimated 
contribution of re-esterification of plasma FA to the total VLDL production was 
Figure 6. Fenofibrate equally increases the incorporation of both plasma FA and liver TG 
in VLDL-TG in E3L.CETP mice.
Mice received a Western-type diet without or with fenofibrate (0.03% w/w). Mice were 
continuously infused with [3H]palmitic acid after 2 h of fasting, and received tyloxapol after 
4 h of fasting, and the increase in plasma TG (A) and [3H]TG (B) was subsequently measured. 
According to the equations as schematically represented (C), the relative contribution of re-
esterified plasma FA to VLDL-TG production was calculated (D). Data are means ± SEM 
(n=5). *P<0.05. V1, incorporation rate of plasma FA in VLDL-TG; V2, incorporation rate of 
liver TG in VLDL-TG; pTG, VLDL precursor pool.
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equal for both control and fenofibrate treated mice (46±15% vs 49±11%; n.s.) 
(Fig. 7D). These data imply that fenofibrate increases VLDL-TG production by 
equally increasing incorporation of re-esterified plasma FA and liver-derived 
TG. Indeed, fenofibrate increased VLDL-TG production by an increased 
incorporation of plasma FA (+38%) as well as liver TG (+25%).
Discussion
We investigated the mechanisms underlying the effect of fenofibrate on VLDL 
metabolism. Our data show that fenofibrate decreases plasma TG levels in 
E3L.CETP mice, which is solely explained by an increased LPL-mediated TG 
clearance from plasma. Despite the generally accepted dogma that fenofibrate 
reduces VLDL-TG production thereby contributing to the plasma TG-lowering 
effect, fenofibrate in fact increases VLDL-TG production as caused in part by 
an increased flux of FA to the liver.
In this study, we have used E3L.CETP mice to study the effect of fenofibrate 
on VLDL metabolism, at a dose relevant to clinical practice in humans. We 
have previously observed that these mice show a human-like response to drug 
interventions aimed at reducing plasma levels of apoB-containing lipoproteins, 
including atorvastatin118, niacin117 and fenofibrate114. In the present study, we 
confirmed that fenofibrate effectively reduces plasma TG levels (-60%) and 
cholesterol levels (-38%), which was the combined result of a decrease in 
VLDL-C (~85%) and an increase in HDL-C (~55%). Recently, we have shown 
that the HDL-raising effect of fenofibrate is explained by a reduction in hepatic 
cholesterol levels, which decreases hepatic CETP expression and consequently 
reduces plasma CETP levels114, an effect that has also been observed in 
humans162.
Since plasma VLDL-TG levels are determined by the balance between 
VLDL-TG production and VLDL-TG clearance, we evaluated the individual 
contribution of both pathways to the TG-lowering effect of fenofibrate. We 
observed that the TG-lowering effect of fenofibrate can be fully explained by 
an accelerated TG clearance from plasma. Fenofibrate appeared to increase the 
total triacylglycerol hydrolase capacity of plasma, as evidenced by increased 
HL activity (+67%) and LPL activity (+110%) in post-heparin plasma, which is 
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likely due to increased whole-body expression of the lipase genes as reflected 
by a large 4.6-fold increase in hepatic Lpl mRNA. It is likely that fenofibrate 
further increases TG clearance by indirectly enhancing LPL activity via reduced 
hepatic mRNA expression of the main LPL inhibitor apoCIII. These changes 
are consistent with previous observations on the effects of fibrates on LPL64 
and apoCIII63 in rodents. Likewise, fibrates have been shown to increase LPL 
activity148, 163 and decrease apoCIII synthesis63, 149, 164 in humans.
In contrast to the generally accepted view that a reduction of the VLDL-
TG production contributes to the TG-lowering effect of fenofibrate, we now 
clearly demonstrate that fenofibrate in fact increases the VLDL-TG production 
in E3L.CETP mice. To exclude that this effect would be genotype-specific, we 
confirmed that fenofibrate increases VLDL-TG production in wild-type mice. 
In both mouse types, fenofibrate did not increase the VLDL-apoB production 
rate, implying that fenofibrate increases the lipidation of VLDL particles rather 
than affecting the VLDL particle production rate.
It is tempting to speculate about the mechanism(s) underlying the 
increasing effect of fenofibrate on VLDL-TG production. VLDL-TG production 
is determined by the balance between hepatic FA b-oxidation, FA/TG entry 
into the liver, hepatic FA/TG synthesis and hepatic TG stores. Fenofibrate 
increased hepatic genes involved in FA b-oxidation, which was expected 
from its PPARa agonistic activity165, 166, 167. Affymetrix analysis indicated that 
hepatic genes involved in FA/TG synthesis were generally not affected. 
However, many genes involved in FA uptake and transport (Slc27a, Cd36, 
Ldlr), FA binding and activation (Fabp, Acsl) and FA esterification (Dgat1) 
were upregulated, in addition to Mttp that is crucial for VLDL assembly. In 
general, these data are in line with previous reports that PPARa induces genes 
involved in TG synthesis and apoB lipidation168, 169. Collectively, these data 
suggest that fenofibrate may increase the uptake of FA by the liver, followed by 
the intrahepatic binding, activation, esterification, and ultimately secretion of 
FA as VLDL-TG. Indeed, by performing kinetic analyses using intravenously 
injected 3H-FA, we demonstrated that fenofibrate increased the incorporation 
rate of plasma FA into nascent VLDL-TG. At the same time, fenofibrate also 
increased the incorporation rate of a hepatic pool of FA/TG into nascent 
VLDL-TG. The observed tendency towards a reduction in liver TG content can 
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thus be explained by a combination of an increased FA b-oxidation as well as 
an increased secretion of hepatic TG stores incorporated in VLDL.
Taken together, the effect of fenofibrate with respect to reduction of plasma 
TG levels is primarily caused by an enhanced TG hydrolysis in the capillary 
bed of LPL-expressing tissues such as skeletal muscle and white adipose tissue. 
Liberated FA are not only taken up by these tissues, but also redirected towards 
the liver as bound to albumin136. An increased FA flux towards the liver may 
then drive increased lipidation of nascent VLDL particles without influencing 
the VLDL particle production rate as judged from an unaltered VLDL-apoB 
production rate. Although the effect of fenofibrate on the VLDL-TG production 
rate has not been studied in humans, fenofibrate has been shown to reduce 
VLDL-apoB levels without affecting the VLDL-apoB production rate170, 149, 
which is agreement with our data.
So, how can we reconcile our data with the accepted dogma that fenofibrate 
would decrease VLDL-TG production? First, it has been generally assumed that, 
via increased FA b-oxidation, fenofibrate reduces the amount of FA available for 
VLDL-TG output147. However, we previously showed that specific inhibition of 
FA b-oxidation using methyl palmoxirate does not affect VLDL-TG production 
despite increasing hepatic TG content171. Moreover, this simplified assumption 
does not take into account that fenofibrate in fact increases the liver-directed 
flux of FA/TG. Second, a few models have suggested that fenofibrate reduces 
VLDL-TG production150, 151, 172, 173. For example, mice deficient for PPARa have 
increased VLDL-TG production150, 151. However, this could easily be caused by 
compensatory changes resulting from complete deficiency of PPARa. It would 
thus be more relevant to study PPARa activation instead of complete PPARa 
deficiency. Activation of PPARa has been shown to inhibit VLDL-TG secretion 
by primary rat hepatocytes in vitro172. This can indeed be explained by an 
increase in FA b-oxidation, but it should be realized that such a study set-up 
obviously does not take into account an increased FA flux from peripheral 
tissues towards hepatocytes. A single in vivo study in mice, which were 
deficient for the LDL receptor (LDLr) and fed a high fat diet, showed that 
fenofibrate reduced VLDL-TG production173. It is likely that the absence of the 
LDLr may have prevented the efficient hepatic uptake of VLDL remnants in 
that study. We observed that fenofibrate increased both the plasma clearance 
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and liver uptake of VLDL core remnants. Furthermore, fenofibrate decreased 
the hepatic cholesterol content (which was also observed in the LDLr-deficient 
mice173 and resulted in an expected increase in hepatic LDLr expression in our 
study. It is thus conceivable that the LDLr plays an important role in the influx 
of remnant-TG upon treatment with fenofibrate. In addition, an alternative 
uptake route of VLDL remnants, in case of LDLr-deficiency, may result in 
a different intracellular distribution of remnant-derived TG that is a less 
accessible source for VLDL-TG production.
In conclusion, our data demonstrate that fenofibrate decreases plasma TG by 
enhancing LPL-mediated VLDL-TG clearance. As a consequence, fenofibrate 
increases VLDL-TG production by the liver as caused by 1) enhanced hepatic 
FA/TG uptake resulting from strongly accelerated peripheral LPL-mediated 
VLDL-TG hydrolysis, and 2) increased incorporation of TG from a separate 
pool in the liver resulting from de novo FA/TG synthesis and/or lipoprotein 
uptake. Since the primary mechanism of action underlying the lipid-lowering 
effect of fibrates (i.e. increased LPL-mediated VLDL-TG clearance) is different 
as compared to that of statins (i.e. decreased hepatic VLDL-TG and VLDL-C 
output), future studies addressing the combined action of these two drug 
classes on lipid metabolism and their combined effect on atherosclerosis 
development are thus warranted.
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Supplemental Figure 1. Hierarchical clustering of scores for biological processes.
T-profiler analysis was performed using expression values corrected for mean expression in 
the control group. Pathways and biological processes with significant scores (>4 or <-4) in 5 or 
6 animals of the fenofibrate group were selected.  A hierarchical clustering of these pathways 
and biological processes and their scores in all samples was generated in GenePattern (Broad 
Institute, MIT, USA). Red indicates positive score (majority of genes in set are up-regulated), 
blue indicate negative score (majority of genes in set are down-regulated).
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Rifampicin, an antibiotic used for the treatment of tuberculosis, is associated with disturbances in hepatic and plasma lipid metabolism. The aim of this study was to evaluate the effect of rifampicin on 
lipoprotein metabolism in ApoE*3-Leiden.CETP mice, a well-established 
model for human-like lipoprotein metabolism, and to investigate the 
underlying mechanisms. Female mice were fed a diet with increasing amounts 
of rifampicin (up to 0.10% w/w). Rifampicin dose-dependently decreased 
plasma cholesterol, explained by a reduction in both HDL-C and VLDL-C. 
The reduction in HDL-C was caused by a reduction in hepatic HDL particle 
synthesis (reduction in apoAI) and HDL maturation (reduction in LCAT, HL 
and PLTP), most likely caused by rifampicin-mediated PXR activation. The 
reduction in VLDL-C was caused by a reduction in hepatic VLDL particle 
synthesis, despite clear induction of hepatic steatosis. We conclude that 
rifampicin dose-dependently reduces plasma HDL-C by inhibiting HDL 
particle synthesis and maturation and reduces plasma VLDL-C by inhibiting 
VLDL particle synthesis.
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Introduction
Rifampicin (RIF) is an antibiotic used for the treatment of tuberculosis174. 
Treatment with RIF has been associated with hepatic lipid accumulation 
in some clinical cases175, 176, 177. In addition, RIF has been reported to cause 
hyperlipidemia in humans178. RIF is an agonist of the pregnane X receptor 
(PXR)179, which is a xenochemical sensing nuclear receptor that regulates 
the expression of genes involved in drug and xenobiotic metabolism. PXR 
activation in rodents induces hepatic steatosis82, 180, 181 associated with increased 
expression of the fatty acid transporter CD36 and lipogenic genes including 
stearoyl CoA desaturase-1 (SCD1)82. In addition PXR activation has been shown 
to reduce hepatic b-oxidation and ketogenesis, which can further contribute 
to the increase in hepatic lipid content81. Taken together, PXR activation most 
likely explains the hepatic steatosis associated with RIF treatment.
Recently, we85 and others182 have shown that the specific PXR agonist 
5-pregnen-3b-ol-20-one-16a-carbonitrile (PCN), reduces plasma HDL levels 
by inhibiting HDL synthesis and/or maturation, and increases plasma VLDL 
levels182. Since RIF also activates PXR, RIF can be expected to have similar 
effects on plasma lipoprotein metabolism. However, the effects of RIF on 
lipoprotein metabolism have been poorly investigated, especially in absence 
of tuberculosis, a Gram-negative bacterial infection that may also affect 
lipoprotein metabolism183. 
The aim of the present study was to evaluate the effect of RIF on plasma 
lipoprotein metabolism and to investigate the underlying mechanisms. We 
used ApoE*3-Leiden.CETP (E3L.CETP) mice108, 116 that express human CETP 
under control of its natural flanking regions129. These mice have an attenuated 
clearance of apoB-containing lipoproteins and, therefore, show a human-like 
lipoprotein profile on a cholesterol-rich Western-type diet as characterized by 
increased plasma levels of cholesterol (C) and TG114, 116. Our results show that 
RIF decreased plasma HDL-C and, in contrast to PCN, decreased VLDL-C, 




Female ApoE*3-Leiden.CETP (E3L.CETP) transgenic mice that express 
human CETP under control of its natural flanking regions were housed under 
standard conditions with access to water and food ad libitum. Mice were fed 
a diet enriched with 15% cacao butter (Diet T; AB Diet Services, Woerden, The 
Netherlands) for 3 weeks to increase plasma cholesterol levels from 2 mM to 
~6 mM. Blood was collected after a 4 h fast from the tail vein into EDTA-
containing cups, and mice were randomized into 3 groups according to their 
plasma total cholesterol, TG and HDL-C. Subsequently, mice were fed control 
diet (diet T) or the same diet with rifampicin (RIF; Sigma) at increasing doses 
of 0.01%, 0.03% and 0.10% (corresponding with ~11, 33 and 110 mg/kg/day) 
for three weeks each. In a separate experiment, mice were fed diet T without 
or with 0.1% RIF after randomization. Experiments were performed after 4 h 
of fasting with food withdrawn at 8:00 am. All experiments were approved by 
the institutional committee on animal care and experimentation.
Hepatic mRNA expression
Total mRNA extraction from liver tissue samples was performed using TRIzol 
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. 
mRNA quality was confirmed with lab-on-a-chip (Bio-Rad Laboratories, 
Hercules, CA, USA), and mRNA was converted to single-stranded cDNA using 
the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Ontario, Canada). 
RT-PCR was performed using the IQ5 multicolor real-time PCR detection 
system using the SYBR Green RT-PCR mix (Bio-Rad Laboratories, Hercules, 
CA, USA). mRNA levels were normalized to mRNA levels of hypoxanthine-
guanine phosphoribosyl transferase (HPRT), cyclophilin and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). Primers are listed in Table I.
Hepatic lipid analysis
Liver samples (~50 mg) were homogenized (20 sec at 4,800 rpm) in ice-cold 
methanol (10 μL/mg tissue) using a Mini Bead Beater (BioSpec Products, 
Bartlesville, USA). Tissue homogenates (45 μL ~ 4.5 mg tissue) were diluted 
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with ice-cold methanol (450 μL) and ice-cold chloroform (1350 μL), and further 
shaken (20 sec at 4800 rpm) to extract lipids from the tissue samples. Mixtures 
were centrifuged (15 min at 14,000 rpm; 4°C) and supernatant was transferred 
into a new tube, dried under nitrogen gas. Lipids were dissolved in 100 μL 2% 
Triton-X100. Total cholesterol, TG and phospholipid levels were assayed as 
described above. 
Table 1. List of primers
Gene Forward primer Reverse primer
Abca1 CCCAGAGCAAAAAGCGACTC GGTCATCATCACTTTGGTCCTTG
Apoa1 GGAGCTGCAAGGGAGACTGT TGCGCAGAGAGTCTACGTGTGT


















Plasma lipid and lipoprotein analysis
Plasma total cholesterol and triglycerides (TG) were measured using commercially 
available enzymatic kits (236691 and 1488872, respectively, Roche Molecular 
Biochemicals, Indianapolis IN, USA) according to the manufacturer’s instructions. 
Phospholipids were determined using an enzymatic Phospholipids kit (Spinreact, 
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Sant Esteve de Bas, Spain). Plasma HDL-C was measured after precipitation of the 
apoB-containing lipoproteins from 20 μL EDTA plasma by adding 10 μL heparin (LEO 
Pharma, The Netherlands; 500 U/mL) and 10 μL 0.2 M MnCl2. Mixtures were incubated 
during 20 min at room temperature and centrifuged for 15 min at 13,000 rpm at 4°C. 
In the supernatant HDL-C was measured. To determine the lipid distribution over 
plasma lipoproteins, lipoproteins were separated using FPLC. Plasma was pooled per 
group, and 50 μL of each pool was injected onto a Superose 6 HR 10/30 column (Äkta 
System, Amersham Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant 
flow rate of 50 μL/min in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 μL were collected 
and assayed for TG and cholesterol as described above.
Plasma CETP activity
Total (lipoprotein-independent) CETP activity was measured as the transfer of [3H] 
cholesteryl oleate (CO) from LDL to HDL184, exactly as described185. Endogenous 
(lipoprotein-dependent) CETP activity was determined by a fluorescent method 
using liposomes enriched with nitrobenzoxadiazole-labeled cholesteryl esters (RB-
CETP, Roar Biomedical, New York)185, 186.
Plasma apoAI protein
Plasma was pooled per group and lipoproteins were separated using FPLC. Each 
fraction (7.5 μL) was run on a 4-20% SDS-PAGE gel (Bio-Rad Laboratories, Hercules 
CA, USA). Gels were stained with Coomassie brilliant blue, and apoAI within the 
main HDL fraction (fraction 18) was quantified by densitometry using the Quantity 
One (Bio-Rad Laboratories, Hercules CA, USA).
Hepatic ABCA1 and SR-BI protein
Immunoblot analysis of hepatic ABCA1 and SR-BI was performed as described187. In 
short, liver samples were lysed, cell debris was removed, and protein concentration 
was determined. Equal amounts of protein (20 μg) were separated on 7.5% SDS-
PAGE gels and transferred to nitrocellulose membrane. Immunolabeling was 
performed using murine monoclonal aABCA1 (AC-10) or rabbit polyclonal aSRBI 
(anti-BI495) as primary antibody and goat-anti-mouse IgG and goat-anti-rabbit IgG, 
respectively, as secondary antibodies. Immunolabeling was detected by enhanced 
chemiluminescence.
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Hepatic VLDL-TG and VLDL-apoB production
Mice were fasted for 4 h prior to the start of the experiment. During the 
experiment, mice were sedated by i.p. injection of 6.25 mg/kg acepromazine 
(Alfasan), 6.25 mg/kg midazolam (Roche) and 0.3125 mg/kg fentanyl 
(Janssen-Cilag). At t=0 min blood was taken via tail bleeding and mice were i.v. 
injected with 100 μL PBS containing 100 μCi Trans35S-label (MP Biomedicals, 
Irvine, USA) to measure de novo total apoB synthesis. After 30 min, the animals 
received 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body 
weight as a 10% (w/w) solution in sterile saline, to prevent systemic lipolysis 
of newly secreted hepatic VLDL-TG 131. Additional blood samples were taken 
at t=15, 30, 60, and 90 min after tyloxapol injection and used for determination 
of plasma TG concentration. After 90 min, the animals were sacrificed and 
blood was collected by orbital bleeding for isolation of VLDL by density 
gradient ultracentrifugation to measure 35S-apoB in the VLDL fraction132, 133.
In vivo clearance of VLDL-like emulsion particles
Glycerol tri[3H]oleate (triolein, TO)- and [1a,2a(n)-14C]cholesteryl oleate 
(CO)-double labeled VLDL-like emulsion particles (80 nm) were prepared as 
described by Rensen et al.135. Mice were fasted 4 h and sedated as described 
above and a large bolus of VLDL-like emulsion particles (1.0 mg TG in 200 μL 
PBS) containing 100 μCi [3H]TO and 10 μCi [14C]CO was injected into the tail. 
At 2, 5, 10, 20 and 30 min blood samples (50 μL) were taken from the tail vein. 
3H and 14C activities were counted in 10 μL serum and corrected for total serum 
volume. At the end of the experiment, organs (i.e. liver, heart, perigonadal fat, 
spleen and skeletal femoralis muscle) were collected, saponified by overnight 
incubation at 60°C in 500 μL Solvable (Perkin-Elmer, Wellesley, USA), and 
radioactivity was measured. The half-life of VLDL-[3H]TO and [14C]CO were 
calculated from the slope after linear fitting of semi-logarithmic decay curves.
Statistical analysis
Data are presented as means ± SEM. Statistical differences were assessed using 
the Student T Test unless stated otherwise. GraphPad (Prism 5 software, La 




Rifampicin is an activator of PXR in mice
E3L.CETP mice were fed a control diet or a diet with increasing doses of RIF 
(0, 0.01, 0.03 and 0.10%). To verify that RIF activates PXR in these mice, we 
determined the effect of RIF on hepatic gene expression of the well-established 
PXR target genes Cyp3a11 and Cyp7a11 (Table 2). Indeed, RIF strongly 
upregulated Cyp3a11 (9-fold) and down-regulated Cyp7a1 (-60%), indicating 
that RIF is indeed a potent PXR agonist in E3L.CETP mice. Since it is known 
that PXR activation causes hepatic steatosis, the effect of RIF treatment on the 
liver lipid content was evaluated (Fig. 1). RIF increased the liver weight (+74%; 
P<0.001) (Fig. 1A), which was accompanied by increased hepatic levels of TG 
(+242%; P<0.001), TC (+229%; P<0.01), and phospholipids (+52%; P<0.05) (Fig. 
1B), fully consistent with PXR agonism85. 
Table 2. Rifampicin affects hepatic gene expression
control RIF control RIF
PXR targets VLDL metabolism
Cyp3a11 1.00 ± 0.38 8.83 ± 2.56*** ApoB 1.00 ± 0.25 0.68 ± 0.16*
Cyp7a1 1.00 ± 0.41 0.44 ± 0.22** Cd36 1.00 ± 0.26 0.91 ± 0.59
Fas 1.00 ± 0.38 0.34 ± 0.13**
HDL metabolism HMGcoA 1.00 ± 0.37 0.36 ± 0.11**
Abca1 1.00 ± 0.16 0.81 ± 0.21 LDLr 1.00 ± 0.25 0.47 ± 0.33**
Apoa1 1.00 ± 0.38 0.42 ± 0.09** Lxr 1.00 ± 0.18 0.93 ± 0.26
CETP 1.00 ± 0.53 0.53 ± 0.19 Scd1 1.00 ± 0.27 0.49 ± 0.18**
Hl 1.00 ± 0.28 0.64 ± 0.14* Srebp1c 1.00 ± 0.38 0.61 ± 0.25*
Lcat 1.00 ± 0.23 0.72 ± 0.16*
Pltp 1.00 ± 0.29 0.50 ± 0.15**
Sr-b1 1.00 ± 0.28 0.64 ± 0.19*
E3L.CETP mice were fed a control diet or a diet with increasing doses of RIF (0, 0.01, 0.03, 
and 0.10%) for three weeks each. After the last treatment period, liver gene expression was 
quantified by RT-PCR. Data are calculated as fold difference as compared to the control 
group. Values are means ± SD (n= 6-7 per group); * P<0.05, ** P<0.01 versus control group.
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Next, we investigated the dose-dependent effect of RIF (0, 0.01, 0.03 and 
0.10%) on plasma lipids (Fig. 2). Whereas RIF did not affect plasma TG levels 
(Fig. 2A), RIF dose-dependently decreased plasma cholesterol levels up to 
-60% (P<0.001) (Fig. 2B). Lipoprotein profiling showed that the highest dose 
of RIF (0.10%) did not affect the distribution of TG over lipoproteins (Fig. 2C), 
and that the reduction in total cholesterol by RIF was caused by a combined 
reduction in HDL-C and VLDL-C (Fig. 2D). Quantitative analysis showed that 
RIF (0.10%) caused a reduction in both non HDL-C (-59%; P<0.01) (Fig. 2E) and 
HDL-C (-71%; P<0.001) (Fig. 2F). However, the absolute reduction in plasma 
TC, induced by RIF (-4.9 mM), was mainly explained by a reduction in non 
HDL-C (-4.2 mM). 
Rifampicin decreases HDL production and maturation
We have previously observed that a decrease in the hepatic cholesterol content 
of E3L.CETP mice e.g. by treatment with fenofibrate114, atorvastatin118 and 
niacin117 decreased both the hepatic expression of CETP and the activity of 
CETP in plasma. Since RIF strongly increased the hepatic cholesterol content, 
we questioned whether the reduction in plasma HDL may be related to 
Figure 1. Rifampicin increases liver lipids. 
E3L.CETP mice were fed a control diet (time-matched control group) or a diet with increasing 
doses of RIF (0, 0.01, 0.03 and 0.10%) for three weeks each. After the last treatment period 
(0.10% RIF), mice were sacrificed and livers were isolated and weighed (A). Livers were 
homogenized, lipids were extracted, and triglycerides (TG), total cholesterol (TC), and 
phospholipids (PL) were determined per mg cell protein (B). Values are means ± SEM (n= 
6-7 per group). *P<0.05; **P<0.01, ***P<0.001 versus control group.
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Figure 2. Rifampicin dose-dependently reduces plasma cholesterol. 
APOE*3-Leiden.CETP (E3L.CETP) mice were fed a control diet (time-matched control 
group) or a diet with increasing doses of rifampicin (RIF) (0, 0.01, 0.03 and 0.10%) for three 
weeks each. Before treatment and at the end of the 3-week periods, blood was drawn and 
plasma was assayed for triglycerides (TG; A), total cholesterol (TC; B). After 3 weeks of 
intervention with 0.10% RIF, the distribution of TG (C) and TC (D) over lipoproteins was 
determined in pooled plasma. Total plasma was assayed for HDL-C (F) and non-HDL 
cholesterol was calculated (E). Values are means ± SEM (n= 7 per group); * P<0.05, ** P<0.01, 
***P<0.001 versus control group.
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increased plasma CETP activity. Therefore, the effect of RIF on CETP activity 
was determined in plasma (Fig. 3). It appeared that 0.10% RIF decreased the 
total exogenous plasma activity of CETP (-45%; P<0.001) (Fig. 3A) without 
affecting the endogenous CETP activity (Fig. 3B), which can thus not explain 
the reduction in HDL-C.
To gain further insight into the mechanism(s) underlying the HDL-decreasing 
effect of RIF, we performed hepatic gene expression analysis (Table I). With 
respect to HDL metabolism, RIF decreased mRNA of proteins involved in HDL 
assembly including Abca1 (-20%, which did not reach significance) and Apoa1 
(-50%). In addition, RIF decreased the expression of genes involved in HDL 
maturation such as Lcat (-30%), Hl (-30%) and Pltp (-50%), as well as the gene 
involved in hepatic clearance of HDL-C, Sr-b1 (-40%). We next evaluated whether 
the relatively large effects of RIF on the hepatic expression of Apoa1 and Sr-b1 
were indeed reflected by lower protein levels (Fig. 4). RIF decreased HDL-apoAI 
in pooled plasma by -37% (Fig. 4A). Western blot analysis of hepatic homogenates 
indicated that RIF did not substantially reduce hepatic ABCA1 protein (-14%), 
but markedly reduced SR-BI protein (-57%, P<0.05) (Fig. 4B). Collectively, these 
data imply that RIF reduces HDL mainly via inhibiting hepatic HDL particle 
synthesis (i.e. reduction in apoAI) and HDL maturation (i.e. reduction in LCAT, 
HL and PLTP), similar to the rodent specific PXR agonist PCN85.
Figure 3. Rifampicin decreases plasma CETP activity. 
E3L.CETP mice were fed a control diet (time-matched control group) or a diet with increasing 
doses of RIF (0, 0.01, 0.03 and 0.10%) for three weeks each. After the last treatment period 
(0.10% RIF), blood was drawn and plasma was assayed for total CETP activity (A) and 
endogenous CETP activity (B). Values are means ± SEM (n= 7 per group); *** P<0.001 versus 
control group.
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Rifampicin decreases VLDL production without largely affecting VLDL clearance
To elucidate the mechanism underlying the VLDL-C-decreasing effect of 
RIF, we first investigated the hepatic expression of genes involved in VLDL 
metabolism (Table I). RIF decreased mRNA of apoB (-20%), required for VLDL 
production. RIF did not affect expression of Cd36, involved in fatty acid uptake. 
Although RIF did not affect the expression of Lxr, RIF decreased the expression 
of the LXR target genes Srebp1c (-40%), Fas (-65%) and Scd1 (-50%), involved 
in fatty acid synthesis. Expression of the Ldlr, involved in the uptake of VLDL 
remnants and LDL, was also decreased (-50%). Since these data suggest that 
RIF may decrease the hepatic assembly of VLDL, we evaluated the effect of RIF 
on VLDL production (Fig. 5). RIF reduced VLDL-TG production to some extent 
(-20%; P=0.084) (Fig. 6 A, B) and markedly reduced the VLDL-apoB production 
rate (-50%; P<0.001) (Fig. 6C). As a consequence, RIF thus selectively increased 
the ratio of TG over apoB (+64%; P<0.01) without affecting the relative TC and 
PL content (Fig. 6D). Since each VLDL particle contains a single molecule of 
apoB, these data show that RIF reduces the production of VLDL particles that 
are nevertheless rich in TG. 
Figure 4. Rifampicin reduces plasma apoAI 
and hepatic SR-BI protein. 
E3L.CETP mice were fed a control diet or 
a diet with increasing doses of RIF (0, 0.01, 
0.03, and 0.10%) for three weeks each. After 
the last treatment period (0.10% RIF), pooled 
plasma was assayed for apoAI (A). Mice were 
sacrificed and livers were isolated. Livers 
were homogenized and equal amounts of 
hepatic proteins were separated by SDS-PAGE 
and transferred to nitrocellulose membrane. 
ABCA1 (B) and SR-BI (C) were visualized by 
immunolabeling. Results of 4 individual mice 
per group are shown. 
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To determine whether increased VLDL-TG clearance also contributes to the 
effect of RIF on VLDL levels, mice were injected with [3H]TO [14C]CO-labeled 
VLDL-like emulsion particles and the plasma clearance was determined (Fig. 
6). As compared to control mice, RIF had no significant effect on the clearance 
rate of [3H]TO (t½ = 5.4 ± 0.6 vs 7.5 ± 1.4 min; Fig. 6A) or [
14C]CO (t½ = 23.2 ± 5.6 
vs 23.9 ± 4.2 min; Fig. 6B). However, RIF reduced the uptake of [14C]CO by the 
liver (21.1 ± 4.1% versus 10.5 ± 2.7%; P<0.01) (Fig. 6C).
Figure 5. Rifampicin decreases hepatic VLDL particle production. 
E3L.CETP mice were fed a control diet (time-matched control group) or a diet with 0.10% 
RIF for 3 weeks. Mice were consecutively injected with Trans35S label and tyloxapol and 
blood samples were drawn up to 90 min after tyloxapol injection. Plasma TG concentrations 
were determined and plotted as the increase in plasma TG relative to t=0 (A). The TG 
production rate was calculated from the slopes of the curves from the individual mice (B). 
After 120 min, the total VLDL fraction was isolated by ultracentrifugation and the rate of 
newly synthesized VLDL-apoB was determined (C). The ratio of TG over apoB production 




Rifampicin (RIF) is an antibiotic used for the treatment of tuberculosis and has 
been reported to cause hepatic lipid accumulation175, 176, 177 and hyperlipidemia 
in humans178. Here, we have evaluated the effect of RIF on lipoprotein 
metabolism in E3L.CETP mice, which is a well-established model for human-
like lipoprotein metabolism114, 116. We show that RIF dose-dependently 
decreased both VLDL-C and HDL-C without affecting TG levels. Mechanistic 
studies showed that the decrease in HDL-C was likely caused by impaired 
HDL production, and inhibited HDL maturation, and that the decrease in 
Figure 6. Rifampicin does not affect the clearance of VLDL-like emulsion particles.
E3L.CETP mice were fed a control diet (time-matched control group) or a diet with 0.10% 
RIF for 3 weeks. Mice were injected with VLDL-like glycerol tri[3H]oleate [14C]cholesteryl 
oleate double labeled VLDL-like emulsion particles (1 mg TG) and plasma samples were 
taken at indicated time points to determine the plasma clearance of [3H]TO (A) and [14C]CO 
(B). At 30 min after injection, liver was harvested to determine the uptake of 3H and 14C (C) 
activity. Values are means ± SEM (n= 5-6 per group). *P<0.05; **P<0.01 versus control group.
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VLDL-C was caused by impaired production of VLDL particles that were 
nevertheless rich in TG.
We have previously reported the response of E3L.CETP mice to the PXR 
agonist 5-pregnen-3b-ol-20-one-16a-carbonitrile (PCN)85. PCN considerably 
increased hepatic Cyp3a11 expression and reduced Cyp7a1 expression, which 
is in accordance with its PXR agonistic activity. Here, we report that RIF 
has a similar effect on these P450 enzymes. In addition, both RIF and PCN 
increased liver weight and increased levels of hepatic TG, total cholesterol 
and phospholipid resulting in a fatty liver85. PXR agonism is associated with 
hepatic steatosis82 81 and our gene expression data suggest that RIF increases 
hepatic lipid content via PXR. Therefore, we can conclude that RIF is indeed a 
potent PXR agonist in mice.
Similar to PCN85, RIF dose-dependently decreased HDL-C levels. HDL 
synthesis, maturation and clearance all determine plasma HDL-C levels. 
The reduction in HDL-C can be explained by reduced hepatic expression of 
apoAI, important for the generation of discoidal HDL precursors188. In fact, 
this is similar to the effect of PCN on the expression of genes involved in HDL 
formation85. Both RIF and PCN85 markedly reduced hepatic Apoa1 mRNA 
(~50-60%) as reflected by decreased plasma apoAI protein (~40%). In addition, 
they tended to reduce hepatic Abca1 mRNA (~20%) and protein (~15-20%), 
which is in line with effects of RIF in HepG2 cells and PCN in primary rat 
hepatocytes189. In addition, RIF decreased the expression of genes involved in 
HDL maturation such as Hl (~40%), Lcat (~30%) and Pltp (~50%). A reduction 
in both LCAT190 and PLTP191 might contribute to the reduction in plasma HDL 
levels. Since these data are similar to the effect of PCN on HDL metabolism85, 
RIF activates PXR and reduces HDL cholesterol by reducing HDL assembly and 
maturation in E3L.CETP mice. Another important protein in HDL maturation 
is CETP, involved in the transfer of cholesterol from HDL to VLDL. Previous 
studies with fenofibrate114, atorvastatin118 and niacin117 showed that HDL-C 
levels increased in response to a decrease in CETP expression in E3L.CETP 
mice. This decrease in CETP expression was associated with lower hepatic 
lipid levels. Since RIF increased hepatic lipid levels, an increase in CETP 
expression might be causing the reduction of HDL-C. However, RIF did not 
significantly affect hepatic CETP expression (not shown) and reduced rather 
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than increased CETP activity192. Finally, similar to PCN, RIF significantly 
reduced hepatic SR-BI mRNA and protein levels in E3L.CETP mice. In mice, 
SR-BI appears solely responsible for the selective clearance of cholesteryl esters 
from HDL19. Decreased SR-BI expression would thus cause the accumulation 
of enlarged HDL193. However, since endogenous CETP activity is unchanged 
and enlarged HDL is a preferred substrate of CETP, this likely explains the 
normal HDL particle size observed after treatment with RIF. Altogether, these 
data show that RIF lowers HDL-C by decreasing HDL synthesis, maturation 
and clearance. Since these effects on HDL metabolism are similar to those seen 
with the PXR activator PCN85, we conclude that the reduction in HDL-C by 
RIF is mediated by activation of PXR. 
Despite similarities in the effects of RIF and PCN on HDL metabolism, 
RIF differentially affected plasma TG and VLDL-C as compared to PCN85. 
RIF did not affect plasma TG levels and reduced VLDL-C levels causing a 
decrease in total cholesterol whereas PCN increased plasma TG together 
with a small increase in plasma cholesterol, as reflected by increased VLDL 
levels85. Plasma VLDL levels are determined by the rates of VLDL production 
and VLDL clearance. Upon RIF treatment, hepatic VLDL particle production 
was reduced, explaining the reduction in VLDL-C. The reduced VLDL particle 
production was associated with reduced hepatic apoB expression. However, 
since total TG levels were unaffected, the produced VLDL particles were 
enriched with TG. PXR-mediated TG enrichment of VLDL has been shown 
before in LDLr knockout mice treated with PCN182. VLDL-TG production is 
determined by hepatic FA uptake and de novo lipogenesis. We did not detect 
changes in the expression of CD36, important for the uptake of plasma derived 
FA. However the expression of genes involved in de novo lipogenesis including 
SREBP1c, FAS and SCD1 was reduced. Changes in the expression of these 
genes were not detected in the LDLr knockout mice treated with PCN182, 
however similar changes were seen in E3L.CETP mice treated with PCN 
(personal communication W. de Haan).VLDL-TG clearance was not affected 
upon treatment with RIF. 
In conclusion we show that RIF treatment in E3L.CETP mice lowers HDL-C 
by reducing HDL synthesis and maturation, which can be attributed to PXR 
activation. The impairment of VLDL particle production by RIF cannot be 
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explained by activation of PXR and may be caused by PXR-selective or non-
PXR mediated mechanisms. 
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Perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), and perfluorooctane sulfonate (PFOS) are stable perfluoroalkyl sulfonate (PFAS) surfactants, and PFHxS and PFOS are frequently 
detected in human biomonitoring studies. Some epidemiological studies have 
shown modest positive correlations of serum PFOS with nonHDL-C. This 
study investigated the mechanism underlying the effect of PFAS surfactants 
on lipoprotein metabolism. ApoE*3-Leiden.CETP mice were fed a Western-
type diet with PFBS, PFHxS or PFOS (30, 6 and 3 mg/kg/day, respectively) for 
4-6 weeks. While PFBS modestly reduced only plasma TG, PFHxS and PFOS 
markedly reduced TG, nonHDL-C and HDL-C. The decrease in VLDL was 
caused by enhanced LPL-mediated VLDL-TG clearance, and by decreased 
production of VLDL-TG and VLDL-apoB. Reduced HDL production related 
to decreased apoAI synthesis resulted in decreased HDL. PFHxS and PFOS 
increased liver weight and hepatic TG content. Hepatic gene expression 
profiling data indicated that these effects were the combined result of PPARa 
and PXR activation. In conclusion, the potency of PFAS to affect lipoprotein 
metabolism increased with increasing alkyl chain length. PFHxS and PFOS 
reduce plasma TG and TC mainly by impairing lipoprotein production, 
implying that the reported positive correlations of serum PFOS and nonHDL-C 
are associative rather than causal.
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Introduction
Perfluoroalkyl sulfonates (PFAS) including perfluorobutane sulfonate 
(PFBS), perfluorohexane sulfonate (PFHxS), and perfluorooctane sulfonate 
(PFOS) are exceptionally stable surfactant molecules that are representative 
members of the perfluoroalkyl sulfonate (PFAS) class of perfluoroalkyls. Due 
to their unique physical and chemical properties PFAS have been used, either 
directly or by use of N-alkyl functionalized perfluoroalkyl sulfonamides, 
in industrial and consumer products with applications requiring stability 
toward corrosion and heat, strong surface-tension reduction, and resistance 
to water and oil. Applications have included paper and textile coatings, food 
packaging, surfactants, repellents and fire-retardant foams194, 195. Although 
used directly as surfactants or ion-pairing agents, these molecules can also 
result from metabolic196, 197 or environmental198 degradation of N-substituted 
perfluoroalkyl sulfonamides. 
In 2001, the widespread distribution of PFOS and PFHxS in humans and 
PFOS in wildlife was reported199, 200. Since that time, due to their structural 
stability, widespread dissemination in the environment, and poor elimination 
in most species, particularly humans201, PFHxS and PFOS have been detected 
frequently in biological and environmental matrices202. These findings led the 
major United States manufacturer, 3M Company, to discontinue manufacture 
of PFOS, PFHxS, and materials that could generate these compounds via 
degradation by the end of 2002. International regulatory action has been taken 
to further restrict the use of PFOS and materials that may generate PFOS202. 
PFBS has a more favorable toxicological and environmental profile than either 
PFHxS or PFOS. In fact, the geometric mean serum elimination half-lives 
of PFOS and PFHxS determined for 26 retired production workers were, in 
years, 4.8 (95% CI 4.0-5.8) and 7.3 (95% CI 5.8-9.2), respectively201. In contrast, 
PFBS had a serum elimination half-life of 25.8 days (95% CI 16.6-40.2) among 
six production workers removed from exposure203. Several epidemiological 
studies have shown modest positive correlations of serum lipids with serum 
PFOS in non-occupationally-exposed populations204, 205 as well as some 
occupationally-exposed populations206, while no correlations of serum PFOS 
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with HDL-C have been noted206, 204. However, it is still unclear whether these 
correlations are causal or associative.
In toxicological studies using cynomolgus monkeys207, rats208, 209, 210 and 
pregnant mice211, PFOS was shown to reduce serum total cholesterol and 
otherwise induce changes in plasma lipid metabolism, and to increase liver 
TG. PFHxS was also shown to reduce serum total cholesterol in rat212, and 
PFBS was not213. However, the mechanism(s) underlying the effects of PFBS, 
PFHxS and PFOS on lipoprotein metabolism, as well as the importance of the 
alkyl chain length to these effects, have not been addressed thoroughly. Thus, 
the objective of this study was to investigate the mechanism(s) underlying 
the effects of PFHxS and PFOS on lipoprotein metabolism, and to assess the 
importance of the alkyl chain length by comparing the effects between PFBS 
and PFHxS and PFOS. ApoE*3-Leiden.CETP (E3L.CETP) mice116 were used, 
which have attenuated clearance of apoB-containing lipoproteins and exhibit 
a human-like lipoprotein metabolism on a Western-type diet.
Materials and Methods
Animals
In this study, male E3L.CETP mice on a C57Bl/6 background116 were used, 
housed under standard conditions in conventional macrolon cages (2-4 mice/
cage, wood dust bedding) with free access to food and water. At the age of 8-10 
weeks, mice were fed a semi-synthetic Western-type diet, containing 0.25% 
(w/w) cholesterol, 1% (w/w) corn oil and 14% (w/w) bovine fat (Hope Farms, 
Woerden, The Netherlands) for 4 weeks in three independent experiments. 
Upon randomization according to body weight, total plasma cholesterol (TC) 
and TG levels, mice received the Western-type diet without or with PFBS 
(0.03% ~30 mg/kg/day), PFHxS (0.006% ~6 mg/kg/day) or PFOS (0.003% 
~3 mg/kg/day) for 4-6 weeks. Test materials were provided by 3M Company, 
St. Paul, MN, USA, and included potassium PFOS (FC-95, Lot 217, 87.6% 
purity), potassium PFHxS (L-9051, 99.9% purity), and potassium PFBS (L-
7038, 98.2% pure). Experiments were performed after 4 h of fasting with food 
withdrawn at 8:00 am. The institutional Ethical Committee on Animal Care 
and Experimentation approved all experiments. 
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Determination of serum concentrations of PFBS, PFHxS, and PFOS
Serum concentrations of PFBS, PFHxS, and PFOS were determined using an 
LC-MS/MS method as described214.
Plasma lipid and lipoprotein analysis
Plasma was obtained via tail vein bleeding and assayed for TC and TG, 
using the commercially available enzymatic kits 236691 and 11488872 (Roche 
Molecular Biochemicals, Indianapolis, IN, USA), respectively. Free fatty acids 
(FA) were measured using NEFA-C kit from Wako Diagnostics (Instruchemie, 
Delfzijl, the Netherlands) and glycerol was measured using the free glycerol 
determination kit (Sigma, St. Louis, USA). The distribution of lipids over 
plasma lipoproteins was determined using fast protein liquid chromatography 
(FPLC). Plasma was pooled per group, and 50 μL of each pool was injected 
onto a Superose 6 PC 3.2/30 column (Äkta System, Amersham Pharmacia 
Biotech, Piscataway, NJ, USA) and eluted at a constant flow rate of 50 μL/min 
in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 μL were collected and assayed for 
TC as described above. HDL was isolated by precipitation of apoB-containing 
lipoproteins from 20 μL EDTA plasma by adding 10 μL heparin (LEO Pharma, 
The Netherlands; 500 U/mL) and 10 μL 0.2 M MnCl2. The mixtures were 
incubated for 20 min at room temperature and centrifuged for 15 min at 13,000 
rpm at 4°C. HDL-C was measured in the supernatant using enzymatic kit 
236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA). Plasma CETP 
mass was analyzed using the CETP ELISA kit from ALPCO Diagnostics (Salem, 
NH, USA). Plasma apoAI concentrations were determined using a sandwich 
ELISA 117, with diluted mouse plasma (dilution 1:400,000). Purified mouse 
apoAI from Biodesign International (Saco, USA) was used as a standard.
In vivo clearance of VLDL-like emulsion particles
Glycerol tri[3H]oleate (triolein, TO)-labeled VLDL-like emulsion particles 
(80 nm) were prepared as described by Rensen et al135. In short, radiolabeled 
emulsions were obtained by adding 100 μCi of [3H]TO to 100 mg of emulsion 
lipids before sonication (isotopes obtained from GE Healthcare, Little Chalfont, 
UK). Mice were fasted for 4 h, sedated with 6.25 mg/kg acepromazine (Alfasan), 
6.25 mg/kg midazolam (Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag) 
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and injected with a large bolus of radiolabeled emulsion particles (1.0 mg TG 
in 200 μL PBS) via the tail vein. At indicated time points after injection, blood 
was taken from the tail vein to determine the serum decay of [3H]TO. At 30 
min after injection, plasma was collected by orbital puncture and mice were 
sacrificed by cervical dislocation. Organs (i.e. liver, heart, perigonadal fat, 
spleen and skeletal femoralis muscle) were harvested and saponified in 500 
μL Solvable (Perkin-Elmer, Wellesley, USA) to determine [3H]TO uptake. The 
half-life of VLDL-[3H]TO was calculated from the slope after linear fitting of 
semi-logarithmic decay curves.
Hepatic lipase and lipoprotein lipase assay
Lipolytic activity of both lipoprotein lipase (LPL) and hepatic lipase (HL) was 
determined as described previously215. To liberate LPL from endothelium, 4 h 
fasted mice were injected intraperitoneally with heparin (0.5 U/g bodyweight; 
Leo Pharmaceutical Products BV., Weesp, The Netherlands) and blood was 
collected after 20 min. 10 μL of post-heparin plasma was incubated with 0.2 
mL of TG substrate mixture containing triolein (4.6 mg/mL) and [3H]TO (2.5 
μCi/mL) for 30 min at 37°C in the presence or absence of 1 M NaCl, which 
completely inhibits LPL activity, to estimate both the HL and LPL activity. The 
LPL activity was calculated as the fraction of total triacylglycerol hydrolase 
activity that was inhibited by the presence of 1 M NaCl and is expressed as the 
amount of free FA released per hour per mL of plasma.
Hepatic VLDL-TG and VLDL-apoB production
Mice were fasted for 4 h prior to the start of the experiment. During the 
experiment, mice were sedated as described above. At t=0 min blood was 
taken via tail bleeding and mice were i.v. injected with 100 μL PBS containing 
100 μCi Trans35S-label (ICM Biomedicals, Irvine, USA) to measure de novo total 
apoB synthesis. After 30 min, the animals received 500 mg of tyloxapol (Triton 
WR-1339, Sigma-Aldrich) per kg body weight as a 10% (w/w) solution in 
sterile saline, to prevent systemic lipolysis of newly secreted hepatic VLDL-
TG131. Additional blood samples were taken at t=15, 30, 60, and 90 min after 
tyloxapol injection and used for determination of plasma TG concentration. 
After 90 min, the animals were sacrificed and blood was collected by orbital 
PFOS and PFHxS decrease lipoprotein production 87
 5
puncture for isolation of VLDL by density gradient ultracentrifugation. 
35S-apoB was measured in the VLDL fraction after apoB-specific precipitation 
with isopropanol132, 133, 134.
Hepatic lipid analysis
Livers were isolated and partly homogenized (30 sec at 5,000 rpm) in saline 
(approx. 10% wet w/v) using a mini-bead beater (Biospec Products, Inc., 
Bartlesville, OK, USA). Lipids were extracted as described216 and separated 
by high performance thin layer chromatography (HPTLC). Lipid spots were 
stained with color reagent (5 g MnCl2.4H2O, 32 mL 95-97% H2SO4 added to 960 
mL of CH3OH:H2O 1:1 v/v) and quantified using TINA
® version 2.09 software 
(Raytest, Straubenhardt, Germany).
Fecal excretion of bile acids and neutral sterols
Fecal secretion of neutral sterols and bile acids was determined in feces, 
collected during a 48-72 h time period at 2 consecutive time points, by gas 
chromatographic (GS) analysis as described previously217.
In vivo clearance of autologous HDL
One mouse of each experimental group was used to obtain autologous HDL 
that was radiolabeled with [3H]CO as described114. Mice were injected via the 
tail vein with a trace of autologous radiolabeled HDL (0.1 μCi in 200 μL PBS). 
At the indicated time points after injection, blood was collected to determine 
the plasma decay of [3H]CO. The fractional catabolic rate was calculated after 
curve fitting. Taking into account that plasma levels of HDL-C were changed 
upon treatment, the FCR was also calculated from these data as mM HDL-C 
cleared per hour, based on the actual level of HDL-C in the various groups.
Hepatic gene expression analysis
Total RNA was extracted from individual livers using RNA-Bee (Bio-Connect, 
Huissen, The Netherlands) and glass beads according to the manufacturer’s 
instructions. The RNA was further purified using the nucleospin RNA II 
kit (Machery-Nagel, Düren, Germany) according to the manufacturer’s 
instructions. The integrity of each RNA sample obtained was examined by 
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Agilent Lab-on-a-chip technology using a RNA 6000 Nano LabChip kit and a 
Bioanalyzer 2100 (Agilent Technologies, Amstelveen, The Netherlands). The 
Affymetrix 3’ IVT-Express labeling Kit (#901229) and the protocols optimized 
by Affymetrix were used to synthesize Biotin-labeled cRNA (from 100 ng of 
total RNA) for microarray hybridization. For the hybridization 15 μg cRNA 
was used for further fragmentation and finally 10 μg for the hybridizations. The 
quality of intermediate products (that is, biotin-labeled cRNA and fragmented 
cRNA) was again checked.
Microarray analysis was carried out using an Affymetrix technology 
platform and Affymetrix GeneChip® mouse genome 430 2.0 arrays. Briefly, 
fragmented cRNA was mixed with spiked controls and hybridized with 
murine GeneChip® 430 2.0 arrays. The hybridization, probe array washing 
and staining, and washing procedures were executed as described in the 
Affymetrix protocols, and probe arrays were scanned with a Hewlett-Packard 
Gene Array Scanner (ServiceXS, Leiden, The Netherlands). Quality control 
of microarray data was performed using BioConductor packages (including 
simpleaffy and affyplm), through the NuGO pipeline that is available as a 
Genepattern procedure on http://nbx2.nugo.org157. All samples passed the 
QC. Raw signal intensities (from CEL-files) were normalized using the GCRMA 
algorithm (gc-rma slow). For annotation of probes and summarization of 
signals from probes representing one gene the custom MNBI CDF-file was 
used (based on EntrezGene, version 11.0.2) (http://brainarray.mbni.med.
umich.edu/Brainarray/Database/CustomCDF/cdfreadme.htm). This resulted 
in expression values for 16331 genes, represented by unique Entrez gene 
identifiers. Genes were filtered for expression above 5 in 3 or more samples, 
resulting in a set of 11587 genes that was used for further analysis. Gene 
expression data were log-transformed (base 2).
Statistical analysis on resulting data was performed using the moderated 
t-test (Limma: http://bioinf.wehi.edu.au/limma/) with correction for multiple 
testing158. Cut-off for statistically significant changes was set at corrected 
P-value (q-value) <0.05. In addition, T-profiler analysis159 was performed using 
expression values corrected for mean expression in the control group. This 
analysis resulted in scores (t-scores) and significance values for functional gene 
sets and biological processes (based on gene ontology annotation). Gene sets 
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and biological processes with significant scores (>4 or <-4) in 5 or 6 animals per 
group were selected. A hierarchical clustering of these pathways and biological 
processes and their scores in all samples was generated in GenePattern (Broad 
Institute, MIT, USA)160. The data discussed in this publication have been 
deposited in NCBI’s Gene Expression Omnibus and are accessible through 
GEO Series accession number GSE22940 (accession for reviewers available).
Statistical analysis
All data are presented as means ± SEM unless indicated otherwise. Most data 
were analyzed using SPSS. A Kruskall-Wallis test for several independent 
samples was used, followed by a Mann-Whitney test for independent samples. 
P-values less than 0.05 were considered statistically significant. Serum PFBS, 
PFHxS, and PFOS data were analyzed using the Tukey-Kramer HSD test for 
multiple comparisons of means in JMP™ 5.1 (Cary, NC, USA).
Results
Serum concentrations of PFBS, PFHxS, and PFOS
Serum concentrations of PFAS for the various experiments performed to measure 
all biochemical and physiological parameters are presented in Table I. Mean 
serum concentrations after 4-6 weeks of feeding were 33-38 μg/mL (PFBS), 
188-218 μg/mL (PFHxS) and 86-125 μg/mL (PFOS). Serum concentrations of 
PFBS measured in the three experiments were not different from each other. 
Even with much higher daily intakes of PFBS than either PFHxS or PFOS, the 
mean PFBS concentrations, on a molar basis, were approximately 25% those 
of PFHxS and 50-75% those of PFOS and. Serum PFHxS concentrations were 
approximately 2-3 times those of PFOS, corresponding to the difference in 
daily intakes of PFHxS as compared to PFOS.
PFBS, PFHxS and PFOS decrease plasma triglyceride levels
To investigate the effect of PFAS on lipoprotein metabolism in E3L.CETP mice, 
mice were fed a Western-type diet for 4 weeks. Mice were randomized (t0), 
and fed the same diet without or with different PFAS (0.03% PFBS, 0.006% 
PFHxS or 0.003% PFOS) for another 4 weeks (t4). Body weight and food intake 
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did not differ between groups throughout the intervention period (data not 
shown). At both t0 and t4, plasma was assayed for lipids (Fig. 1). As compared 
to the control group, plasma TG levels were decreased by both PFBS (-37%; 
P<0.01), PFHxS (-59%; P<0.0001) and PFOS (-50%; P<0.001) (Fig. 1A).
Table 1. Mean serum concentrations of perfluoroalkyl sulfonates.











PFBS 0.03 (1003)a 36.7 ± 7.4
A,* 
(123 ± 25)b
37.8 ± 6.6A 
(126 ± 22)
32.7 ± 10.2A (109 
± 34)
PFHxS 0.006 (150) 217.6 ± 13.3
A 
(545 ± 33)
197.3 ± 10.4A,B 
(494 ± 26)
188.3 ± 31.5B 
(472 ± 72)
PFOS 0.003 (60) 124.7 ± 8.1
A (250 
± 16)
85.6 ± 9.5B 
(172 ± 19)
95.3 ± 4.2B 
(191 ± 9)
Mice received a Western-type diet without or with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS during the indicated time periods, and plasma concentrations of PFBS, PFHxS, and 
PFOS were measured.
* Values that share the same capital letter designation within a row of data are not statisti-
cally significantly different (P<0.05) by the Tukey-Kramer HSD test.
a Dietary concentrations in parentheses are in units of μmoles/kg of diet.
b Fluorochemical serum concentrations in parentheses are in μM.
PFHxS and PFOS decrease plasma VLDL- and HDL-cholesterol levels
Besides TG metabolism, PFAS also affected cholesterol metabolism. Plasma 
TC levels tended to be decreased by PFBS (-16%: n.s.) and were significantly 
decreased by PFHxS (-67%: P<0.0001) and PFOS (-60%: P<0.0001) (Fig. 1B). 
The tendency towards reduction of total cholesterol by PFBS was caused by a 
selective reduction in VLDL-cholesterol, whereas PFHxS and PFOS reduced 
both VLDL-cholesterol and HDL-cholesterol (Fig. 1C). Quantitative analysis 
showed that nonHDL-cholesterol was decreased by PFBS (-28% P=0.065), 
PFHxS (-68% P<0.0001) and PFOS (-60% P<0.0001) (Fig. 1D). In addition, HDL-
cholesterol was only decreased by PFHxS (-62%; P<0.001) and PFOS (-74% 
P<0.0001) (Fig. 1E), which was accompanied by even larger reductions in 
plasma apoAI induced by PFHxS (-76%; P<0.0001) and PFOS (-81%; P<0.0001) 
(Fig. 1F).
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Figure 1. Effect of perfluoroalkyl sulfonates on plasma triglycerides, total cholesterol and 
HDL-cholesterol. 
Mice received a Western-type diet without and with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS for 4 weeks. At baseline (t0) and after 4 weeks of intervention (t4), 4 h-fasted blood 
was taken and plasma was assayed for triglycerides (A) and total cholesterol (B). After 
4 weeks of intervention, cholesterol distribution over lipoproteins was determined (C). 
Plasma at t0 and t4 were also assayed for nonHDL-cholesterol (D), HDL-cholesterol (E) and 
apoAI (F). Data are means ± SEM (n = 6). **P<0.01; #P<0.001; ##P<0.0001 as compared to the 
control group. 
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PFBS, PFHxS and PFOS increase VLDL-triglyceride clearance
Plasma VLDL-TG levels are determined by the balance between VLDL-TG 
production and VLDL-TG clearance. To evaluate whether an increased VLDL-
TG clearance may have attributed to the reduction in VLDL-TG levels caused 
by all PFAS, the plasma clearance of [3H]TO-labeled VLDL-like emulsion 
particles was determined (Fig. 2). As compared to control mice, the plasma 
half-life of [3H]TO was reduced by PFBS (-51%, P<0.05), PFHxS (-61%, P<0.001) 
and PFOS (-52%, P<0.01) (Fig. 2A,B), reflected by a significant increase in the 
uptake of [3H]TO-derived activity by the liver and trends towards an increased 
uptake by skeletal muscle and white adipose tissue (Fig. 2C). 
Figure 2. Effect of perfluoroalkyl 
sulfonates on the clearance of VLDL-
like emulsion particles. 
Mice received a Western-type diet 
without or with 0.03% PFBS, 0.006% 
PFHxS or 0.003% PFOS for 4 weeks. 
After 4 h fasting, mice were injected with 
VLDL-like [3H]TO-labeled VLDL-like 
emulsion particles (1 mg TG) and plasma 
samples were taken at indicated time 
points to determine the plasma clearance 
of [3H]TO (A). From the slopes of the 
curves, the half-lives of 3H-activity were 
calculated (B). At 30 min after injection, 
various organs [liver, heart, skeletal 
muscle and gonadal white adipose tissue 
(gWAT)] were harvested to determine 
the uptake of 3H-activity (C). Data are 
means ± SEM (n = 4-6). *P<0.05; **P<0.01; 
#P<0.001; ##P<0.0001 as compared to the 
control group.
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Since these data are consistent with an increased lipolytic processing, HL and 
LPL activity were determined in post-heparin plasma (Fig. 3). HL activity was 
decreased to some extent by PFBS (-28%; P<0.05) and increased by PFHxS 
(+15%; n.s.) and PFOS (+22%; P<0.05). LPL activity tended to be increased by 
PFBS (+20%; n.s.) and was significantly and markedly increased by PFHxS 
(+74%; P<0.001) and PFOS (+54%; P<0.001).
PFHxS and PFOS decrease VLDL production
We next determined whether a reduction in VLDL-TG production may also 
have contributed to the TG-lowering effect of PFAS (Fig. 4). PFBS did not 
affect VLDL-TG production (Fig. 4A,B) and modestly reduced VLDL-apoB 
production (-17%; P=0.055) (Fig. 4C). In contrast, the VLDL-TG production 
rate was markedly decreased by PFHxS (-74%; P<0.0001) and PFOS (-86%; 
P<0.0001) (Fig. 4A,B). The VLDL-apoB production rate was decreased to 
similar extents by PFHxS (-76%; P<0.0001) and PFOS (-87%; P<0.0001) (Fig. 
4C), indicating that PFHxS and PFOS both reduce the production of VLDL 
particles without altering their TG content.
PFHxS and PFOS increase liver weight and hepatic triglyceride content
To get further insight into the mechanism how PFHxS and PFOS decrease 
hepatic VLDL-TG production, we determined the weight and lipid content of 
the liver (Fig. 5). The liver weight was markedly increased by PFHxS (+110%; 
P<0.0001) and PFOS (+107%; P<0.0001) (Fig. 5A), accompanied by an increased 
hepatic TG content (+52%; P<0.05 and +192%; P<0.0001, respectively) (Fig. 5B). 
Figure 3. Effect of perfluoroalkyl sulfonates on 
plasma hepatic lipase and lipoprotein lipase 
activity. 
Mice received a Western-type diet without or 
with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS for 4 weeks. After 4 h fasting, heparin was 
injected and postheparin plasma was collected. 
Plasma was incubated with a [3H]TO-containing 
substrate mixture in the absence or presence of 1 
M NaCl, to estimate both the HL and LPL activity. 
Data are means ± SEM (n = 8). *P<0.05; #P<0.001 
as compared to the control group.
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PFOS also markedly increased hepatic cholesteryl esters (+94%; P<0.001) 
(Fig. 5C) and mildly increased free cholesterol (+16%; P<0.05) (Fig. 5D). PFBS 
on the other hand decreased both hepatic cholesteryl esters (-36%; P<0.05) and 
free cholesterol (-19%; P<0.05) (Fig. 5C,D). These data indicate that PFHxS and 
PFOS decrease VLDL-TG production as a result of impaired TG secretion from 
the liver, leading to hepatomegaly and hepatic steatosis, rather than being a 
consequence of reduced hepatic lipids available for VLDL production.
Figure 4. Effect of perfluoroalkyl sulfonates on 
hepatic VLDL production. 
Mice received a Western-type diet without or with 
0.03% PFBS, 0.006% PFHxS or 0.003% PFOS for 4 
weeks. After 4 h fasting, mice were consecutively 
injected with Trans35S label and tyloxapol and 
blood samples were drawn up to 90 min after 
tyloxapol injection. Plasma TG concentrations were 
determined and plotted as the increase in plasma 
TG relative to t=0 (A). The rate of TG production 
was calculated from the slopes of the curves from 
the individual mice (B). After 120 min, the total 
VLDL fraction was isolated by ultracentrifugation 
and the rate of newly synthesized VLDL-apoB was 
determined (C). Data are means ± SEM (n = 7-8). 
##P<0.0001 as compared to the control group.
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PFHxS and PFOS decrease white perigonadal fat pad weight, plasma free fatty acids 
and plasma glycerol
Since the accumulation of hepatic TG as induced by PFHxS and PFOS, 
accompanied by a marked reduction in VLDL-TG production, may result 
in reduced supply of VLDL-TG-derived FA for storage in adipose tissue, we 
determined the effect of PFAS on perigonadal fat pad weight (Fig. 6A). Indeed, 
perigonadal fat pad weight was decreased by PFHxS (-28%; P<0.01) and PFOS 
(-25%; P<0.05), whereas PFBS had no effect. This was accompanied by reduced 
plasma FA (-41%; P<0.0001 and -37%; P<0.0001) (Fig. 6B) and plasma glycerol 
(-50%; P<0.0001 and -42%; P<0.0001) (Fig. 6C), both of which are mainly 
derived from TG lipolysis in adipose tissue.
Figure 5. Effect of perfluoroalkyl sulfonates on liver weight and lipid content. 
Mice received a Western-type diet without or with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS for 4 weeks. After 6 weeks, livers were collected after a 4 h fast and their weight 
was determined (A). Liver lipids were extracted and triglycerides (TG) (B), cholesteryl 
esters (CE) (C) and free cholesterol (FC) (D) were quantified. Data are means ± SEM (n = 6). 
*P<0.05; #P<0.001; ##P<0.0001 as compared to the control group.
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PFHxS and PFOS decrease fecal bile acid excretion
To determine whether the changes in hepatic lipid content were accompanied 
by an effect on cholesterol excretion into feces, the effect of the PFAS on fecal 
output of neutral sterols and bile acids was determined (Fig. 7). The various 
PFAS did not affect neutral sterol secretion (Fig. 7A), but excretion of bile acids 
was decreased by PFHxS (-41%, P<0.05) and PFOS (-50%, P<0.01) (Fig. 7B).
PFHxS and PFOS decrease HDL-cholesterol clearance
Since both PFHxS and PFOS decreased plasma levels of HDL-cholesterol and 
apoAI, we investigated whether this was caused by increased HDL turnover. 
HDL-cholesterol clearance was determined using autologous [3H]CO-labeled 
HDL (Fig. 8). Treatment with PFHxS and PFOS increased the clearance of the 
[3H]CO tracer (Fig. 8A), reflected by an decrease of the half-life of [3H]CO 
(PFHxS -33%; P<0.001, PFOS -35%; P<0.0001) (Table 2). However, calculation 
Figure 6. Effect of perfluoroalkyl sulfonates on 
perigonadal fat pad weight, plasma fatty acids 
and plasma glycerol. 
Mice received a Western-type diet without or with 
0.03% PFBS, 0.006% PFHxS or 0.003% PFOS for 4 
weeks. After 4 weeks the perigonadal fat pads were 
collected and their weights were measured (A). 
At baseline (t0) and after 4 weeks of intervention 
(t4), blood samples were taken after a 4 h fast and 
plasma was assayed for free fatty acids (FA) (B) and 
glycerol (C). Data are means ± SEM (n = 6). *P<0.05; 
**P<0.01; ##P<0.0001 as compared to the control 
group.
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of the fractional catabolic rate (FCR) of HDL-cholesterol, taking into account 
the different pool size of HDL-cholesterol after treatment with the various 
PFAS, showed that the clearance of HDL-cholesterol (calculated as mM HDL-
cholesterol cleared per hour) was actually decreased by PFHxS (-48%; P<0.01) 
and PFOS (-65% P<0.001). The reduction in HDL-cholesterol clearance may 
be related to a decrease in plasma CETP activity. Indeed, plasma CETP mass 
was decreased by PFBS (-20%; P<0.01), PFHxS (-36%; P<0.001) and PFOS 
(-38%; P<0.0001) (Fig. 8B). Collectively, these data indicate that the observed 
reduction in plasma HDL-cholesterol is likely caused by impaired production 
and/or maturation of HDL particles rather than enhanced clearance.
Table 2. Effect of perfluoroalkyl sulfonates on the fractional catabolic rate of 
HDL-C.
Control PFBS PFHxS PFOS
t½ (h) 3.26 ± 0.11 2.89 ± 0.15 2.19 ± 0.12 # 2.13 ± 0.09 ##
FCR (pools HDL-C/h) 0.21 ± 0.01 0.24 ± 0.01 0.32 ± 0.02 # 0.33 ± 0.01 ##
FCR (mM HDL-C/h) 0.23 ± 0.02 0.25 ± 0.04 0.12 ± 0.03 ** 0.08 ± 0.02 #
Mice received a Western-type diet without or with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS for 4 weeks. Mice were injected with autologous [3H]CO-labeled HDL. The data 
from Fig. 8A were used to calculate the plasma half-life and fractional catabolic rate (FCR) 
as pools or mM of HDL-C cleared per hour. Values are means ± SEM (n=6). **P<0.01, 
#P<0.001 and ##P<0.0001.
Figure 7. Effect of perfluoroalkyl sulfonates on fecal bile acid excretion. 
Mice received a Western-type diet without or with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS for 4 weeks. Feces were collected during a 48-72 h time period at 2 consecutive time 
points, and neutral sterols (A) and bile acids (B) were quantified by gas chromatographic 
analysis. Data are means ± SEM (n = 6). *P<0.05; **P<0.01 as compared to the control group.
98 PFHxS and PFOS affect hepatic expression of genes involved in lipid metabolism
To further investigate the mechanism(s) by which PFAS affect lipid metabolism, 
we determined the hepatic expression profile of 16331 well characterized 
mouse genes. As compared to the control group, PFAS resulted in 438 (PFBS), 
4230 (PFHxS), and 3986 (PFOS) differentially expressed genes (Supplemental 
Fig. 1). A selection of genes involved in lipid metabolism is depicted in Table 3. 
In general, the expression of many of these genes was affected by PFHxS and 
PFOS, but not by PFBS.
Both PFHxS and PFOS affected genes involved in VLDL metabolism. 
PFHxS and PFOS largely increased Lpl expression, in line with increased 
VLDL-TG clearance and plasma LPL activity. Despite some differences with 
respect to the individual effects of both compounds, PFHxS and PFOS both 
upregulated genes involved in FA uptake and transport (Slc27a1, Slc27a2, 
Slc27a4, and Cd36), FA binding and activation (Fabp4, Acsl1, and Acsl3, 
Acsl4), and FA oxidation (Cpt1b, Acox1, Acox2, Ehhadh, Acaa1a, and Acaa1b). 
PFHxS and PFOS also increased important genes involved in TG synthesis 
and VLDL assembly/secretion (Dgat1, Scd2, and Mttp). Taken together, these 
data indicate that the liver attempts to compensate for the large reduction in 
Figure 8. Effect of perfluoroalkyl sulfonates on the clearance of HDL-cholesterol. 
Mice received a Western-type diet without or with 0.03% PFBS, 0.006% PFHxS or 0.003% 
PFOS for 4 weeks. Mice were injected with autologous [3H]CO-labeled HDL and plasma 
samples were taken at indicated time points to determine the plasma clearance of [3H]CO 
(A). In a separate experiment, 4 h-fasted blood was taken at baseline (t0) and after 4 weeks 
of intervention (t4) and plasma was assayed for CETP mass (B). Data are means ± SEM (n = 
5). **P<0.01; #P<0.001; ##P<0.0001 as compared to control.
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VLDL production by increasing FA oxidation, binding and activation, and 
by mobilisation of FA for TG synthesis and secretion as VLDL. Most likely, 
these pathways are overshadowed by increased FA uptake and transport 
resulting in hepatomegaly with hepatic TG accumulation, possibly related 
to PXR activation218. PFHxS and PFOS also affected genes involved in HDL 
metabolism. They decreased genes involved in HDL synthesis (Apoa1) and 
maturation (Abca1, Lcat) and decreased the principle gene involved in HDL 
clearance (Scarb1). These data indicate that the observed large reduction in 
both HDL-C and apoAI are actually caused by decreased HDL synthesis and 
maturation, which results in a compensatory increase in SR-BI expression. 
Finally, PFHxS and PFOS affected genes in hepatic cholesterol metabolism. 
Both increased Acat1, involved in storage of cholesterol as cholesteryl esters, 
and decreased genes involved in bile acid formation (Cyp7a1) and secretion 
(Slc10a1, Slc10a2, and Abcb11) as well as cholesterol excretion (Abcg5, Abcg8). 
These data are in line with the observation that PFOS increases the hepatic 
cholesterol content and that both PFHS and PFOS decrease fecal bile acid 
secretion.
Table 3. Effect of perfluoroalkyl sulfonates on hepatic expression of genes encoding tran-
scription factors and proteins involved in lipid metabolism.
PFBS PFHxS PFOS
protein gene Δ q-value Δ q-value Δ q-value
Transcription factors
LXR alpha Nr1h3 -1.00 0.692 -1.19 0.039 -1.27 0.008
LXR beta Nr1h2 -1.16 0.304 -1.24 0.046 -1.08 0.277
PPAR alpha Ppara 1.10 0.453 -1.40 0.002 -1.40 0.003
PPAR gamma Pparg 1.07 0.619 1.25 0.179 1.52 0.042
CAR Nr1i3 -1.13 0.546 -1.01 0.443 1.82 0.007
FXR Nr1h4 -1.01 0.676 1.19 0.035 1.21 0.028
PXR Nr1i2 -1.03 0.622 1.28 0.006 1.59 <0.001
PGC1alpha Ppargc1a -0.18 0.547 -1.39 <0.001 -1.27 <0.001
PGC1beta Ppargc1b -0.30 0.458 -0.47 0.119 -0.44 0.139
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PFBS PFHxS PFOS
protein gene Δ q-value Δ q-value Δ q-value
Lipolysis
LPL Lpl 1.02 0.666 4.27 <0.001 2.13 <0.001
ApoCI Apoc1 -1.04 0.285 -1.03 0.209 -1.07 0.020
ApoCII Apoc2 1.01 0.672 -1.16 0.056 -1.30 0.003
ApoCIII Apoc3 -1.00 0.683 -1.04 0.139 -1.01 0.370
ApoAV Apoa5 -1.32 0.013 -2.01 <0.001 -1.61 <0.001
GPIHBP1 Gpihbp1 -1.25 0.189 1.19 0.103 1.36 0.012
FA uptake and  transport
FATPa1 Slc27a1 1.20 0.414 2.90 <0.001 2.33 <0.001
FATPa2 Slc27a2 1.10 0.060 1.08 0.022 1.07 0.043
FATPa4 Slc27a4 -1.01 0.684 2.84 <0.001 2.08 <0.001
FATPa5 Slc27a5 -1.00 0.683 -1.11 0.047 -1.08 0.127
CD36 Cd36 1.62 0.001 3.48 <0.001 3.40 <0.001
LDLR Ldlr 1.02 0.672 1.14 0.234 -1.23 0.137
PCSK9 Pcsk9 -1.08 0.636 1.40 0.172 -1.48 0.142
FA binding and activation
FABP1 Fabp1 -1.02 0.573 1.07 0.048 1.06 0.087
FABP2 Fabp2 -1.30 0.069 -2.04 <0.001 -2.20 <0.001
FABP4 Fabp4 1.51 0.077 3.25 <0.001 2.21 <0.001
FABP6 Fabp6 1.03 0.643 -1.12 0.199 -1.08 0.303
FABP7 Fabp7 -1.16 0.546 -2.20 0.004 -1.35 0.169
ACSL1 Acsl1 1.31 0.008 1.85 <0.001 1.73 <0.001
ACSL3 Acsl3 1.19 0.482 2.98 <0.001 1.71 0.016
ACSL4 Acsl4 1.19 0.170 2.08 <0.001 1.40 0.001
ACSL5 Acsl5 -1.10 0.437 1.42 0.002 1.03 0.407
ACSS1 Acss1 -1.01 0.671 1.23 0.021 1.18 0.057
ACSS2 Acss2 -1.24 0.498 1.95 0.023 -1.26 0.257
ACSM1 Acsm1 1.03 0.568 -1.19 0.004 -1.04 0.305
ACSM2 Acsm2 1.19 0.057 1.02 0.360 -1.02 0.371
ACSM3 Acsm3 -1.27 0.080 -1.32 0.005 -1.40 0.001
ACSM5 Acsm5 -1.24 0.116 -1.05 0.316 1.06 0.300
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PFBS PFHxS PFOS
protein gene Δ q-value Δ q-value Δ q-value
FA oxidation
CPT1a Cpt1a 1.01 0.675 -1.16 0.067 -1.12 0.143
CPT1b Cpt1b 1.04 0.645 2.91 <0.001 2.37 <0.001
ACO1 Acox1 1.14 0.071 1.46 <0.001 1.39 <0.001
ACO2 Acox2 1.02 0.629 1.20 0.003 1.33 <0.001
ACO3 Acox3 1.07 0.506 -1.16 0.081 -1.08 0.240
Bifunctional 
enzyme Ehhadh 1.37 0.008 3.19 <0.001 2.89 <0.001
Thiolase 1a Acaa1a 1.21 0.154 1.83 <0.001 1.82 <0.001
Thiolase 1b Acaa1b 1.10 0.069 1.29 <0.001 1.24 <0.001
Thiolase 2 Acaa2 -1.03 0.479 1.08 0.029 1.06 0.107
FA/TG synthesis
FAS Fasn -1.42 0.403 1.53 0.135 -1.13 0.374
DGAT1 Dgat1 -1.05 0.581 1.39 0.006 1.37 0.008
DGAT2 Dgat2 -1.09 0.360 -1.25 0.005 -1.16 0.042
SCD1 Scd1 -1.54 0.109 1.18 0.226 -1.03 0.420
SCD2 Scd2 1.14 0.282 1.65 <0.001 1.25 0.013
ACLY Acly -1.49 0.292 1.11 0.366 -2.47 0.003
S14 Thrsp -1.28 0.516 1.17 0.349 1.12 0.389
VLDL assembly
ApoB Apob -1.00 0.672 -1.07 0.073 -1.11 0.012
ApoBEC Apobec1 1.50 0.045 1.16 0.174 1.03 0.413
MTP Mttp 1.18 0.171 1.27 0.007 1.22 0.020
Cholesterol synthesis
ACLY Acly -1.49 0.292 1.11 0.366 -2.47 0.003
HMG CoA 
reductase Hmgcr -1.07 0.629 1.62 0.045 -1.28 0.204
HMG CoA 
synthase Hmgcs2 1.03 0.573 -1.03 0.337 1.05 0.244
Squalene 
synthase Fdft1 -1.25 0.342 1.78 0.003 -1.08 0.360
Cholesterol storage
ACAT1 Acat1 -1.06 0.370 1.17 0.002 1.10 0.034
ACAT2 Acat2 -1.10 0.569 1.77 0.006 -1.03 0.429
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PFBS PFHxS PFOS
protein gene Δ q-value Δ q-value Δ q-value
Cholesterol uptake
LDLR Ldlr 1.02 0.672 1.14 0.234 -1.23 0.137
PCSK9 Pcsk9 -1.08 0.636 1.40 0.172 -1.48 0.142
Cholesterol metabolism
CYP7A1 Cyp7a1 -1.19 0.624 -3.20 0.037 -3.78 0.021
IBAT Slc10a2 1.52 0.300 -2.45 0.005 -2.80 0.002
BSEP Abcb11 -1.19 0.198 -1.65 <0.001 -1.74 <0.001
NTCP Slc10a1 -1.24 0.191 -1.32 0.020 -1.34 0.014
Cholesterol excretion
ABCG5 Abcg5 -1.38 0.061 -2.06 <0.001 -1.83 <0.001
ABCG8 Abcg8 -1.61 0.061 -2.46 <0.001 -2.38 <0.001
HDL formation
ApoAI Apoa1 -1.10 0.148 -1.35 <0.001 -1.45 <0.001
ApoAII Apoa2 -1.05 0.289 -1.02 0.270 -1.01 0.373
HDL maturation
ABCA1 Abca1 1.01 0.635 -1.14 0.024 -1.09 0.092
LCAT Lcat 1.01 0.669 -1.43 <0.001 -1.35 <0.001
HDL remodeling
PLTP Pltp -1.07 0.629 2.28 0.002 1.31 0.171
Endothelial 
lipase Lipg -1.15 0.457 -1.04 0.398 -1.19 0.185
HL Lipc -1.17 0.081 -1.70 <0.001 -1.40 <0.001
HDL uptake
SRB1 Scarb1 -1.20 0.168 -2.31 <0.001 -1.76 <0.001
Mice received a Western-type diet without or with perfluoroalkyl sulfonates. Livers were 
collected after a 4 h fast, total RNA was extracted from livers of individual mice (n=6 
per group), and gene expression analysis was performed using Affymetrix GeneChip® 
mouse genome 430 2.0 arrays. Data represent mean fold change (Δ) as compared to the 
control group. Q-values are corrected for multiple testing. Values in bold are considered 
significant (q-value <0.05).
Discussion
This study investigated the mechanism underlying the effect of PFHxS and 
PFOS on plasma lipoprotein metabolism, as well as the importance of the 
alkyl chain length using E3L.CETP mice, a well-established model for human-
like lipoprotein metabolism114, 117, 118, 185, 219. At high exposure levels, PFHxS and 
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PFOS lowered plasma TG, VLDL-cholesterol and HDL-cholesterol, which 
is consistent with previous observations in toxicological studies207 - 211, 220, 221. 
In addition, it was demonstrated that the potency of PFAS to lower plasma 
lipids decreases with decreasing alkyl chain length (PFOS>PFHxS>PFBS). 
Mechanistic studies revealed that PFHxS and PFOS decreased lipoprotein levels 
primarily by severely impairing the production of VLDL and HDL, resulting in 
hepatomegaly with steatosis as well as combined hypolipidemia.
VLDL levels were decreased by all PFAS tested, albeit with different potency. 
Considering that the daily intake of PFBS (30 mg/kg/d) was five times that 
of PFHxS (6 mg/kg/d) and ten times that of PFOS (3 mg/kg/d), PFBS had 
considerably less effects compared with PFHxS and PFOS. This may, in part, 
be due to the much lower serum PFBS concentrations than those observed for 
PFHxS and PFOS. All PFAS tested accelerated VLDL-TG clearance from plasma 
to a similar extent. PFHxS and PFOS increased plasma LPL activity as well as 
LPL mRNA in the liver, suggesting LPL activity is increased due to an overall 
higher LPL expression, which increases the capacity of plasma to enhance VLDL-
TG clearance. Accordingly, the uptake of fatty acids was increased in the LPL-
expressing organs, skeletal muscle and white adipose tissue (WAT) as well as 
the liver (i.e. mainly within VLDL remnants). In contrast, PFBS did not increase 
hepatic LPL mRNA or plasma LPL activity, nor did it differentially affect hepatic 
gene expression of activators (apoA5, apoC2) or inhibitors (apoC1, apoC3) of LPL 
activity as compared to PFHxS and PFOS. This suggests that PFBS accelerates 
VLDL-TG clearance through a different, as yet unidentified mechanism.
The observation that PFHxS and PFOS were more effective in VLDL lowering 
than PFBS can be explained by the fact that PFHxS and PFOS, but not PFBS, 
severely impaired hepatic VLDL-TG production by as much as ~80%. This was 
a result of reduced VLDL particle production, because PFHxS and PFOS equally 
decreased the production of VLDL-TG and VLDL-apoB. The decreased VLDL-
TG production rate is presumably not explained by reduced availability of liver 
TG for VLDL synthesis, because both PFHxS and PFOS increased rather than 
reduced the hepatic TG content, similarly as observed in rats209. More likely, 
PFHxS and PFOS prevent the secretion of VLDL from the liver, resulting in lipid 
accumulation within the liver. This increase in liver lipid content may have led 
to upregulation of hepatic genes involved in FA binding and activation and FA 
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b-oxidation, and in mobilisation of FA for TG synthesis (Dgat1) and secretion as 
VLDL (Mttp) in an attempt to lower hepatic FA and thus TG levels.
Collectively, the data suggest that PFHxS and PFOS primarily impair 
the secretion of VLDL by the liver, leading to hepatic steatosis. The reduced 
production of VLDL-TG limits substrate availability for LPL on peripheral 
tissues, leading to less FA delivery to WAT and skeletal muscle. Because LPL-
mediated delivery of VLDL-TG-derived FA is a strong determinant of WAT mass 
and obesity138, this can explain why PFHxS and PFOS, but not PFBS, reduced 
gonadal WAT mass accompanied by a reduction of plasma free FA and glycerol 
that are mainly derived from TG lipolysis in adipose tissue.
PFHxS and PFOS also markedly decreased HDL levels, reflected by a 
reduction in HDL-C and apoAI. Since PFHxS and PFOS decreased HDL 
turnover in terms of mM HDL-C cleared per hour, these compounds thus lower 
HDL levels by reducing the synthesis and maturation of HDL. This is further 
supported by the fact that PFHxS and PFOS, but not PFBS, decrease the hepatic 
expression of Apoa1, Abca1 and Lcat, important for the generation of discoidal 
HDL precursors (apoAI), lipidation of these HDL precursors (ABCA1), and 
maturation of HDL (LCAT). The mechanism underlying the decrease in HDL 
turnover may relate to the observed decrease in hepatic Scarb1 expression and 
plasma CETP mass.
Nuclear receptors are important regulators of lipid metabolism, and changes 
in their expression patterns might thus underlie the effects of PFHxS and PFOS 
on lipid metabolism. PFOS has been demonstrated to trans-activate PPARa222 
and most effects of PFAA have in fact been attributed to activation of the PPARa 
pathway208, 209, 223, 224. Indeed, PFHxS and PFOS increased the hepatic expression 
of genes involved in both FA uptake and FA b-oxidation, and induced 
hepatomegaly similar as observed after treatment of E3L.CETP mice with the 
PPARa agonist fenofibrate219. However, PFHxS and PFOS also caused hepatic 
steatosis, decreased VLDL-TG production and decreased HDL levels, whereas 
fenofibrate did not induce hepatic steatosis, increased VLDL-TG production and 
increased HDL levels219, indicating that additional pathways must be involved.
Xenobiotic metabolism that is provoked by chemical pollutants for 
detoxification likely represents such an additional pathway. This involves the 
xenosensor receptors, pregnane X receptor (PXR) and constitutive androstane 
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receptor (CAR). Initially identified as xenosensors, it is now evident that PXR 
(and CAR) also trigger pleiotropic effects on liver function218. PFOS has been 
shown to interact with PXR and CAR85. In the present study, PFOS increased 
PXR expression, accompanied by an increase in Cyp3a11 (1.2-fold) and decrease 
in Cyp7a1 (-3.8-fold), both typical for PXR activation. In fact, the effect of PFOS 
on both liver TG and cholesterol accumulation, and reduction in HDL and 
fecal bile acids may all be explained by PXR activation. Indeed, specific PXR 
activation in E3L.CETP mice also reduces HDL accompanied by decreased 
hepatic expression of apoAI, ABCA1, LCAT and HL85. In addition, both PCN85 
and constitutive PXR expression82 caused accumulation of TG and cholesterol in 
the liver218, which is likely explained by the profound induction of FA transport 
genes including CD36 and FATP as observed in this study. Collectively, our 
data thus suggest that the effects of PFAS on lipid metabolism are the combined 
result of activation of nuclear receptors that include at least PPARa and PXR 
with PFHxS and PFOS as most potent activators.
This study confirms the findings from previous toxicological 
studies in animal models that PFHxS and PFOS reduce plasma 
TG and TC207 - 211, 220, 221, and provides mechanistic explanations. These 
observations are in seeming contrast with epidemiological studies in humans 
that have shown modest increases in nonHDL-C. Reductions in TC and TG have 
not been observed among exposed workers206 with serum PFOS concentrations 
as high as 10 μg/mL. On the contrary, recent cross-sectional studies in general 
population cohorts from the United States even showed positive correlations 
between PFOS levels and serum cholesterol, due to a positive correlation with 
nonHDL-C204, 205. However, a positive association of PFOS with nonHDL-C in 
workers with significantly higher serum concentrations than those found in the 
general population studies was not found206. In a recent report, no association of 
serum PFOS was found for either LDL or nonHDL-C, while a positive association 
was found for HDL-C in 723 adult Nunavik Inuit225. These observations and 
the mechanistic work reported in our present study suggest that the positive 
correlation between serum PFOS levels and cholesterol levels that has been 
found in some general population cohorts is not causal.
Large species differences have been reported with respect to the relative 
PFOS-induced activation of PPARa, PXR and CAR85. Since it is known that 
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humans are less sensitive to PPARa-related effects than rodents, with approx. 
10-fold lower expression of PPARa in liver compared with mice226, it is possible 
that in humans PPARa effects do not manifest themselves until higher body 
burdens are achieved, which would be consistent with the observations in 
cynomolgus monkeys given daily capsule doses of PFOS207. In the latter study, a 
marker of peroxisome proliferation was increased marginally but with statistical 
significance in male and female cynomolgus monkeys only in the high-dose 
group (0.75 mg/kg/d for six months). Serum TC and HDL-C were strongly 
reduced in this group without a reduction in TG, and hepatic steatosis was 
clearly apparent. Thus, these findings support the potential of a mixed PPARa 
and PXR response in the monkey.
In conclusion, we have demonstrated that PFHxS and PFOS reduce plasma 
TG and TC in E3L.CETP mice, by lowering both VLDL and HDL. Lowering of 
VLDL was the result of a decreased hepatic VLDL-TG production and increased 
VLDL-TG clearance. Lowering of HDL was explained by decreased production 
and maturation. These effects are dependent on the alkyl chain length, as PFBS 
had negligible effects, and can be explained by the combined action of PPARa 
and PXR/CAR activation.
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Supplemental Figure 1. Hierarchical clustering of scores for biological processes.
T-profiler analysis was performed using expression values corrected for mean expression in 
the control group. Pathways and biological processes with significant scores (>4 or <-4) in 
5 or 6 animals of at least one of the PFAS groups were selected. A hierarchical clustering of 
these pathways and biological processes and their scores in all samples was generated in 
GenePattern (Broad Institute, MIT, USA). Red indicates positive score (majority of genes in set 
are up-regulated), blue indicate negative score (majority of genes in set are down-regulated).
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High-fat diet-induced hepatic triglyceride accumulation or steatosis is associated with hepatic insulin resistance and hypothesized to play a role in the development of the pathology associated with the 
metabolic syndrome. However, steatosis is also induced by prolonged fasting, 
which is not associated with hepatic insulin resistance. To investigate whether 
different pathways lead to steatosis, we performed microarray analysis on 
livers of mice either fasted for 16 hours or fed a high fat diet for 2 weeks. We 
analysed expression of 7,500 genes and subsequently performed a pathway 
analysis to identify changes in hepatic gene expression in both models. Fasting 
induced a high number of differentially expressed hepatic genes, resulting 
in a change towards an energy saving phenotype. In contrast, only a small 
number of genes were differentially expressed after high fat diet. Fasting 
promoted gluconeogenesis and b-oxidation, strongly suppressed cholesterol 
synthesis and activated pathways to preserve hepatic function. High fat diet 
induced steatosis was accompanied by the activation of Scd1 and the lipogenic 
transcription factor Srebp-1c, both implicated in the development of hepatic 
insulin resistance. Thus, hepatic lipid overload caused by either prolonged 
fasting or a high-fat diet activates significantly different gene expression 
programs.
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Introduction
The metabolic syndrome represents a cluster of well-documented risk 
factors for the development of type 2 diabetes and cardiovascular disease. In 
addition to visceral obesity, dyslipidemia and insulin resistance (IR), excessive 
triglyceride (TG) accumulation in the liver has been implicated to play a role 
in the development of the metabolic syndrome227. Whether hepatic steatosis is 
primary or secondary to the development of insulin resistance may depend on 
specific pathology228. Numerous studies have shown that high fat diet induces 
hepatic steatosis, insulin resistance and obesity in rodents. Fasting, on the 
other hand, also increases hepatic TG content and this is due to the uptake of 
of adipocyte derived free fatty acids (FA’s). This form of hepatic steatosis, in 
response to a physiological stimulus most living beings are exposed to on a 
regular basis, develops in the absence of hepatic insulin resistance229.
This raises the question what the difference is between the development 
of hepatic steatosis due to increased dietary intake of fat and an increase 
of available FA’s due to release from adipose tissue. Since the liver plays a 
central role in coordinating the metabolic effects in response to alterations in 
nutrient availability, we speculated that the control of the expression of key 
genes involved in metabolism is differently regulated in these distinct forms 
of hepatic steatosis.
To examine hepatic gene expression in response to hepatic steatosis of 
different aetiology, we performed a microarray analysis on steatotic livers 
from mice fed a high fat diet for 2 weeks or fasted for 16 hours. Fasting-
induced steatosis is not associated with hepatic insulin resistance229 while 1 
week of high fat diet is enough to induce hepatic insulin resistance230. Here, we 
show that a number of genes that have been proposed to be involved in the 
development of hepatic insulin resistance are differently regulated in fasting 
compared to high fat induced steatosis. Furthermore, we show that a number 
of genes involved in detoxification and regulation of hepatic regeneration 
are induced in fasted livers while no such activation takes place in high fat 
diet treated animals. High fat diet on the other hand induces the activation of 
Scd1 and Srebp-1c, two genes that have been implicated as key factors in the 




Male C57Bl6/J, 12-16 week old mice (n=30) were housed in a 12h light/dark cycle 
under standard conditions. Animals had free access to food and water. Control 
mice were fed standard chow. Animals of the high fat group received a diet 
with 21.5 wt% saturated bovine fat (Hope Farms, Woerden, The Netherlands). 
Animals were sacrificed at 09:00 h AM after a 16 h fast for the fasted group 
or 4 h fast for the high fat and control group. Two separate experiments were 
performed. For each experiment 15 mice were randomly assigned to the different 
experimental groups (n=5 per group). Livers from experiment 1 were extracted 
at day 15 and used for RNA isolation and subsequent microarray and RT-PCR 
analysis. From animals of experiment 2, blood was collected at day 0, day 10 and 
day 15. All experiments were approved by the Animal Ethics Committee of the 
Leiden University Medical Center.
Plasma parameters
Plasma was obtained via tail vein bleeding in chilled paraxonized capillary 
tubes to prevent ex vivo lypolysis231, and assayed for glucose, insulin, TG, 
and total cholesterol using commercially available Kits (glucose hexokinase 
method (Instruchemie, Delfzijl, The Netherlands), ultra sensitive mouse insulin 
ELISA (Mercodia, Uppsala, Sweden), 1488872 and 236691 Roche Molecular 
Biochemicals, (Indianapolis, IN, USA), respectively). 
Isolation, amplification and labelling of RNA
Total RNA was isolated from livers of mice fed a high fat diet or chow for 2 weeks 
or an overnight fast (16 h). RNA was isolated with the NucleoSpin RNA® II-kit 
(Machery-Nagel, Düren, Germany). The RNA concentration was determined by 
absorbency at 260 nm with a NanoDrop (Isogen Life Science, Ijsselstein, The 
Netherlands), and RNA integrity was verified by use of the RNA 6000 Nano 
assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Amstelveen, 
The Netherlands). RNA was reverse transcribed with incorporation of amino-
allyl-UTP (aa-UTP) using the MessageAmpTM aRNA kit, according to the 
manufacturer’s instructions, then column purified and eluted in nuclease-free 
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water. A total of 3.75 mg column-purified aRNA of each liver was labelled with 
both monofunctional dyes, cyanine-3 (Cy3) and cyanine-5 (Cy5) (Amersham 
Biosciences, GE Healthcare, Diegem, Belgium), as previously described232 to 
allow all experiments to be performed as dye-swaps. Cy3 labelled aRNA of 
one experimental group was combined with Cy5 labelled aRNA of the other 
experimental group and vice versa. Combined probes were concentrated with 
Montage PCR columns (Millipore, Amsterdam, The Netherlands), recovered in 
TE and dye incorporation efficiency was then determined by wave-scan with 
the NanoDrop.
Hybridization of glass oligonucleotide microarrays
Murine oligonucleotide microarrays were produced in the Leiden Genome 
Technology Center by spotting the Sigma-Genosys mouse 7.5K oligonucleotide 
library (v. 1.0) (65mer, 20 μl in 50% DMSO) in duplicate on poly-L-lysine-
coated slides232. Hybridization was done as described previously232 with minor 
modifications. To the combined aRNA’s hybridization mix was added (final 
concentrations, 0.15 mg/ml yeast tRNA, 0.15 mg/ml poly(A)+ RNA, 3 x SSC and 
0.3% SDS), probes were denatured at 95°C for 2 min and centrifuged for 10 min 
at 13 000g. Hybridizations were performed overnight in Corning Hybridization 
chambers at 55°C in a water bath. Slides were washed with increasing stringency 
and then dehydrated by short washes in 70, 90 and 100% ethanol. After drying 
arrays were scanned with the Agilent G2565BA microarray scanner. Feature 
analysis was done with GenePix Pro 5.0 (Axon, Molecular Devices, Sunnyvale, 
U.S.A). Fluorescence intensities were normalized to median array densities to 
generate normalized measurements for each gene across all samples. 
Quantitative real-time PCR
One microgram of total RNA of individual animals was reverse transcribed 
into cDNA with the RevertAid™ H Minus first strand Kit (Fermentas, St.Leon-
Rot, Germany) primed with random hexamers. Thirty nanogram cDNA were 
amplified with gene specific primers in a 15 μl reaction containing 1 x SYBR-
green mix (BioRad, Veenendaal, The Netherlands). All primers were tested to 
have efficiency between 90 and 110%. All samples were amplified in duplicates 
on a MyiQ machine (BioRad). Values were normalized to the amount of two 
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endogenous control genes (Cyclophilin B and b-2-microglobulin) and relative 
changes in gene expression were then calculated with the iQ5-software version 
2.0 (BioRad). Three animals of each experimental group were analysed.
Statistical Analysis
All data are expressed as mean ± SD. Statistical analysis was performed by one-
way ANOVA with post hoc using Newmann-Keuls test. Microarray data were 
analysed with the limma-package233 from the Bioconductor software project 
(http://bioconductor.org) in the R environment for statistical computing (http://
www.R-project.org). Only genes with an average expression level exceeding 1.5 
times the background over all arrays and channels and a P-value < 0.05 were 
included in the pathway analysis. Associations with GO biological process, 
molecular function, cellular component groups, and biological pathways were 
obtained with the Web-based integrated data mining system WebGestalt234. A 
hypergeometric test was performed with the whole list of genes as the reference.
Results
Plasma parameters 
Plasma TG, total cholesterol, insulin and glucose were determined in 16 hour 
fasted, high fat fed and control animals. Table 1 summarizes plasma parameters 
at day 0, day 10 and day 15. Cholesterol was elevated in animals receiving 
the high fat diet at day 10 and increased further until day 15. TG was slightly 
decreased in 16 hour fasted mice at day 15 compared to controls. Glucose levels 
did not differ between controls and high fat diet fed mice at any time point. As 
expected, glucose was significantly reduced after 16 hours of fasting compared 
to controls at day 15. Insulin levels were not altered by high fat feeding and 
dropped bellow detection limits after 16 hours of fasting (data not shown). 
Gene expression changes induced by 16 hours of fasting or high fat diet 
We performed three comparisons by microarray analysis. A comparison was 
made between individual mice of the control and high fat fed or 16 hour fasted 
groups of mice. In addition, a direct comparison was made between high fat fed 
and 16 hour fasted animals. Based on the performed microarray experiments, 
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we could identify 390 differentially expressed genes comparing livers from 
high fat fed animals with livers from 16 hour fasted mice, 407 differentially 
expressed genes comparing 16 hour fasted animals to control animals and 65 
differentially expressed genes comparing high fat fed animals to control mice. 
Only 23 genes showed overlap in gene expression between the 16 hours fasted 
animals compared to control and high fat fed animals compared to control 
mice as is shown in figure 1.
Table 1. Plasma values measured in control, high fat fed and 16 hour 
fasted mice.
control high fat 16 hour fasted
Triglycerides (mmol/L)
day 0 0.8 ± 0.2 0.7 ± 0.1 n.d.
day 10 0.8 ± 0.1 0.7 ± 0.1 n.d.
day 15 0.9 ± 0.1 0.8 ± 0.2 0.5 ± 0.1 
Cholesterol (mmol/L)
day 0 2.8 ± 0.2 2.2 ± 0.2 n.d.
day 10 2.9 ± 0.3 4.0 ± 0.8 ***/a n.d.
day 15 2.5 ± 0.3 4.8 ± 0.5 ***/a 2.4 ± 0.1
Glucose (mmol/L)
day 0 6.4 ± 0.9 6.3 ± 0.6 n.d.
day 10 6.2 ± 0.8 7.1 ± 1.0 n.d.
day 15 6.2 ± 1.0 6.1 ± 1.1 4.1 ± 1.0 **
Values are expressed as means ± SD (n=5 in each group). *p<0.05, **p<0.01, 
***p<0.001 compared to controls and a <0.001 compared to day 0 of the 
same treatment group. Significance was determined by ANOVA followed by 
Newman-Keuls post-hoc test. n.d. not determined.
Figure 1 Venn diagram of differentially 
expressed genes
Hepatic expression of genes in 16 hour fasted 
mice compared to control and high fat fed 
mice compared to control and the overlap in 
gene expression between both groups.
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To get a better understanding of coordinated changes in their biological context 
we performed an analysis with the web-based tool “WebGestalt” to group 
genes according to their Gene Ontology (GO) categories. Table 2 summarizes 
pathways enriched with differentially expressed genes of the comparisons 
of high fat fed versus fasted, 16 hour fasted versus controls and high fat 
fed versus control. 16 hours of fasting induced the majority of differentially 
expressed genes detected as is implied by the overlap of affected pathways 
in the comparisons of high fat fed versus 16 hour fasted and 16 hour fasted 
versus controls. Only a relative small number of genes were differentially 
expressed in high fat fed animals compared to control. This small number of 
differentially expressed genes clearly hampered the pathway analysis. This is 
reflected by the higher P-values calculated by the hypergeometric test as well 
as the fact that only very general GO terms were relatively enriched (Table 2).
Table 2. Gene expression pathway analysis
16 fasted vs control 16h fasted vs high fat high fat vs control





alcohol catabolism     3 4.20E-03
alcohol metabolism 27 4.99E-09 20 2.67E-05 5 5.96E-03
carbohydrate catabolism     3 7.50E-03
carbohydrate metabo-
lism 31 1.25E-06     
carbon-oxygen lyase 
activity 11 1.86E-06     
carboxylic acid metabo-
lism 40 6.75E-11 34 3.37E-08   
cellular carbohydrate 
metabolism 22 8.54E-05   3 7.50E-03
cellular catabolism     7 3.13E-03
cellular lipid metabolism 49 2.58E-16 38 4.23E-10   
cholesterol biosynthesis 5 9.01E-05     
cholesterol metabolism 10 1.36E-05     
cofactor metabolism   16 1.53E-05   
complement activation 9 6.81E-06     
complement activation, 
classical pathway 8 5.00E-06     
electron transport 30 7.97E-09 22 5.97E-05 9 9.91E-06
Gene expression profiles in hepatic steatosis 117
 6
16 fasted vs control 16h fasted vs high fat high fat vs control






activity     4 3.81E-03
endoplasmic reticulum 42 8.72E-10   9 5.31E-04
energy derivation by 
oxidation of organic 
compounds
17 1.71E-06     
fatty acid metabolism 19 6.20E-08 14 7.50E-05   
generation of precursor 
metabolites and energy 47 4.15E-13 34 9.15E-07 12 1.60E-06
glucose catabolism     3 3.86E-03
glucose metabolism     4 1.93E-03
glutathione transferase 
activity     3 2.61E-04
glycolysis     3 2.96E-03
hexose catabolism     3 3.86E-03
hexose metabolism     4 4.31E-03
humoral defense mecha-
nism (sensu Vertebrata) 9 9.38E-05     
hydro-lyase activity 10 3.90E-06     
lipid biosynthesis 26 3.43E-11 18 5.94E-06   
lipid binding     7 3.28E-03
lipid metabolism 53 1.08E-15 42 5.19E-10   
lipid transport     4 1.41E-04
lipid transporter activity     3 3.61E-03
lipoprotein metabolism     3 1.77E-03
mitochondrial envelope 23 1.80E-07 19 2.99E-05 23 1.97E-03
mitochondrial inner 
membrane 18 1.18E-05     
mitochondrial mem-
brane 18 2.67E-05     
mitochondrion 58 2.75E-16 46 1.03E-09   
monooxygenase activity 17 1.37E-08   6 1.82E-05
monosaccharide catabo-
lism     3 3.86E-03
monosaccharide me-
tabolism     4 4.31E-03
organelle envelope 24 4.32E-06     
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brane 19 7.09E-06 17 7.51E-05   
organelle membrane 28 7.23E-05     
organic acid metabolism 40 6.75E-11 34 3.37E-08   
peroxisome 14 2.29E-07 14 1.83E-07   
protease inhibitor activ-
ity     4 3.81E-03
steroid biosynthesis 16 1.07E-12 10 2.95E-06   
steroid dehydrogenase 
activity 6 7.75E-06 6 6.81E-06   
steroid metabolism 22 1.41E-11 20 3.03E-10   
sterol biosynthesis 7 1.97E-06     
sterol metabolism 12 4.12E-07     
Pathways with a P-value <0.01 determined by hypergeometric test in the comparison of 
16 hour fasted versus controls, 16 hour fasted versus high fat fed and high fat fed versus 
controls.
Expression of key genes involved in energy homeostasis by RT-PCR
We confirmed the changes detected with the microarray analysis by 
performing RT-PCR on a number of differentially expressed genes. We selected 
five up- (Pcx, Cpt1a, Crat1, Cyp8b1 and Cyp3a13) and four down-regulated 
genes (Cyp51, Elovl3, Gck, and Sqle) from the 16 hour fasted versus control 
and high fat versus control comparison to confirm our array findings. Table 
3 summarizes the results of the RT-PCR experiments. We could confirm the 
findings of the microarray experiment with the exception that 3 genes reached 
statistical significance in the RT-PCR experiment in the high fat fed group that 
had not been significant in the microarray experiment.
A number of genes known from the literature to be involved in the 
development of obesity and the metabolic syndrome did not pass the technical 
selection threshold or were not present on the microarray at all. We therefore 
decided to extend the analysis with additional RT-PCR experiments to analyze 
the expression of a selected set of transcription factors and genes suspected to 
play a role in the development of obesity and the metabolic syndrome (Fig. 2). 
Compared to control, the Farnesoid X receptor (Fxr, gene name: Nr1h4) was 
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increased in both groups, but more pronounced in 16 hour fasted animals. The 
same was true for the Liver X receptor alpha (Lxra, Nr1h3), Pregnane X receptor 
(Pxr, Nr1i2) and the Hepatic Nuclear Factor 4 alpha (Hnf4a, Nr2a1) (Fig. 2a). In 
contrast, we detected an increase in hepatic peroxisome proliferate activated 
receptor alpha (Ppara, Nr1c1) expression in high fat fed mice which was absent 
in 16 hour fasted livers and was not detected on microarray. The PPAR delta 
isoform (Ppard, Nr1c2) was not altered in either group while the PPAR gamma 
isoform (Pparg, Nr1c3) was up-regulated in livers of 16 hour fasted animals 
but not in those fed a high fat diet. This up-regulation of Pparg in 16 hour 
fasted animals was accompanied by a concomitant increase in PPAR gamma 
co-activation factor 1a (Ppargc1a) expression which was absent in high fat fed 
mice while no change in Ppargc1b expression was detectable in either group 
(Fig. 2b).  For the sterol regulatory element binding proteins family (Srebp’s), 
Srebp-1a showed the same pattern as Ppara with only an increase in expression 
in high fat fed mice. Srebp-1c on the other hand, was upregulated in high fat 
fed animals but downregulated in 16 hour fasted animals, compared to control. 
This same pattern of expression was seen for stearoyl-CoA desaturase (Scd1). 
The constitutive androstane receptor (Car) was exclusively up-regulated in 
livers of 16 hour fasted animals.
Table 3. Validation of microarray gene expression data with RT-PCR
16 hr fasted vs control high fat vs control
Gene Array, Ratio PCR, relative expression Array, Ratio 
PCR, relative 
expression 
Pcx + 1.56** 3.43*** + 1.16 1.43   
Cpt1a + 1.46*    3.85*** + 1.16 1.82* 
Crat1 + 1.53**  5.87*** + 1.04 1.20   
Cyp8b1 + 2.42*** 4.39*** -  1.18 1.14   
Cyp3a13 + 1.66** 3.45*** -  1.12 0.90   
Cyp51 -  2.47*** 0.33** + 1.10 1.06    
Elovl3 -  4.10*** 0.26** -  1.19 1.34**
Gck -  3.60*** 0.35** + 1.12 2.30**
Sqle -  1.37*   0.24*   -  1.05 1.18    
Relative expression to controls as determined with the ΔΔCt-method. PCR Values are 
means of 3 animals per group. *p<0.05, **p<0.01, ***p<0.001 as determined by ANOVA 
followed by Newman-Keuls post-hoc test.
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Figure 2 Expression levels of selected transcription factors determined by real-time PCR 
in livers from high fat fed or fasted mice relative to controls.
Relative expression to controls as determined with the ΔΔCt-method. Data represent means 
of 3 animals per group. *p<0.05, **p<0.01, ***p<0.001 as determined by ANOVA followed 
by Newman-Keuls post-hoc test.
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Discussion
Hepatic steatosis can be induced in mice by fasting for 16 hours and is 
accompanied by an increase in hepatic TG content comparable to that induced 
after two weeks of high fat diet230. In contrast to steatosis induced by high fat 
diet, the fasting response does not result in the development of hepatic insulin 
resistance. We have investigated the alterations in hepatic gene expression 
induced by 16 hour fasting or two week high fat diet exposure to identify genes 
that are differentially expressed in these distinct forms of steatosis. Fasting 
had a profound effect on pathways involved in lipid metabolism, fatty acid 
metabolism, steroid metabolism and biosynthesis, carbohydrate metabolism 
as well as on energy generation related genes. These changes reflected the 
expected shift from glucose utilization towards energy generation derived 
from fatty acid oxidation. Interestingly, we also detected the up-regulation of 
a number of genes involved in hepatic detoxification. 
Fasting induces a shift in fuel utilization for energy generation from 
glucose to FA’s. This was reflected by significant changes in enzymes 
involved in glycolysis: glucokinase (Gck) was down-regulated and aldolase 
A (AldoA) was up-regulated in fasted liver, which was detected in the 
microarray experiments. We further detected the up-regulation of the lactate 
dehydrogenases A (Ldha) and B (Ldhb) (microarray) together with pyruvate 
carboxylase (Pcx) (both microarray and RT-PCR (Table 3)). Pcx encodes the 
mitochondrial enzyme that converts pyruvate to oxaloacetate and thus 
provides intermediates for the citric acid cycle235. 
The shift towards FA utilization upon fasting was further reflected by an 
up-regulation of several genes involved in mitochondrial FA b-oxidation. 
With microarray analysis, we detected up-regulation of acyl-CoA synthetase 
long-chain family member 1 (Acsl1), carnitine palmitoyltransferase 1a (Cpt1a), 
solute carrier family 25 (Slc25a20), acyl-Coenzyme A dehydrogenase very 
long chain (Acadvl), acyl-Coenzyme A dehydrogenase long-chain (Acadl), 
acyl-Coenzyme A dehydrogenase, medium chain (Acadm), dodecenoyl-
Coenzyme A delta isomerase (Dci) and enoyl-Coenzyme A, hydratase/3-
hydroxyacyl Coenzyme A dehydrogenase (Ehhadh). Interestingly, we saw 
a down-regulation of peroxisomal trans-2-enoyl-CoA reductase (Pecr), the 
hepatic microsomal enzyme that catalyses the reduction of trans-2-enoyl-
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CoAs of varying chain lengths from 6:1 to 16:1. None of these genes were 
identified as differentially expressed in livers from mice fed a high fat diet 
(data not shown). The change in the expression of Cpt1 was also confirmed 
with RT-PCR (Table 3). 
One of the most prominently affected pathways in fasted livers was 
cholesterol biosynthesis. The SREBP family of transcription factors is known 
to represent the master regulators of lipogenesis and cholesterogenesis. They 
are able to directly activate genes involved in the synthesis and uptake of 
cholesterol, fatty acids, TG’s and phopsholipids236. Of the three isoforms 
SREBP-1a, -1c and -2 it is known that SREBP-2 is the main regulator of 
cholesterol synthesis if expressed at physiological levels. We did not detect a 
change in the microarray experiments and only a minor decrease in SREBP-2 
transcript with PCR in the fasted livers, but this was not significant. One 
of the known target genes of SREBP-2, HMG-CoA reductase (Hmgcr) was 
also not changed. However, both SREBP-2 and HMG-CoA reductase have 
been shown to be subject to post-transcriptional regulation237, 238. Since we 
have not measured activated protein levels of SREBP-2, we can not exclude 
that these might be diminished in the situation of fasting. Nonetheless, 
even in the absence of changes in gene expression levels of SREBP-2, we 
did see reduced expression levels of the SREBP-2 regulated genes Mevalonate 
kinase (Mvk), farnesyl diphosphate farnesyl transferase (Fdft1), Squalene epoxidase 
(Sqle), cytochrome P450 family 51 (Cyp51), sterol C5 desaturase (Sc5d) and 
7-dehydrocholesterol reductase (Dhcr7)78 in fasted livers compared to control 
mice fed chow diet (data not shown). The down-regulation of Cyp51 and 
Sqle was also confirmed by RT-PCR (Table 3). Overall, these data confirm 
previous results showing that fasting results in downregulation of the 
cholesterol biosynthesis pathway239.
Another pathway affected by fasting included the regulators of hepatic 
detoxification processes, pregnane X receptor (Pxr) and constitutive 
androstane receptor (Car). Car was exclusively up-regulated in livers of fasted 
animals as detected by microarray and RT-PCR while Pxr was up-regulated 
in livers of fasted animals and also modestly increased in high fat fed mice 
(Fig. 2). Target genes regulated by these lipid-activated nuclear transcription 
factors include, among others, the family of cytochrome P-450 enzymes and 
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cytosolic binding proteins240. We could detect up-regulation of 8 Cyp-family 
members (Cyp3a13, Cyp3a25, Cyp4a10, Cyp4a14, Cyp8b1, Cyp17a1, Cyp26a1 and 
Cyp39a1) and down-regulation of 3 members (Cyp2f2, Cyp2j6 and Cyp4f14) in 
our microarray experiments when we compared fasted livers with those of 
controls. In livers of high fat fed mice all 6 detected Cyp-family members 
(Cyp2a4, Cyp2f2, Cyp3a25, Cyp4a10, Cyp4a14 and Cyp4a41) were down-
regulated when compared to controls. Two of these, Cyp4a10 and Cyp4a14, 
appear to be regulated diametrically opposed in fasted and high fat fed mice, 
which makes them potential target genes of Car. The activation of hepatic 
detoxification was further supported by the up-regulation of two members 
of the sulfotransferase family of phase-II conjugation enzymes, Sult1a1 and 
Sult1d1. These enzymes help to conjugate endo- and xenobiotics with a 
sulfonate group to render them water soluble and excretable. Interestingly, 
it has recently been demonstrated that CAR and PXR also play a role in the 
regulation of hepatic energy metabolism by influencing gluconeogenesis, 
beta-oxidation, ketogenesis, lipogenesis and thyroid hormone activity via 
crosstalk with transcription factors such as FOXO1241.
As can be seen in Figure 2a, changes in the expression of nuclear 
transcription factors belonging to the PPAR family were mainly seen in fasted 
livers. High fat diet did induce a mild up-regulation of Pparg. Pparg activation 
stimulates FA transport, FA oxidation, ketogenesis and gluconeogenesis. 
Pparg is a regulator of adipogenesis and induces FA uptake and storage when 
activated. It has therefore been proposed that the up-regulation of Pparg is 
a mechanism that allows hepatocytes to facilitate storage of excess FA's in a 
way that will not cause damage to the cell242. There are several mouse models 
of obesity in which the development of hepatic steatosis was correlated with 
increased hepatic levels of Pparg243, 244. The transcription of Ppargc1a is a co-
activator of FOXO-1 and has been shown to be intimately involved in the 
regulation of energy metabolism in response to fasting245. 
We have not found direct evidence of altered insulin signalling, but two 
genes, Scd1 and Srebp-1c, which have been associated with the development of 
hepatic steatosis and IR, were inversely regulated in fasting and high fat diet. 
We detected a significant down-regulation of Srebp-1c, the main regulator 
of the fatty acid biosynthesis pathway in fasted livers and a significant 
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up-regulation in livers of high fat fed mice (Fig. 2). There is evidence that 
hepatic steatosis and IR is associated with an up-regulation of Srebp-1c, 
which is increased in response to the elevated insulin levels as seen in the 
leptin deficient ob/ob mice78. Furthermore, hepatic overexpression of Srebp-1c 
in transgenic mice leads to an increased de novo synthesis of TG which can 
cause hepatic steatosis 246. A potential mechanism for the role of SREBPs in 
the development of IR is a direct interaction with the promoter of the insulin 
receptor substrate 2 (IRS-2). The IRS-2 promoter contains an insulin response 
element and is regulated by the forkhead proteins. It has been shown that 
this binding site can be occupied by all three SREBP isoforms and results in 
decreased IRS-2 transcription and protein, providing a potential molecular 
mechanism that explains the switch to increased lipogenesis and decreased 
hepatic glycogen synthesis seen in obesity and the metabolic syndrome247.
Scd1 was exclusively regulated in response to high fat diet and has been 
shown to be modulated in response to dietary, physiological and hormonal 
stimuli, including insulin and polyunsaturated FA’s248. Absence of Scd1 
has been associated with the resistance to diet induced obesity and IR248, 249. 
Experiments with anti-sense oligo (ASO) treatment confirmed a role of Scd1 
in IR. In these experiments, severe hepatic insulin resistance as determined 
by insulin clamp studies was reversed by 5 day treatment with a ASO against 
Scd1 which resulted in a 80% reduction of hepatic mRNA levels of Scd1, 
comparable to the reduction seen in livers of fasted mice (Fig. 2c).
The most striking difference comparing livers from fasted mice with high 
fat diet fed mice was the number of differentially expressed genes.  While 
fasting induced changes in the expression of more than 400 hepatic genes 
compared to chow fed mice, only a small number of differentially expressed 
genes could be detected in response to a two week period of high fat diet 
feeding. Apparently, the metabolic adaptation induced by high fat feeding 
does not represent a strong adaptive signal and can be achieved without 
all too dramatic changes in the hepatic transcriptional program. Since 
prolonged fasting endangers survival and fertility and thus survival of the 
species, selective evolutionary pressure for a strong adaptive response upon 
fasting would have been beneficial.
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Nowadays, our energy intake chronically exceeds the energy we use, and therefore fat accumulates resulting in overweight and obesity. The energy in our diet is stored as carbohydrates and fat. Since the 
storage of carbohydrates in the body is limited, excess energy is stored as 
fat and mobilized again during fasting to provide energy. This mobilization 
occurs by the release of fatty acids (FA) by adipose tissue into the circulation. 
Part of the FA are used directly for ATP supply following oxidation, but a large 
fraction of the FA enters the liver where FA are re-esterified into triglycerides 
(TG) that are secreted as part of the core of VLDL particles by the liver. These 
VLDL particles deliver FA to peripheral tissues where they can be used to 
generate energy. The cycling of FA and TG enables us to adapt to changes in 
energy demand, but the western daily energy intake exceeds our ability to 
maintain homeostasis. 
Obesity is strongly associated with metabolic dyslipidemia, which is 
characterized by low levels of HDL-cholesterol (C) and high levels of TG. 
Additional pathologies associated with obesity include high blood pressure 
and systemic inflammation and, collectively, these abnormalities are known 
as the metabolic syndrome (MetS). MetS is probably the most prevalent cause 
for the current increase in patients with diabetes mellitus type 2 (DM2) and 
cardiovascular disease (CVD). The studies described in this thesis evaluated 
several aspects of the regulation of VLDL-TG metabolism and the main 
conclusion and implications of our findings are discussed in this chapter.
CETP and VLDL metabolism
Cholesteryl ester transfer protein (CETP) transfers TG and cholesteryl esters 
between lipoproteins and has a major impact on cholesterol metabolism by 
decreasing HDL-C and increasing LDL-C. Although CETP also transfers TG, it 
was not clear whether and to what extent CETP would affect TG metabolism. 
In a small study with three heterozygous CETP deficient persons, it was 
shown that the postprandial TG response after an oral fat load was decreased 
compared to normal persons, suggesting that CETP may retard TG clearance 
from plasma250. In naturally CETP-deficient mice, it was shown that expression 
of human CETP increased the postprandial TG response after an oral fat load 
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by reducing the clearance rate of chylomicron-like lipoprotein particles, due 
to reduced LPL activity140. Thus, CETP may have the capacity to affect TG 
metabolism. 
In chapter 2, we studied the role of CETP on VLDL metabolism in ApoE*3-
Leiden (E3L) mice. E3L mice have a more human-like VLDL metabolism than 
wild type mice and have been extensively used to dissect the effects of diets 
and drugs on lipoprotein metabolism114, 115, 117, 118. The expression of human 
CETP, under control of its natural flanking regions, in the E3L background 
enables us to study both VLDL and HDL metabolism in a more human-
like setting. Our experiments in chapter 2 indicate that CETP mainly affects 
cholesterol metabolism and not TG metabolism. In addition, expression of 
CETP did not affect high fat diet-induced obesity. This suggests that also 
under conditions where TG/FA metabolism is stressed, CETP does not affect 
TG metabolism. The major implication of these findings is that it is unlikely 
that pharmaceutical modulation of CETP activity affects TG metabolism and 
obesity in humans. Although this does require validation in human studies, it 
indicates that potential negative side-effects of CETP inhibitors in relation to 
obesity and related diseases are less likely to occur.
Recently, several drugs have been developed to inhibit CETP, thereby 
increasing HDL-C and reducing the risk for CVD. Of these CETP inhibitors, 
torcetrapib was the first drug used in large clinical trials (RADIANCE251, 
ILLUSTRATE252, and ILLUMINATE122). Although the outcome of these trials 
were negative, probably related to off-target side-effects of torcetrapib, 
combination therapy of atorvastatin and torcetrapib for 2 years increased 
HDL-C by almost 60% compared to patients receiving atorvastatin alone. In 
these studies, torcetrapib caused only a minor reduction in plasma TG (-16%). 
Short-term treatment with anacetrapib, a more recent CETP inhibitor, had 
no effect on plasma TG levels253. These data support our findings that CETP 
inhibition does not evoke major effects of plasma TG metabolism. 
Our data also indicate that CETP does not affect the development of diet 
induced obesity. However, obese subjects do present with increased circulating 
levels of CETP, indicating that obesity per se does affect CETP level and activity. 
It is likely that this is a direct consequence of the increase in adipose tissue, 
which has been demonstrated to be an important source of plasma CETP254, 255, 256. 
130
This is further supported by the reduction in CETP mass and activity after 
marked weight loss257, 258, 259. However, since obesity is associated with multiple 
metabolic abnormalities, it cannot be excluded that alternative mechanisms 
explain the association of obesity with increased CETP activity.
Plasma CETP activity is dependent on CETP levels, protein levels of 
activators and inhibitors, as well as on the presence and composition of 
donor and acceptor particles for lipid exchange. Variations in the CETP 
gene, characterized by single point mutations (called single nucleotide 
polymorphisms, SNPs), are related to changes in CETP plasma levels and 
activity. The most studied SNP in the CETP gene is the so-called Taq1B 
polymorphism. CETP mass and activity are higher in carriers of the Taq1B1 
allele compared to carriers of the Taq1B2 allele, which is associated with lower 
HDL-C levels in B1 carriers260. Most meta-analyses show that high TG levels 
are causal to the interaction of the Taq1B polymorphism with HDL-C in obese 
subjects by providing more acceptors for the transfer of cholesterol from HDL 
to apoB containing lipoproteins261. Low levels of HDL-C and high levels of TG 
are risk factors for the development of CVD. Therefore it appears that although 
CETP does not directly affect TG metabolism, TG levels do determine the effect 
of genetic variation in CETP on cholesterol metabolism thereby increasing the 
risk to develop CVD.
Nuclear receptor ligands and VLDL metabolism
Nuclear receptors play an important role in the orchestration of energy 
metabolism and are important targets for drug development for diseases 
associated with the MetS. Nuclear receptors regulate the expression of genes 
involved in energy homeostasis and numerous other processes by binding to 
specific DNA regulatory elements. The natural ligands of nuclear receptors 
include hormones and lipid intermediates. One of the physiological roles 
of a subset of nuclear receptors is to function as sensors of energy status 
by activating or inhibiting specific target genes and pathways to maintain 
homeostasis. 
Various drugs act by functioning as synthetic ligands for specific nuclear 
receptors and thus affect energy metabolism. For example, the fibrate class of 
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compounds activate peroxisome proliferator-activated receptor alpha (PPARa) 
and are prescribed to lower plasma TG levels. Thiazolidinediones (TZDs) 
activate PPARg and are prescribed to lower plasma glucose and lipid levels 
in DM2 patients. However, TZDs also lower FA turnover, thereby effectively 
lowering hepatic fat content262. More drugs that target nuclear receptors do also 
influence lipid and energy metabolism as a side effect. For example, rifampicin 
is an antibiotic drug that activates pregnane X receptor (PXR) and can cause 
hepatic lipid accumulation and steatosis86, 180, 181. In this thesis, a number of 
compounds that act via nuclear receptors have been investigated to determine 
the precise mechanism by which they affect VLDL-TG metabolism.
Fenofibrate
In chapter 3 we focussed on the effect of the TG-lowering drug and PPARa 
activator fenofibrate on VLDL-TG metabolism. In the past, it has been shown 
that activation of PPARa lowers plasma TG levels by increasing the clearance 
of VLDL-TG. However, it was also suggested that PPARa reduces VLDL-TG 
production. First, in vitro experiments showed that incubation of cultured 
hepatocytes with fenofibrate reduced TG secretion153. Second, experiments 
using the strong PPARa agonists Wy14643 also showed a reduction of VLDL 
secretion in vivo152. In addition, mice lacking PPARa show increased VLDL 
production150, 151. However, the effect of fibrates on VLDL secretion in humans 
remains inconclusive as either decreased or no changes in apoB production 
were observed whereas no effects on VLDL-TG production have been 
reported263, 149. 
To dissect the effect of PPARa modulation on VLDL-TG metabolism in 
a more human-like setting, we used E3L.CETP mice receiving a clinically 
relevant dose of fenofibrate. In chapter 3 we showed that fenofibrate actually 
increases rather than decreases VLDL-TG secretion without altering the rate 
of VLDL-apoB production. Furthermore, VLDL-TG clearance was strongly 
enhanced explaining the overall reduction in plasma TG, which can be 
explained by an increase in of lipoprotein lipase (LPL) activity. Part of the FA 
liberated by lipolysis are not directly taken up by the underlying tissue but add 
to the plasma pool of albumin-bound FA, which is taken up by the liver. The 
increased hepatic uptake of albumin-bound FA contributed to the increased 
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flux of FA through the liver, resulting in higher VLDL-TG production and an 
increased particle size of nascent VLDL particles. This implies that PPARa 
activation by fenofibrate increases FA turnover.
In MetS, and especially obesity, FA overflow also occurs and it is believed 
that the increased FA turnover plays a role in the development of DM2. 
However, treatment with fenofibrate in diet-induced obese mice showed that 
activation of PPARa actually prevented severe obesity, adipocyte hypertrophy 
and maintained normal glycaemia264, 265. Together these data suggest that the 
increased FA turnover per se is not sufficient to induce pathology associated 
with MetS and is likely compensated by the regulation of additional pathways 
affected by PPARa activation.
Systemic inflammation is another feature of MetS that might trigger 
pathology in obese people. PPARs have been shown to play a role in 
macrophage activation in the vasculature thereby reducing atherosclerosis266. 
PPARa has been shown to have a more general effect on inflammation by 
inhibiting the activation of peritoneal macrophages by lipopolysaccharide 
(LPS)267. Activation of PPARa inhibits the expression of genes involved in the 
acute phase response and inflammatory cytokines including interleukin-6 
(IL-6) and tumor necrosis factor alpha (TNF-a)268. Patients with dyslipidemia 
indeed show reduced levels of IL-6 and TNF-a when treated with fenofibrate269. 
Therefore the suppression of inflammation might be the reason why increased 
FA turnover by fenofibrate does not induce pathology. This is supported by a 
study in mice showing that hepatic PPARa activation suppresses expression of 
hepatic TNF-a and reduces hepatic fat accumulation during the development 
of fatty liver disease270. Small studies in humans showed no reduction of 
hepatic TG content upon treatment with fenofibrate263, 271. However in one 
of these studies, patients with NAFLD treated with fenofibrate did show 
improvement of MetS and liver function271. It would therefore be interesting 
to determine whether this anti-inflammatory effect of PPARa activation is 
sufficient to prevent pathology associated with increased FA turnover.
Since side-effects have been reported for fenofibrate including 
gastrointestinal disorders and skin reactions, new PPARa therapeutics are 
being developed that exhibit tissue- and gene-selective activities. Collectively, 
such agonists are known as selective PPAR modulators (SPPARMs). These 
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SSPARMs may provide novel insight in the role of specific PPARa-induced 
pathways in specific tissues in the development of MetS. 
Rifampicin
Rifampicin is an antibiotic prescribed for the treatment of tuberculosis and is also 
a ligand for the nuclear receptor pregnane X receptor (PXR). Activation of PXR is 
associated with alterations in lipid metabolism and hepatic steatosis85, 86, 180, 181, 182,  272. 
Furthermore, rifampicin might also directly affect lipoprotein metabolism 
since its metabolites (known as ansamycins) can directly bind lipoproteins 
which might influence lipoprotein clearance273, 274. In chapter 4 we determined 
the effect of rifampicin on VLDL-TG metabolism. Treatment with rifampicin 
induced hepatic steatosis and strongly reduced plasma cholesterol levels 
whereas plasma TG levels were unaltered. The reduction of cholesterol was 
mainly confined to the VLDL-sized fraction and due to reduced VLDL-particle 
production by the liver. However, this was not reflected by a reduction in 
plasma TG levels. This could be explained by TG enrichment of secreted VLDL 
itself. 
Rifampicin treatment in obese people should be critically considered. In 
obesity, insulin resistance of the liver and adipose tissues is associated with 
hypertriglyceridemia due to increased VLDL-TG production. This can be 
attributed to the failure of insulin to suppress the FA flux from adipose tissue 
to the liver and the failure of insulin to inhibit VLDL production. Increased 
levels of VLDL-TG result in increased CETP activity and reduced HDL-C 
levels. Treating obese patients with rifampicin might further reduce HDL-C 
levels in a CETP-independent manner by reducing the formation of HDL. 
Overall this may further increase their risk to develop CVD.
Liver insulin resistance in obesity is also associated with hepatic steatosis. 
Similar to our findings in mice, rifampicin treatment has been reported to 
cause hepatic steatosis, especially in patients that consumed large amounts of 
alcohol. People consuming more than 6 alcoholic drinks per day are at great 
risk to develop alcoholic hepatic steatosis since alcohol affects multiple steps 
in hepatic FA metabolism. Thus, care should be taken in the administration of 
rifampicin to heavy drinkers as well as patients with the MetS, since this might 
exacerbate the exisiting hepatic steatosis.
134
Perfluoroalkyl sulfonates
Chemical pollutants such as pesticides, industrial solvents and plasticizers 
can disrupt energy homeostasis by interfering with nuclear receptor-mediated 
gene expression. We are exposed to these pollutants via water, air and our diet 
and they mimic lipids or hormones due to their chemical structure. However, 
how and to what extent FA/TG metabolism is affected by these pollutants is 
hardly known. 
Perfluoroalkyl sulfonates (PFAS) are widely used as repellents, surfactants 
and fire-retardant foams195, 199. They are extremely resistant to metabolic and 
environmental degradation and therefore bio-accumulate. Studies in animal 
models have shown that PFAS affect plasma lipid parameters although the 
exact mechanism is not known. In chapter 5, we show that PFAS activate 
multiple nuclear receptors and mainly PPARa and the xenobiotic receptors 
Constitutive Androstane Receptor (CAR) and PXR. This results in an almost 
complete blockade of both VLDL-TG and VLDL-apoB production, whereas 
VLDL-TG clearance is increased. 
In addition to PFAS, there are various chemical pollutants present in our 
environment that can affect energy homeostasis of which some have recently been 
shown to cause obesity (called obesogens). Obesogens can be functionally defined 
as chemical agents that promote lipid accumulation and adipogenesis275, 276. 
These obesogens include bisphenol A, various xenoestrogens, organotins 
and phthalates, many of which end up in the human due to their use as, for 
example, surfactants or due to the ubiquitous use of pesticides and plastics 
from which they are derived. In addition to influencing energy homeostasis 
by activating multiple nuclear receptors, these pollutants might also affect 
inflammatory gene expression via the same nuclear receptors. However, the 
net effect of these compounds on the various pathways that are regulated via 
nuclear receptors are largely unexplored.
Role of nuclear receptors in metabolic stress
Whole body energy homeostasis is tightly regulated. During fasting or 
excessive caloric intake, energy balance is disrupted and adaptations in energy 
metabolism are necessary to maintain homeostasis. Both PPARa and CAR 
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are involved in the metabolic adaptations that occur during fasting. PPARa 
regulates the uptake and transport of FA in the cell, activates b-oxidation, and 
activates ketone body synthesis. CAR on the other hand inhibits b-oxidation 
by competing with PPARa for its binding site in the 3-hydroxyacyl-CoA 
dehydrogenase gene promoter, an important enzyme of peroxisomal FA 
b-oxidation. CAR also inhibits gluconeogenesis79, 277. There are reports 
indicating that PPARa ligands such as Wy14643 and ciprofibrate induce CAR 
expression278, 279. However, activation of CAR was not seen in our fenofibrate 
study in chapter 3. It is more than likely that under physiological conditions 
subtle changes in the activation of multiple nuclear receptors regulate the 
response of TG and energy metabolism. It is interesting to study if these 
nuclear receptor mediated changes in energy homeostasis are associated with 
pathology. We therefore compared the effect of fasting and high fat diet feeding 
on the expression of genes involved in lipid metabolism in the liver as shown 
in chapter 6. 
Since the liver plays an important role in adjusting lipid and energy 
homeostasis, we investigated the changes in liver gene expression after 
prolonged fasting and 2 weeks of high fat feeding in mice. One of the major 
findings in chapter 6 is the level of gene regulation involved in the adaptation 
of energy homeostasis. During fasting, over 400 genes were differently 
expressed compared to control, whereas during high fat feeding, only 65 genes 
were differently expressed compared to control. This suggests a very complex 
transcriptional regulation of energy homeostasis during fasting
Both during fasting and high fat feeding, the liver switches to lipid 
metabolism thereby increasing b-oxidation. One of the major differences 
between fasting and high fat feeding includes the up-regulation of genes 
involved in FA biosynthesis upon high fat feeding, while these genes are 
down-regulated after prolonged fasting. During both fasting and high fat 
feeding, the liver becomes steatotic. However, only after high fat feeding 
the accumulation of liver lipid is associated with the development of insulin 
resistance230. The origin of this difference may reside in the fate of the TG pool 
in response to fasting, which is oxidation. Whereas the fate of the TG pool in 
response to high fat feeding is ectopic storage. The exact mechanism involved 
in the development of insulin resistance in response to high fat feeding requires 
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further investigation. 
It is believed that metabolic inflexibility plays a role in the pathology of 
the MetS. Both during fasting but also in obesity and insulin resistance, FA 
oxidation increases280, 281, 282, 283. However, when glucose becomes available 
again, for example during re-feeding, the body switches from FA to glucose 
oxidation. In obese and DM2 subjects switching between fat and glucose 
oxidation is impaired, a phenomenon described as metabolic inflexibility284, 285. 
PPARa plays a dominant role in lipid oxidation and therefore likely plays a 
key role in metabolic flexibility286. 
However, it has become apparent that in obese subjects lipogenesis is 
activated in addition to increased b-oxidation by PPARa activation. This 
increased lipogenesis has been attributed to activation of SREBP-1c78. In obese 
rodents, liver lipogenesis is associated with the activation of forkhead box 
O1 (FOXO1) signalling287. Recently, activation of FOXO1 has been identified 
to influence VLDL metabolism by increasing the expression of microsomal 
triglyceride transfer protein (MTTP) and the secretion of VLDL-TG288. It has 
long been known that, under fasting conditions, FOXO1 expression is increased 
and promotes hepatic gluconeogenesis, whereas under fed conditions, insulin 
inhibits the effects of FOXO1 on hepatic gluconeogenesis289, 290. The effect of 
FOXO1 on promoting VLDL production shows that FOXO1 plays a critical 
role in the metabolic adaptations necessary to respond to fasting and refeeding 
and influences metabolic flexibility. In insulin resistant obese subjects, the 
regulation of FOXO1 activity by insulin is impaired thereby causing both 
hyperglycemia and hypertriglyceridemia291. 
Another feature of the MetS is systemic low-grade inflammation. In 
obese individuals, adipose tissue expands resulting in the release of less anti-
inflammatory and more pro-inflammatory adipokines from adipocytes292. As a 
result, the adipose tissue becomes inflamed and this is believed to play a role 
in the low grade systemic inflammation seen in obese subjects. Several studies 
have shown that pro-inflammatory cytokines can induce insulin resistance293, 294, 
which may be reversed by anti-inflammatory medication295, 296. It seems likely 
that the double role of nuclear receptors in both energy/lipid metabolism 
and inflammation is central to the pathology associated with the MetS. Since 
nuclear receptors play a key role in metabolic flexibility it is interesting to 
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determine to what extent they also modulate our inflammatory responsiveness. 
In fact, while the prevalence of obesity increases in our population so does 
the incidence of allergy. Although there is controversy about the relation 
between obesity and allergy symptoms297, 298, 299, 300, it is suggested that obesity 
is associated with predisposition to allergy, especially allergy for food, and 
that systemic inflammation plays a key role in this association301. It would be 
interesting to determine whether allergy increases the risk to develop obesity 
or obesity increases the risk to develop allergy.
Concluding remarks
Regulation of VLDL-TG metabolism plays a role in energy homeostasis 
which is disturbed in obesity and associated pathology. Nuclear receptors are 
important in the regulation of VLDL-TG metabolism and therefore interesting 
targets for the development of drugs to treat MetS. The overall focus of this 
thesis was on the effects of several nuclear receptors on VLDL-TG metabolism, 
but these nuclear receptors clearly also affect inflammation. Since the MetS is 
a multifactorial disease, targeting both energy homeostasis and inflammation 
with nuclear receptors agonists may be an excellent approach to treat obesity 
related diseases. Unfortunately, most studies neglect the pleiotropic effects of 
nuclear receptors and therefore more integrated research focussed on both 
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Obesity is characterized by excessive fat storage and is associated with various 
diseases like cardiovascular disease (CVD) and type 2 diabetes (DM2), thereby 
being a serious problem of public health. Excessive energy intake is an important 
cause of obesity since excess energy is primarily stored as fat. The stored fat is 
mobilized again during fasting in the form of fatty acids (FA). These FA are re-
esterified in the liver in triglycerides (TG) that are secreted in VLDL particles to 
deliver FA to peripheral tissues where they can be used for energy. 
One of the current views of the cause of diseases related to obesity is the (mis)
handling of TG derived FA. Therefore it is important to understand pathways 
involved in the uptake, distribution, oxidation and storage of TG. In this thesis we 
have evaluated the effect of different interventions on VLDL-TG metabolism to 
gain a better understanding of its complex regulation. For these studies we used 
APOE*3-Leiden (E3L) and E3L.CETP transgenic mice that have a human-like 
lipoprotein metabolism and respond to lipid-modifying drugs in a ways similar 
to humans.
The first part of this thesis focuses on the effect of cholesteryl ester transfer 
protein (CETP) on VLDL-TG metabolism. CETP transfers cholesteryl esters and TG 
between lipoproteins and has been shown to have a major impact on cholesterol 
metabolism. Previous studies in E3L mice have shown that expression of CETP 
reduces HDL-C, increases LDL-C and thereby increases the risk to develop 
atherosclerosis. Whether CETP also has impact on TG metabolism was explored 
in chapter 2. Expression of CETP hardly affected VLDL-TG metabolism and did 
not influence high fat diet induced obesity in E3L mice. We concluded that CETP 
inhibitors are not likely to have adverse health effects related to TG metabolism.
The second part of this thesis addressed the effect of different pharmaceutical 
interventions on the regulation of VLDL-TG metabolism by nuclear receptors. 
Intermediates of lipid metabolism and hormones activate nuclear receptors after 
which they are transported to the nucleus where they regulate amongst other 
the expression of genes involved in energy homeostasis. These nuclear receptors 
include peroxisome proliferators activated receptors (PPARs) and the xenobiotic 
receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR). 
In chapter 3 we investigated the effect of the pharmacologic PPARa activator 
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fenofibrate on VLDL-TG metabolism. To this end, E3L.CETP mice were fed 
a western-type diet without or with fenofibrate. Treatment with fenofibrate 
lowered total plasma TG levels by increasing lipolysis of VLDL-TG. 
Unexpectedly, fenofibrate increased VLDL-TG production which is partly 
explained by increased FA turnover.  
The effect of rifampicin on VLDL metabolism was studied in chapter 4. 
E3L.CETP mice were treated with the PXR agonist rifampicin, an antibiotic 
prescribed for the treatment of tuberculosis. Treatment with this drug is 
associated with hepatic steatosis and dyslipidemia. E3L.CETP mice were fed a 
western-type diet for 3 weeks followed by an additional 3 weeks diet without 
or with increasing doses of rifampicin. The highest dose of rifampicin used 
(0.10%) showed a decrease of both HDL and VLDL cholesterol levels whereas 
total TG levels were unaltered. This decrease in cholesterol was mainly 
explained by lowering of both HDL and VLDL particle production by the liver. 
However, the VLDL particles secreted were enriched in TG explaining why 
total TG levels were not affected by rifampicin. 
In addition to drugs affecting nuclear receptors and lipid metabolism, 
chemical pollutants might also act as agonists for nuclear receptors. In chapter 
5 we describe the hypolipidemic effects of perfluoroakyl sulfonates (PFAS), a 
group of chemicals used for stain repellence and coatings. These compounds 
are higly resistant to degradation and bioaccumulate. PFAS activate PPARa as 
well as the xenobiotic receptors PXR and CAR, altogether reducing HDL and 
VLDL production by the liver as well as increasing VLDL-TG clearance by 
increasing lipolysis.
In chapter 6 we examined the differences in hepatic gene expression in 
response to fasting or a high fat diet, both known to induce hepatic steatosis. 
However, only after high fat diet feeding this steatosis is associated with hepatic 
insulin resistance. To gain insight in the transcriptional processes leading to 
steatosis associated insulin resistance, C57Bl6/J mice were fed standard chow 
diet or a high fat diet for 2 weeks. After 2 weeks half of the mice fed chow were 
fasted for 16 hours whereas the other part of the chow fed mice and the high 
fat diet fed mice were fasted for 4 hours. Strikingly, fasting affected far more 
genes compared to control than feeding a high fat diet. Furthermore, hardly 
any overlap in gene expression profile was seen between fasting and a high 
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fat diet, suggesting completely different gene programmes are activated. High 
fat diet feeding was especially associated with activation of PPARa whereas 
fasting activated xenobiotic receptors PXR and CAR.
Chapter 7 discusses the observation that nuclear receptors have a major 
impact on lipoprotein metabolism and play a key role in the pathology 
associated with obesity. Nuclear receptors are used as targets for the 
development of drugs to treat the metabolic syndrome. However, although 
we only focussed on the effect of nuclear receptors on lipoprotein metabolism 
in this thesis, inflammation is also regulated by these nuclear receptors. 
Development of new drugs that target nuclear receptors focuses on organ-
specificity as well as gene-specificity. However, a focus on dyslipidemia only 






Nederlandse samenvatting voor niet-ingewijden
Ongezond overgewicht
Zwaarlijvigheid (obesitas) is het overmatig opslaan van vet in ons lichaam 
en leidt tot ziektes als hart- en vaatziekten en suikerziekte en is daarom een 
groot probleem in de gezondheidszorg. Of iemand obees is wordt bepaald 
aan de hand van je Body Mass Index (BMI): het lichaamsgewicht in kilogram, 
gedeeld door de lichaamslengte in meters in het kwadraat (kg/m2). Een BMI 
tussen 18,5 en 25 wordt beschouwd als ideaal voor een gezond individu; een 
BMI van meer dan 25 wordt beschouwd als te zwaar (overgewicht); een BMI 
van meer dan 30 wordt beschouwd als obesitas. Overmatige inname van 
calorieën is één van de belangrijkste oorzaken van obesitas omdat de extra 
calorieën voornamelijk als vet worden opgeslagen. Wanneer we vasten wordt 
dit vet weer vrijgemaakt in de vorm van vetzuren zodat we het vet kunnen 
gebruiken als energie bron. De meeste van deze vetzuren gaan direct naar de 
lever waar ze worden omgezet in triglyceriden (TG). Deze TG bestaan uit een 
glycerol keten met drie vetzuren. TG worden vanuit de lever vervolgens weer 
vrijgelaten in de bloedbaan. 
Transport van vet in ons lichaam
Omdat vet slecht oplost in water en bloed, moet vet ‘oplosbaar’ verpakt worden 
om getransporteerd te worden in ons lichaam. De verpakking van vet wordt 
ook wel een lipoproteïne genoemd. Afhankelijk van hun samenstelling hebben 
deze lipoproteïnen een ander dichtheid en worden ze als volgt ingedeeld: zeer 
lage dichtheid lipoproteïnen (VLDL) met voornamelijk TG, lage dichtheid 
lipoproteïnen (LDL) met TG en cholesterol en hoge dichtheid lipoproteïnen 
(HDL) met voornamelijk cholesterol. Het hebben van veel LDL is een risicofactor 
voor het ontstaan van aderverkalking terwijl HDL er juist voor beschermd. 
LDL is in de volksmond ook wel bekend als slecht cholesterol en HDL als goed 
cholesterol. 
TG uit de lever komen in de bloedbaan terecht in VLDL om bij andere weefsels 
vetzuren af te leveren die als energie bron gebruikt kunnen worden. Omdat TG 
zeer groot is moeten deze eerst weer omgezet worden in losse vetzuren voordat 
ze door de weefsels opgenomen kunnen worden. Dit proces heet lipolyse. De 
reden dat vetzuren eerst via de lever in TG worden omgezet heeft te maken met het 
feit dat vetzuren zelf toxisch zijn. In weefsels worden ze daarom zo snel mogelijk 
óf verbrand óf weer omgezet in TG zodat ze geen schade kunnen aanrichten. 
Samenvatting 167
 8
Verstoring TG transport in obesitas
Er wordt momenteel heel veel onderzoek gedaan naar de reden waarom mensen 
met obesitas een hoog risico lopen om hart- en vaatziekten en suikerziekte te 
ontwikkelen. Men denkt dat één van de oorzaken hiervoor is dat het lichaam 
verkeerd omgaat met TG en de vetzuren hiervan. Daarom is het belangrijk 
dat we meer inzicht krijgen in de stofwisseling processen betrokken bij de 
opname, het transport, de verbranding en de opslag van TG en vetzuren (TG 
metabolisme). In dit proefschrift onderzoeken we het effect van verschillende 
interventies op het metabolisme van VLDL-TG om zo beter inzicht te krijgen 
in de regulatie hiervan. 
In het eerste deel van dit proefschrift hebben we gekeken naar het effect 
van cholesteryl ester transfer proteïne (CETP) op het VLDL-TG metabolisme. 
CETP is betrokken bij het verplaatsen van cholesteryl esters en TG tussen 
lipoproteïnen en we hebben eerder al laten zien dat CETP een grote invloed 
heeft op het cholesterol metabolisme. De werking van CETP leidt tot verlaagde 
niveaus van HDL cholesterol (goed cholesterol) en een toename van LDL 
cholesterol (slecht cholesterol) waardoor de kans op aderverkalking toeneemt. 
Of CETP ook effect heeft op TG is onderzocht in hoofdstuk 2. De werking van 
CETP heeft nauwelijks effect op het VLDL-TG metabolisme en heeft geen effect 
op de ontwikkeling van obesitas door het aangeboden dieet. Omdat CETP 
cholesterol verplaatst van HDL naar LDL en het goede cholesterol hierdoor 
afneemt, worden er medicijnen ontwikkeld om CETP te remmen en zo het 
goede cholesterol te verhogen. Het is belangrijk dat het remmen van CETP 
geen negatieve bijwerkingen heeft omdat CETP ook TG verplaatst tussen 
lipoproteïnen. We concluderen dan ook dat CETP remmers waarschijnlijk geen 
negatieve bijwerkingen zullen hebben met betrekking tot het TG metabolisme.
 
Regulatie van TG metabolisme
In het tweede deel van dit proefschrift hebben we gekeken naar de effecten 
van verschillende farmacologische interventies op de regulatie van het 
VLDL-TG metabolisme. Nucleaire receptoren spelen hierbij een grote rol. 
Dit zijn eiwitten in de cel die zijn betrokken bij de communicatie in de cel. 
Nucleaire receptoren herkennen specifieke moleculen in de cel, bijvoorbeeld 
vetzuren, en verplaatsen zich vervolgens naar de kern van de cel waar ze de 
werking (expressie) van genen beïnvloeden. Genen zijn onderdeel van ons 
DNA en bevatten de receptuur om ‘machines’ te maken. Deze machines zijn 
de werktuigen in onze cellen en hebben allemaal een eigen functie. Wanneer 
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de expressie van een gen toeneemt wordt er meer van die machine gemaakt. 
Op deze manier worden processen in onze cellen, en dus in ons lichaam, 
beïnvloed. Andere moleculen die herkend kunnen worden door nucleaire 
receptoren zijn hormonen en xenobiotica. Xenobiotica zijn moleculen die van 
nature niet in het lichaam voorkomen, bijvoorbeeld medicijnen die we slikken. 
Tot de nucleaire receptoren behoren de peroxisoom proliferator geactiveerde 
receptoren (PPAR), en de xenobioticum receptoren pregnaan X receptor (PXR) 
en constitutieve androstaan receptor (CAR). 
In hoofdstuk 3 hebben we het effect van de farmacologische PPARa 
activator fenofibraat op het VLDL-TG metabolisme onderzocht. Fenofibraat 
behoort tot de groep van de fibraten en hebben als belangrijkste functie het 
verlaging van TG in het bloed. Er werd altijd vanuit gegaan dat deze verlaging 
wordt veroorzaakt door minder productie van VLDL-TG én meer opname van 
VLDL-TG. Onze studie laat zien dat de verlaging van TG door fenofibraat geheel 
wordt verklaard door meer opname van VLDL-TG. Onverwacht veroorzaakt 
fenofibraat zelfs een verhoging van de productie van VLDL-TG door de lever. 
Deze toename wordt deels veroorzaakt door een toename in de omvorming en 
verplaatsing van vetzuren, oftewel meer vetzuur omzet. Verhoogde omzetting 
van vetzuren in het lichaam wordt als één van de oorzaken beschouwd voor 
het ontstaan van ziekten gerelateerd aan obesitas. Het is dus belangrijk dat we 
niet alleen weten wat medicijnen op totale niveau’s doen van TG en cholesterol 
maar ook hoe medicijnen dit doen. Waarschijnlijk is de verhoogde omzetting 
van vetzuren met fenofibraat niet schadelijk omdat fenofibraat ook ontsteking 
remt. Ontsteking is ook belangrijk bij het ontstaan van hart- en vaatziekten en 
suikerziekte in mensen met obesitas.
Het effect van rifampicine op het VLDL metabolisme is onderzocht in 
hoofdstuk 4. Rifampicine is een antibioticum dat wordt voorgeschreven voor 
de behandeling van tuberculose. Maar rifampicine activeert ook PXR. Bij 
behandeling met dit medicijn zijn bijwerkingen als vervetting van de lever 
en verstoring van TG en cholesterol in het bloed bekend. In onze studie laten 
we zien dat rifampicine inderdaad PXR activeert en leidt tot een verlaging 
zowel HDL als VLDL cholesterol terwijl de TG niveau’s onveranderd blijven. 
De afname van het cholesterol wordt veroorzaakt door minder productie van 
voornamelijk VLDL door de lever. Omdat de VLDL deeltjes uitgescheiden 




Chemische verontreinigende stoffen hebben ook invloed op nucleaire 
receptoren. In hoofdstuk 5 beschrijven we het effect van perfluoroakyl 
sulfonaten (PFAS) op het TG en cholesterol metabolisme. PFAS zijn chemische 
stoffen die worden gebruikt in anti-vlek middelen en in coatings. Nadeel van 
deze stoffen is dat ze biologisch slecht afbreekbaar zijn en daardoor ophopen 
in het milieu. We laten zien dat PFAS de nucleaire receptoren PPARa, PXR en 
CAR activeren, wat leidt tot remming van zowel de HDL als VLDL productie 
door de lever. Daarnaast stimuleren PFAS de lipolyse van VLDL-TG. Bij elkaar 
verklaart dit waarom cholesterol en TG sterk verlagen in onze studie.
In hoofdstuk 6 hebben we gekeken naar de verschillen in lever gen expressie 
in reactie op langdurig vasten of een hoog vet dieet. Zowel langdurig vasten 
als een hoog vet dieet leiden tot vervetting van de lever maar alleen bij een 
hoog vet dieet is er ook sprake van dat de lever niet langer reageert op insuline. 
Dit wordt ook wel insuline resistentie genoemd en kan leiden tot suikerziekte. 
We hebben deze studie uitgevoerd om meer inzicht te krijgen in de regulatie 
van het vet metabolisme bij zowel lever vervetting als insuline resistentie. 
Opvallend is dat vasten de werking van veel meer genen beïnvloed vergeleken 
met controle dieren dan een hoog vet dieet. Daarnaast was er ook nauwelijks 
overlap in de genen die tot werking kwamen vergeleken tussen vasten en hoog 
vet dieet. Dit suggereert dat er compleet andere gen expressie programma’s 
betrokken zijn bij het ontstaan van een vette lever tussen vasten en een hoog 
vet dieet. Hoog vet dieet geïnduceerde vette levers waren geassocieerd met 
activatie van PPARa terwijl na vasten vooral de xenobioticum receptoren PXR 
en CAR werden geactiveerd.
In dit proefschrift laten we zien dat nucleaire receptoren een grote invloed 
hebben op het VLDL-TG metabolisme en ook betrokken zijn bij het ontstaan 
van ziektes gerelateerd aan obesitas. Momenteel wordt er veel aandacht besteed 
aan het ontwikkelen van medicijnen die nucleaire receptoren beïnvloeden om 
zo ziekten in obese mensen te behandelen. Onze onderzoeken laten vooral 
zien wat het effect is van nucleaire receptoren op VLDL-TG maar ze hebben 
vaak ook invloed op ontsteking. Bij het ontstaan van ziektes bij obesitas zijn 
vaak vele verschillende processen betrokken waaronder het TG metabolisme 
en ontsteking. Door geïntegreerd onderzoek te doen naar deze verschillende 
processen kunnen we een beter beeld krijgen waarom mensen met obesitas 
ziek worden en goede medicijnen ontwikkelen.
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